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Abstract
The aim of this work is to investigate new and classical techniques, methods and formu-
lations for topical and buccal release.
All the formulations proposed are based on natural and biocompatible polymer ma-
trices such as gellan gum, scleroglucan and hydroxypropylmethylcellulose.
The proposed formulations are tested by in vitro release tests. In fact they represents
a valid support and a useful starting point for the realization of a potentially usable
in-vivo pharmaceutical formulation that may have commercial utility.
The research work is both experimental and theoretical. Each topic presents a more
chemical-pharmaceutical part, based on the formulation preparation and release exper-
iments, and a more theoretical-numerical approach that allows a correct interpretation
and description of the experimental data obtained.
Release from hydrogels and thin films require different modelling approaches. Also
the physico-mathematical description of different release experiments (different release
devices such as Franz cell, millifluidic device and USP II) requires different theoretical
and numerical techniques.
The outcome of an accurate model development is of fundamental importance for
future design of pharmaceutical formulations with prescribed release properties.
In addition the formulations are investigated through rheological, mechanical, thermo-
analytic and mucoadhesive tests in order to have a more comprehensive picture of their
practical utilization.
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Chapter 1
General Introduction
1.1 Thin films for buccal drug delivery
The oral route is the most important method of administration for systemic effect, due
to low cost, ease of administration and high level of patient compliance. Among the
pharmaceutical dosage form for oral delivery, the conventional tablet seems to be most
popular, because of its ease of transportability and comparatively low manufacturing
cost [1]. Nonetheless, two main types of disadvantages can be ascribed to the oral route:
first pass drug metabolism in the liver and pre-systemic elimination of the drug in the
gastrointestinal tract (GI first pass) could lessen the effective biodisponibility to an un-
acceptable level, or even destroy the drug, as it is the case of biological active ingredients
as proteins and peptides; moreover, a fast administration of emergency drugs and agents
with a rapid onset action could not be possible [2]. In these cases, the traditional choice
is parenteral drug administration, which is, on the patient side, uncomfortable, uneasy
and undesired. Difficulties associated with parenteral delivery and poor drug availability,
together with substantial efforts focused on placing a drug or drug delivery system in
a particular region of the body for extended periods of time, provided the impetus for
exploring alternative routes, such as the mucosal layer lining a number of regions of the
gastrointestinal tract, the airways, mouth, the ear, nose, and the eye.
Mucosal tissues can interact with the hydrophilic macromolecules of drug matrices,
bringing about an adhesive attachment called mucoadhesion. This interaction retains
a formulation in intimate contact with the adsorption site. The buccal region of oral
cavity is the most attractive site for the delivery of drugs. Buccal drug delivery involves
the administration of desired drug through the buccal mucosal membrane lining of the
oral cavity. This route is useful for mucosal (local effect) and transmucosal (systemic
effect) drug administration. In the first case, the aim is to achieve a site-specific release
of the drug on the mucosa, whereas the second case involves drug absorption through
the mucosal barrier to reach the systemic circulation [3–7].
The buccal mucosa is permeable, with a rich blood supply, more robust and have
more tolerance to potential sensitizers in comparison to the other mucosal tissues. No
activation of the drug absorption is required. Local modification of tissue permeability,
inhibition of protease activity and reduction in immunogenic response are allowed.
On the other hand, the environment of the oral cavity presents some significant chal-
lenges for systemic drug delivery, given that the mucosa has barrier properties. The
principle physiological environment of the oral cavity, in terms of pH, fluid volume and
composition, is shaped by the secretion of saliva.Saliva covers the surface area of the
mouth (around 217 cm2)with a layer of average thickness 70-100 µm for adults and 60-
90 µm for children. It is continuously secreted at average flow rate of 0.3-1 ml/min, but
can be elicitated up to 7.07 ml/min by stimulating agents; flow rates < 0.1 ml/min must
be considered pathological. The volume of saliva in the mouth ranges from 0.8 ml, after
swallowing, to 1.1 ml just before swallowing [8–11]. The continuous secretion of saliva
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Figure 1.1: Structure of oral cavity.
leads to subsequent dilution of the drug; saliva swallowing can provoke the partial or
total removal of the dosage form. The volume of saliva constantly present in the mouth,
around 1 ml, provides a relatively low fluid volume available for drug release from delivery
systems compared to the GI tract [12,13].
The different types of buccal dosage forms are buccal tablets, ointments, gels, patches
and thin films [14]. Over and above the mentioned demands, oral delivery systems
alternative to tablets and syrups have been of interest since the latest 1970’s, as a possible
improvement for a particular, and not so small, class of patients who have difficulties in
swallowing. This disorder affects more frequently for old people, children and mentally
illness, but the oral administration without swallowing could be helpful also for travelling
or military patients who may not have ready access to water [15,16].
1.1.1 Anatomy of the oral mucosa
Buccal region is that part of the mouth bounded anteriorly and laterally by the lips and
the cheeks, posteriorly and medianly by the teeth and/or gums, and above and below by
the reflections of the mucosa from the lips and cheeks to the gums.
Numerous racemose, mucous, or serous glands are present in the sub mucous tissue of
the cheeks. The buccal glands are placed between the mucous membrane and buccinator
muscle: they are similar in structure to the labial glands, but smaller ( figure 1.1).
About five, of a larger size than the rest, are placed between the masseter and buc-
cinator muscles around the distal extremity of the parotid duct; their ducts open in the
mouth opposite the last molar tooth. They are called molar glands. Maxillary artery sup-
plies blood to buccal mucosa and blood flow is faster and richer (2.4ml/min/cm2) than
that in the sub lingual, gingival and palatal regions, thus facilitates passive diffusion of
drug molecules across the mucosa.
The thickness of the buccal mucosa is measured to be 500–800 µm and is rough
textured, hence suitable for retentive delivery systems. The turnover time for the buccal
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epithelium has been estimated at 5–6 days. Buccal mucosa composed of several layers
of different cells as shown in figure 1.2. The epithelium is similar to stratified squamous
epithelia found in rest of the body and is about 40–50 cell layers thick.
Lining epithelium of buccal mucosa is the nonkeratinized stratified squamous epithe-
lium that has thickness of approximately 500–600 µm and surface area of 50.2 cm2.
Basement membrane, lamina propria followed by the sub mucosa is present below the
epithelial layer. Lamina propria is rich with blood vessels and capillaries that open to
the internal jugular vein [17].
The barriers such as saliva,mucus,membrane coating granules, basement membrane
etc retard the rate and extent of drug absorption through the buccal mucosa. The main
penetration barrier exists in the outermost quarter to one third of the epithelium.
Oral mucosa, a barrier to permeability
The effective permeability coefficient (Peff) values reported in the literature across the
buccal mucosa for different molecules range from a lower limit of 2.2 · 10−9 cm/s for
dextran 4000 across rabbit buccal membrane to an upper limit of 1.5 · 10−−5 cm/s for
both benzylamine and amphetamine across rabbit and dog buccal mucosa, respectively.
This range clearly demonstrates the presence of a permeability barrier in the oral mucosa,
which is mostly imposed by the oral epithelium acting as a protective layer for the tissues
beneath, and as a barrier to the entry of foreign material and microorganisms. However,
this range is estimated to be 4–4000 times more permeable than that of skin. The
permeability barrier property of the oral mucosa is predominantly due to inter cellular
materials derived from the so-called "membrane coating granules" (MCGs). MCGs are
spherical or oval organelles that are 100–300 nm in diameter and found in both keratinized
and non-keratinized epithelia.
These organelles have also been referred to as "small spherically shaped granules",
"corpusula", "small dense granules", "small lamellated bodies", "lamellated dense bod-
ies", "keratinosomes", "transitor dense bodies", and "cementsomes" . However, most
of these descriptive names have not fully defined the functions of this cellular species.
MCGs were first named as such because it was believed that they were subject to ex-
ocytosis from the cytoplasm of the stratum spinosum of keratinized epithelia following
thickening of these cells. Nonetheless, it is actually the contents of MCGs that are subject
to exocytosis prior to the onset of membrane thickening.
The main mechanisms responsible for the penetration of various substances include
simple diffusion (paracellular, transcellular), carrier-mediated diffusion, active transport,
and pinocytosis or endocytosis. Recent evidence has shown that passive diffusion is
the primary mechanism for the transport of drugs across the buccal mucosa, although
carrier-mediated transport has been reported to have a small role.
Two routes of passive transport are available in the buccal epithelium(figure 1.3); one
involves the transport of compounds through the inter cellular spaces between the cells
(paracellular), and the other involves passage into and across the cells (transcellular). De-
pending on the nature of the permeant, the molecular geometry, lipophilicity, and charge,
either of the transport pathways across buccal epithelium can be selected. While consid-
erable evidence has been presented to document that most compounds diffuse through
the buccal mucosa by passive diffusion or simple Fickian diffusion, some are transported
by a carrier mediated process across the buccal mucosa. Glucose, monocarboxylic acids
and salicylic acid, and nicotinic acid, are examples of substances which utilize a carrier-
mediated diffusion mechanism for permeation across buccal epithelium [18].
Mucus
The epithelial cells of buccal mucosa are surrounded by the intercellular ground substance
called mucus with the thickness varies from 40 µm to 300 µm. Though the sublingual
glands and minor salivary glands contribute only about 10% of all saliva, together they
produce the majority of mucus and are critical in maintaining the mucin layer over the
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Figure 1.2: A sketch of the buccal mucosa.
Figure 1.3: Schematic representation of penetration routes in buccal drug delivery.
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oral mucosa. It serves as an effective delivery vehicle by acting as a lubricant allowing
cells to move relative to one another and is believed to play a major role in adhesion of
mucoadhesive drug delivery systems.
At buccal pH, mucus can form a strongly cohesive gel structure that binds to the
epithelial cell surface as a gelatinous layer. Mucus molecules are able to join together to
make polymers or an extended three-dimensional network.Different types of mucus are
produced, for example G, L, S, P and F mucus, which form different network of gels.
Other substances such as ions, protein chains, and enzymes are also able to modify the
interaction of the mucus molecules and, as a consequence, their bio-physical properties.
Mucus is composed chiefly of mucins and inorganic salts suspended in water. Mucins
are a family of large, heavily glycosylated proteins composed of oligosaccharide chains
attached to a protein core. Three quarters of the protein core are heavily glycosylated
and impart a gel like characteristic to mucus. Mucins contain approximately 70–80%
carbohydrate, 12–25% protein and up to 5% ester sulphate.
The dense sugar coating of mucins gives them considerable water-holding capacity
and also makes them resistant to proteolysis, which may be important in maintaining
mucosal barriers. Mucins are secreted as massive aggregates by prostaglandins with
molecular masses of roughly 1 to 10 million Da. Within these aggregates, monomers
are linked to one another mostly by non covalent interactions, although intermolecular
disulphide bonds also play a role in this process.
Oligosaccharide side chains contain an average of about 8–10 monosaccharide residues
of five different types namely L-fucose, D-galactose, N-acetyl-D-glucosamine, N-acetyl-
D-galactosamine and sialic acid. Amino acids present are serine, threonine and proline.
Because of the presence of sialic acids and ester sulfates, mucus is negatively charged at
physiological salivary pH of 5.8–7.4 [19–21].
Saliva
The mucosal surface has a salivary coating estimated to be 70 µm thick, which act as
unstirred layer. Within the saliva there is a high molecular weight mucin named MG1
that can bind to the surface of the oral mucosa so as to maintain hydration, provide
lubrication, concentrate protective molecules such as secretory immunoglobulins, and
limit the attachment of microorganisms. Several independent lines of evidence suggest
that saliva and salivarymucin contribute to the barrier properties of oral mucosa.
The major salivary glands consist of lobules of cells that secrete saliva; parotids
through salivary ducts near the upper teeth, submandibular under the tongue, and the
sublingual through many ducts in the floor of the mouth. Besides these glands, there are
600–1000 tiny glands called minor salivary glands located in the lips, inner cheek area
(buccal mucosa), and extensively in other linings of the mouth and throat.
Total output from the major and minor salivary glands is termed as whole saliva,
which at normal conditions has flow rate of 1–2 ml/min. Greater salivary output avoids
potential harm to acid-sensitive tooth enamel by bathing the mouth in copious neutral-
izing fluid.
With stimulation of salivary secretion, oxygen is consumed and vasodilator sub-
stances are produced; and the glandular blood flow increases, due to increased glandular
metabolism.
Saliva is composed of 99.5% water in addition to proteins, glycoproteins and elec-
trolytes. It is high in potassium (7·plasma), bicarbonate (3·plasma), calcium, phospho-
rous, chloride, thiocyanate and urea and low in sodium(1/10·plasma).
The normal pH of saliva is 5.6-7. Saliva contains enzymes namely α-amylase (breaks
1–4 glycosidic bonds), lysozyme (protective, digests bacterial cell walls) and lingual lipase
(break down the fats). Saliva serves multiple important functions. It moistens the mouth,
initiates digestion and protects the teeth from decay. It also controls bacterial flora of
the oral cavity. Because saliva is high in calcium and phosphate, it plays a role in
mineralization of new teeth repair and precarious enamel lesions. It protects the teeth
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by forming “protective pellicle”. This signifies a saliva protein coat on the teeth, which
contains antibacterial compounds.
However, salivary flow rate may play role in oral hygiene. Intraoral complications
of salivary hypofunction may cause candidiasis, oral lichen planus, burning mouth syn-
drome, recurrent aphthous ulcers and dental caries.
A constant flowing down of saliva within the oral cavity makes it very difficult for
drugs to be retained for a significant amount of time in order to facilitate absorption in
this site.
In general, intercellular spaces pose as the major barrier to permeation of lipophilic
compounds, and the cell membrane which is lipophilic in nature acts as the major trans-
port barrier for hydrophilic compounds because it is difficult to permeate through the
cell membrane due to a low partition coefficient. Permeabilities between different regions
of the oral cavity vary greatly because of the diverse structures and functions. In gen-
eral, the permeability is based on the relative thickness and degree of keratinization of
these tissues in the order of sublingual> buccal> palatal. The permeability of the buccal
mucosa was estimated to be 4–4000 times greater than that of the skin [13,17,18,22,23].
1.1.2 Oral thin films: a general presentation
Similar in size, shape and thickness to a postage stamp, pharmaceutical thin films (figure
1.4) were developed from skin patches technology. They firstly appeared in the 1970’s as
breath mint in the confectionery industry and gradually spread in cosmetics, nutraceuti-
cal and over-the-counter products. After the approval of Zuplenz and Ondasetron from
the Food and Drug Administration (USA) in 2010, they can be considered now as the
most advanced oral solid dosage form [24,25]. Pharmaceutical thin films are equivalently
called in literature "strips", "dissolving films" and "orodispersible films" by the Euro-
pean Medicines Agency [26,27]. Also the term "wafer" is improperly used, although this
word refers to a similar kind of dosage form. Pharmaceutical films are typically designed
to be placed on or under the tongue for oral administration, but they can be used in
principle for any other mucosal tissue [28].
Films for oral administration are equivalently called "buccal" or "oral" films. De-
pending on thickness and disintegration time, three categories can be qualitatively iden-
tified. In order of size (increasing): flash release films, mucoadhesive melt-away wafers
and mucoadhesive sustained release wafers [29]. Disintegration time is usually scaled to
thickness. In the present default of any standardized definition or method, this classi-
fication should be considered merely suggestive. Focus of this work is mainly on films
with thickness < 100µm.
Figure 1.4: Oral thin films(OTF).
Chapter 1 7
In conctat with biological fluids, films rapidly disintegrate and dissolve to release the
medication, in the mouth (buccally or sublingually) and/or via the small intestines (en-
terically), without the need of water and improving the efficacy of the active ingredients.
In the mouth, a thin film gets instantly wet by saliva, rapidly hydrates and adheres onto
the site of application. [30]. Unlike other rapid dissolving dosage forms, films can be
produced with a manufacturing process that is competitive with the manufacturing costs
of conventional tablets [31]. Just few drugs have been already commercialized in this
form because of the complexity associated mainly with its novelty. Among marketed
products, there are anti-emethic, antihistaminic, analgesic. The first marketed product
under medical prescription has been Zuplenz/Ondasetron.
An extensive pioneer medical work exploring the administration of this drug in oral
strips is [32]. Strips have been recognized as an effective and highly patient compliant
drug delivery system [33]. Compliance is significative in particular when considering
cases of mental-illness, emesis, or children, geriatric, disphagic patients. In addition,
pharmaceutical industries show an increasing interest in oral films, as they can be used
to elongate patent-life of existing active principles by a new administration form [34,35].
In summary, the principal advantages of oral strips are [36–38,55]:
• unobstructivity, high compliance for patients with swallowing problems, no special
training is required for the administration of dosage form;
• no need of water, drug is wet by saliva;
• quick dissolution and release, with a relatively large surface area and a very high
ratio area/thickness, for rapid wetting;
• precision in the administered dose is ensured from each of the strips;
• systemic and local action;
• they can be mucoadhesive;
• overcoming of first pass effect;
• to be not so brittle as oral dissolving tablets, and so there are less transport and
storage difficulties;
• no special set up for industries are required and production costs are competitive;
• new business opportunities, like patent extension, product promotion and product
differentiation.
On the other hand, most significative disadvantages are:
• expensive packaging, since the dosage form is moisture sensitive;
• taste masking of drug should be done and there are limited taste masking options;
• drugs which irritate the mucosa are forbidden;
• high doses of drug cannot be incorporated.
OTF are typically made of [39]:
• a filming hydrophilic polymer (around 45% by weight);
• an active pharmaceutical ingredient (API, up to 30 % );
• plasticizer (0-20 %);
• other additives, such as fillers, surfactants, saliva stimulating agents and sweeting
agents (up to % 40).
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Drug and polymer are the essential components of OS. Knowledge and techniques about
including drugs in thin films have been continuously increasing in the last ten years
[40–54]. Desiderable characteristics are a low required dose ( < 40 mg), low molecular
weight, possibly good taste.
The drug should also be stable and soluble both in saliva and water and partially
unionized in water. The active component must be able to pass the mucosa barrier, not
provoking irritations. Eligible API are anti emetic, neuroleptics, cardiovascular agents,
analgesics, anti allergic, anti epileptics, anxiolytics, sedatives, hypnotics, diuretics, an-
tiparkinsonism agents, anti-bacterial agents and drugs used for erectile dysfunction, an-
tialzheimers,expectorants, antitussive.For mucosal and transmucosal administration, con-
ventional dosage forms are not able to assure therapeutic drug levels in the mucosa and
circulation because of the physiological removal of the oral cavity (washing effect of saliva
and mechanical stress), which take the formulation away from the mucosa, resulting in
a very short exposure time and unpredictable distribution of the drug on the site of
action/absorption. To obtain the therapeutic action, it is therefore necessary to prolong
and improve the contact between the active substance and the mucosa [20].
1.1.3 Polymers for the preparation of thin films
Polymers are the backbone of film formulations and various polymers are available for
the preparation of thin films [55]. The polymers can be used alone or in combination with
other polymers to achieve the desired film properties. The polymers employed should
be non-toxic, non-irritant, and absence of leachable impurities is required.Water-soluble
polymers are used as film formers to produce a thin film with rapid disintegration, good
mechanical strength, and good mouth feel effects. Both natural and synthetic polymers
are used for film preparation [56, 57]. Availability of diverse polymers allows imparting
specific properties in the thin films. For instance, gelatine are available in different
molecular weights, and thus the appealing and glossy films could be obtained with the
gelatin having a high molecular weight. Pullulan is frequently used for producing a
thin film with great solubility,high mechanical strength and they are stable over a wide
range of temperatures. The blending of chitosan and high methoxy pectin (HMP) or
low methoxy pectin (LMP) resulted in a thin film exhibiting an excellent mechanical
strength. The film forming polymers such as hydroxypropyl cellulose (HPC), methyl
cellulose, and carboxymethyl cellulose (CMC) produce a thin film with less water vapor
barrier due to hydrophilic nature which aids in water retention [58,59].
The basic idea of pharmaceutical thin strips is exactly that a dissolved component
could be immobilized in a solid film, and be released from a gel as soon as the dosage
form comes in conctat with biological fluids.
Natural and semi-natural polymers have also been reported in the literature as mu-
coadhesive. Chitosan was first introduced in 1994 by Guo for its use in mucoadhesive
film formulations [68]. Following Carbopol and HPMC as polymeric matrices for mu-
coadhesive films, chitosan exhibited better adhesion than acacia in a peeling test using
an Instron 4201.
Mucoadhesive films are thin and flexible retentive dosage forms, and release drug di-
rectly into a biological substrate. They facilitate in extending residence time at the appli-
cation site leading to prolonged therapeutic effects [65]. Majority of the thin film having
mucoadhesive properties are hydrophilic in nature and undergoes swelling and form a
chain interaction with the mucin.Among the several studied polymers, the most com-
pelling mucoadhesion properties are exhibited by chitosan, hyaluronan, cellulose deriva-
tives, polyacrylates, alginate, gelatin and pectin [66]. Compared with non-ionic polymers,
the cationic and anionic polymers facilitate strong interaction with mucus [67].
Plasticizers can significatively help OTF formulation. They improve mechanical prop-
erties such as flexibility and brittleness, by reducing the glass transition temperature of
the filming polymer. Plasticizers should be compatible with the drug, as well as other
additives used in the preparation of OTF. Most attractive plasticizers for OTF are glyc-
erol, propylene glycol, low molecular weight polyethylene glycols, phthalate derivatives
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like dibutyl phthalate, citrate derivatives such as tributyl, triethyl, acetyl citrate, cas-
tor oil [60, 61]. Improving palatability is probably the first reason that why additives
are added in OTF. A simple obscuration technique, which means mixing and blend-
ing bitter tasting API with pleasurable taste substances, can be used. Also, barrier
techniques, which includes complexation, polymeric coating and coated particle, have
recently appeared. Sweetening and flavoring agents are typical additives for palatabil-
ity improvement. Sweetening agents are the most major part of the food product or in
pharmaceutical dosage forms proposed to be disintegrated or dissolved in the oral cavity.
Natural as well as artificial sweetening agents are used to improve the palatability of
the formulation. Common agents are sugar, dextrose, lactose, mannitol, sucrose, xyli-
tol, malitol, acesulfame potassium, talin, glycyrrhizin, sucralose, aspartame, saccharin,
essential oils or water soluble extracts of menthol, wintergreen, peppermint, sweet mint,
spearmint, vanillin, cherry, chocolate, cinnamon, clove, lemon, orange. Sweetening agent
are generally used either alone as in combination between the concentrations of 3 to 6 %
by weight of the film. Selection of flavoring agents is depending on which type of drug
is to be incorporated in the formulation. The recognition of the oral disintegrating /
dissolving formulation by an individual, depends on the initial flavor quality, which is
observed in the first few seconds after the product has been consumed, and on the after
taste of the formulation, which lasts for at least about 10 min.
Other functional additives are surfactants and saliva stimulating agents. Surfactants
are used as a solubilizing or wetting dispersing agent so that the film gets dissolved within
seconds and releases active agent immediately. Some of the commonly used are sodium
lauryl sulfate, benzalkonium chloride, tweens, poloxamer 407. Saliva stimulating agents,
as citric acid, malic acid, lactic acid, ascorbic acid and tartaric acid, are used to increase
the rate of production of saliva. This would aid in the more rapidly disintegration of
fast dissolving film formation. Saliva stimulating agents are used alone as well as in
combination between 2 to 6 % w/w by weight. Finally, fillers and colorants can be added
to improve film’s aspect and handling. Typical colorants are natural coloring agents,
and natural juice concentrates, pigments such as titanium oxide, silicon dioxide and zinc
oxide. Maximum colorants’s concentration is 1 % by weight [62–64].
In common terms, polymers are understood as excipients, but it has become an es-
sential component while designing and formulating thin films.Therefore, understanding
the properties of polymers such as chemistry, rheology, and physicochemical proper-
ties of polymer seems to be imminent for maximizing their uses to develop a thin film.
The selection of appropriate polymer during the development of polymeric thin films
may be critical; thereby, several points should be considered according to the require-
ments.Therefore, it is imperative to consider the appropriate polymer for producing a
thin film with a better performance that assures high therapeutic success.
1.1.4 Mucoadhesive properties of buccal films
Bioadhesion is the general term describing adhesion between any biological and synthetic
surface. Mucoadhesion is a specific term describing the particular interaction of a mucosal
membrane with a synthetic surface [69]. The phenomenon of mucoadhesion has been
explained by applying any of the five theories of adhesion into the interaction of the
dosage form and the biological substrate [70, 71]: electronic [72], adsorption [73, 74],
wetting [75], diffusion [76], and fracture theory [77]; here, we briefly summarize theories
related to mucoadhesion theory. Since mucoadhesive buccal films include the interaction
of a dry polymeric matrix that undergoes hydration, drug release, and sometimes erosion,
the phenomenon is very complex. Smart has defined four possible scenarios for the
analysis of the mucoadhesion process based on the hydration state of the dosage form
and on the amount of mucus layer available for mucoadhesion [78].
Mucoadhesive buccal films can be classified as a "case 3" scenario since they are
solid dry substrates that come in contact with a mucosa having thin or discontinuous
mucus layers. Relevant to the analysis of the mucoadhesion of polymeric films on the
buccal mucosa are the adhesion theories of adsorption and diffusion. The adsorption
10 General Introduction
theory states that the main contributors to the adhesive bond are the inter-polymer
interactions, such as hydrogen bonds and van der Waals forces [79]. The diffusion theory
assumes that polymeric chains from the solid substrate, i.e. the mucoadhesive film, and
the biological substrate, i.e. mucin in the mucosa layer, interdiffuse across the adhesive
interface. Important variables in this process are the diffusion coefficient of the polymer
into the mucin layer and vice versa, the contact time, and the molecular chain length
and their mobility [79,80].
Most of the mucoadhesive phenomena have two main stages that control the perfor-
mance of the dosage form: the contact stage and the consolidation stage (figure 1.5) [81].
Since mucoadhesive films are dosage forms that are brought in contact with the biological
membrane by the patient, the contact stage is initiated by the patient. During the con-
tact process, the film will start dehydrating the mucus gel layer and will itself hydrate,
initiating the interpenetration of the polymeric chains into the mucus and vice versa.
Figure 1.5: Contact and consolidation stage of mucoadhesion.
For mucoadhesive films, which usually are designed to remain for prolonged times
in contact with the buccal mucosa, a second stage, the consolidation stage, needs to
take place in order to maintain this bond. In the consolidation stage, the mucoadhe-
sive strength will be determined by the polymer in the formulation, and how readily the
dosage form hydrates upon contact with the mucus gel layer. This process is explained
by the dehydration theory, which explains that when a material capable of gelation, such
as a mucoadhesive polymer in a buccal film, is brought into contact with an aqueous
viscous colloid, water will move until equilibrium is reached between the two layers [77].
The strength of the mucoadhesive bond will then be determined by the extent of in-
termixing that occurs after water migrates and reaches equilibrium. Mucoadhesive films
have been designed to remain in contact with the buccal mucosa for therapeutic purposes
for prolonged periods of time. The measurement of the mucoadhesive strength and time
of mucoadhesion [82] are very important parameters.
1.1.5 Films evaluation
Many different characteristics play a significative role in production and handling of
pharmaceutical strips, such as mechanical strength, structure, dissolution or storage be-
haviour. Tests on films assess basic properties which are meaningful in research and
quality control. Here we go into details of the main type of analysis.
Tensile/mechanical properties. Mechanical properties indicate at what extent the
film can withstand force or stress during processing, packaging, transport and handling.
Tensile testing is usually conducted using a texture analyzer device (figure 1.6,1.7), con-
ceptually similar to a classical stress-strain test. The film is inserted and elongated until
it breaks. Tensile strength, percent elongation at break, elastic modulus (Young’s modu-
lus), tensile energy to break are measured.Some general behaviors of films observed from
stress—strain curves are shown in figure 1.8. Part of the literature suggests to follow
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ASTM International Test Method for Thin Plastic Sheeting D882. Moderate tensile
strength and low elastic modulus are desidered features. The mechanical properties of
pharmaceutical strips are main determined by the hydrophilic polymer and plasticizer
used in formulation. Typical values are tensile strength 1-30 MPa, Young’s module 10-
2000 MPa, elongation at break 1-150 % [83–86,107].
Film forming capacity and appearance. Film forming capacity and appearance
Figure 1.6: Experimental setup (left) and sample holder for the film preparation (right),
where rs indicates radius of samples, and rp indicates radius of probe. Geometry of
cylindrical probes A and B and spherical probe C is shown on the right bottom [105].
Figure 1.7: Determination of percent elongation of thin films using a texture analyzer,
where a = initial length of the film in the sample holder opening, a
′
= initial length -
radius of probe, b = displacement of the probe, c
′
+ r = length after strain, c
′
= length
of a
′
after strain, r = radius of the probe [105].
of films are two qualitative concepts. Film forming capacity is the ability of film formers
to form desired films. It is categorized according to strip forming capacity such as very
poor, poor, average, good, very good, excellent. Appearance of strip is evaluated by
visual observation such as transparent, semi transparent,opaque [87,88].
Thickness. Thickness is measured at different points (normally 5) by a micrometric
screw gauge.
Folding endurance. Folding endurance is determined by folding a film up to it break
at the folding point. The number of attempt required to break the film is the folding
endurance value [89,90].
Solid state characterization. Solid state properties of films can be analyzed by
means of differential scanning calorimetry, Fourier transform infrared spectroscopy, X-
Ray diffraction [91].
Swelling properties. Hydrophilic polymers undergo swelling, which is defined as an
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Figure 1.8: Examples of stress–strain curves obtained from polymeric thin films.
Figure 1.9: Schematic illustration of the apparatus used for dissolution studies of films.
expansion of the matrix in aqueous media. This phenomenon is simultaneous to the
set-up of a gel phase. These polymers form physical-linked gels and are bio erodible. So
as, a true swelling equilibrium, as in the sense of cross-linked gel such as Poly-methyl-
metacrilate, does not exist. Nonetheless, a pseudo-swelling equilibrium can be individ-
uated [92]. Swell is measured by immerging a sample in a swelling medium (generally
saliva or water at fixed pH and temperature), then weighing the sample, time by time,
until an equilibrium weight is reached. The film can be put in a Petri dish, in a net wire
or a beaker. The swelling degree S is usually calculated as (equation (4.10)):
S =
M −M0
M0
(1.1)
where M is the measured weight and M0 is the initial weight. Common polymers for
OTF can swell from 0.2 to 50 times, depending on the formulation [93,94].
In-vitro dissolution testing. Dissolution testing evaluates the duration of drug re-
lease from the dosage form and its pace. Dissolution tests for OTF have been performed
in diffusion cells [95], USP paddle II(figure 1.9) or basket (I) apparatus, USP IV flow-
through apparatus [96]. In the literature, many authors have done some improvisation
on the dissolution apparatus, while others have employed Franz diffusion cells (FDC) for
testing the drug release from the polymeric films.A major barrier with respect to film in
dissolution testing is the placing of the samples. Several methods have been practiced,
where the film is attached on the inner side of the glass vessels or the stirring element
using an adhesive tape [106].
Uniformity of drug content. A prerequisite for therapeutic efficacy, safety, and
regulatory approval of a medicine is drug content uniformity. Failure to achieve a high
degree of accuracy with respect to the amount of drug in individual unit doses of the film
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can result in therapeutic failure, non reproducible effects, and, importantly, toxic effects
to the patient. Drug content is measured by dissolving a known weight of the film for
analysis. An assay of film area rather than weight would be more appropriate for assess-
ing drug content uniformity. Drug uniformity in OTF can normally have a variation of
± 15 %. Drug content uniformity is a crucial aspect in film manufacturing [97].
In vitro Bioadhesion measurement. In vitro bioadhesion measurement method was
first reported [98] in evaluation of the adhesive properties of patches using a micropro-
cessor based on advanced force gauze equipment with porcine buccal membrane as a
model tissue under simulated buccal conditions. Data collection and calculations were
performed using the Data Plot software package of the instrument. Two parameters,
namely the work of adhesion and peak detachment force were used to study the buc-
cal adhesiveness of patches. The work of adhesion was determined from the area under
force-distance curve while the peak detachment force was the maximum force required
to detach the film from the tissue [107].
1.1.6 Manufacturing techniques
Manufacturing processes for OTF preparation have thrived in the last two decades. Sol-
vent casting, semi solid casting, hot-melt extrusion, solid-dispersion extrusion, and rolling
are the main technological families. An overview is presented here [99–104].
Casting solution. This technique require raw materials with few trivial prerequisites:
the polymer must be soluble in a volatile solvent or water, a stable solution with a reason-
able minimum solid content and medium viscosity is sought, formation of a homogeneous
film and release from the casting support must be possible. Water soluble polymers-
hydrocolloids good to prepare OTF include: hydroxypropylmethyl cellulose (HPMC),
hydroxypropyl cellulose (HPC), Pullulan, sodium alginate, pectin, carboxymethyl cellu-
lose (CMC), Poly-vinyl alcohol (PVA). Water-soluble ingredients are dissolved to form
a clear, viscous solution. The API and other agents are dissolved apart in a suitable
solvent. This second mixture is later vigorously mixed with the water solution. The
entrapped air is removed by vacuum. Deaeration is necessary to obtain uniform film
property and thickness. The resulting solution is cast as a film, allowed to dry, and cut
into pieces to the desired size (figure 1.10). Specific types of equipment, such as rollers,
are required for pouring the solution on an inert base. The clearance between the roller
and the substrate determines the required thickness of the film. Drying the film, removes
the solvent and helps to obtain the finished product. Usually, glass, plastic, inox or teflon
plates are used as an inert base for film casting.
This manufacturing technology is the most frequent in laboratory. When transferred
to production scale, several problems can be encountered, that include how casting the
film, obtaining uniform thickness, and proper drying [108, 109] . Air entrapment may
tend to produce non- uniform films. Deaeration step is imperative to get a uniform film
which may be achieved by vacuum assisted machines.
Hot-melt extrusion. In the hot-melt extrusion (HME) process, appropriate amounts
of polymer, drug, plasticizer and additives are blended into an uniform powdered mix-
ture, prior to feeding through the hopper of the preheated extruder and be transferred
into the heated barrel by a rotating extruder screw (figure 1.11). The API and other
excipients are mixed in a dry state. An advantage of this process is the complete elimi-
nation of the solvent. Films cool and are cut to the desired size. The high temperature
makes the process suitable only for thermostable drugs. Homogeneous films are obtained,
with thickness < 1 mm [110,111].
Semi-solid casting. Firstly, a water solution of film forming polymer is prepared.
This mixture is added to a solution of an acid insoluble polymer (e.g. cellulose acetate
phthalate, cellulose acetate butyrate), which was prepared in ammonium or sodium hy-
droxide. The appropriate amount of plasticizer is added to obtain a gel mass. Finally,
the gel mass is casted in films or ribbons, using heat controlled drums. The thickness
of the film is about 0.1-1.1 mm. The ratio of the acid insoluble polymer to film forming
polymer should be 1:4 [112].
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Figure 1.10: Commercial manufacturing of film based on solvent-casting [55].
Figure 1.11: Hot-melt extrusion system for the preparation of films [55].
Solid dispersion extrusion. Immiscible components are extrude with drug, preparing
solid dispersions. The latter are shaped in to films by means of dies [112].
Rolling-method. The film is prepared by pre-mixing of an active ingredient and excipi-
ents, followed by subsequent addition of the solvent. The pre-mix or master batch, which
includes the film- forming polymer, polar solvent, and any other additives except drug
is added to the master batch feed tank. A pre-determined amount of the master batch
is controllably fed via a metering pump and control valve to first and second mixers.
The required amount of the drug is added through an opening in each of the mixers.
After the drug has been blended with the master batch pre-mix for a sufficient time to
provide a uniform matrix, a specific amount of the uniform matrix is then fed to the pan
through the second metering pump. The film is finally formed on the inert substrate and
carried away via the support roller ( figure 1.12). Thus the wet film is then dried using
controlled bottom drying, desirably in the absence of external air currents or heat on the
top (exposed) surface of the film [113].
Figure 1.12: Schematic overview of Rolling-print technology for the preparation of films
[55].
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1.1.7 In vitro dissolution testing of buccal thin films
Absorption of drugs in living organisms schematically depends on three steps [114]:
• release from the dosage form;
• dissolution or solubilization of the drug under physiological conditions;
• permeability across targeted tissues.
The purpose of in-vitro dissolution testing is to offer substantial information about steps
1 and 2, without resorting to test animals. Because of the critical nature of the first
two of these steps, in-vitro dissolution testing may be relevant to the prediction of in-
vivo performance. It concerns all solid pharmaceutical dosage forms. Most common
applications of dissolution testing are:
• assess the lot-to-lot quality of a drug product;
• guide development of new formulations;
• ensure continuing product quality and performance after certain changes,such as
changes in the formulation, the manufacturing process, the site of manufacture,
and the scale-up of the manufacturing process.
New drug applications (NDAs) submitted to the Food and Drug Administration (FDA)
contain bio availability data and in-vitro dissolution data, that, together with chemistry,
manufacturing, and controls (CMC) data, characterize the quality and performance of
the drug product. In-vitro specifications for generic products should be established based
on a dissolution profile. For new drug applications, as well as generic drug applications,
dissolution specifications should be based on acceptable clinical, bio availability, and/or
bio equivalence batches. Dissolution specifications are set depending on the class of the
active substance, with the aim of predicting the likelihood of achieving a successful in
vivo-in vitro correlation (IVIVC). FDA Bio pharmaceutics Classification System (BCS)
divides active substances in four classes high permeability-high solubility (1), low solu-
bility - high permeability (2), high solubility - low permeability (3), low solubility - low
permeability (4). This classification is focused on oral administration and it is derived
from a classical mathematical model of drug absorption through the bowels [115].
Considering the release time, drugs are classified as "immediate release" if 85 % of the
substance is released from the dosage form in 30-45 min. Slower dissolution corresponds
to modified release dosage forms, such as extended and delayed release [116]. The agencies
responsible of dissolution testing standardization are the national Pharmacopeias.
In the last thirty years, European Pharmacopeia, Japanese Pharmacopeia and US
Pharmacopeia have been working for a common harmonization of dissolution testing
procedures. Thanks to this, regulatory requirements have progressively reached a good
grade of agreement [117,118].
Buccal films have not been included yet in any standardization. At present all liter-
ature works have assumed traditional oral dissolution as a starting point [119].
Some words in the nomenclature of dissolution testing [120]:
• apparatus: the basic unit for the in-vitro performance testing of dosage units.
The apparatus consists of a container (vessel) for the dosage unit and dissolution
medium, a device for promoting motion of the dissolution medium (stirring ele-
ment), temperature control and support to hold the vessel and stirring element in
a fixed orientation. Typically, six to eight apparatuses are grouped in a dissolution
test assembly.
• stirring element: a paddle, rotating basket and shaft, or other device for pro-
moting the movement of dissolution medium relative to the dosage unit under test.
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• assembly: a combination of multiple apparatuses providing temperature control,
controlled unified motion of stirring elements, and providing the opportunity for
simultaneous or individual start of the apparatuses.
• dissolution system: test assembly connected to sampling and filter unit but with-
out instrumentation such as UV/VIS spectrophotometer or HPLC chromatograph.
Four different apparatuses are in use [121]:
• Basket apparatus (USP 1), figure 1.13;
• Paddle apparatus (USP 2), figure 1.14;
• Reciprocating Cylinder (USP 3), not accepted in the Japanese Pharmacopeia, figure
1.15;
• Flow through cell (USP 4), figure 1.16.
Figure 1.13: USP1-Basket apparatus.
Immediate-release, modified release and extended release tablets are usually tested in
dissolution baths, using USP 2 paddles. Floating capsules and tablets generally prefer
USP 1 baskets [122, 123]. Both USP 1 and UPS 2 apparatuses comprehend a stirred
vessel with nominal capacity from 1 to 4 liters. They differ only in the stirring element.
USP 2 is generally recommended as the first choice in dissolution apparatuses.
Despite of its universal diffusion, USP 2 have been deeply criticized [124]. Its hy-
drodynamic conditions have been judged highly unreliable and great part of the uncon-
trolled variability typical of the dissolution test have been ascribed to hydrodynamic
effects. Tests is conducted in a small agitated vessel operated at Reynolds numbers in
the transitional regime (2100< Re < 10000): under such conditions, flow behavior in
stirred-tanks is known to be both time-dependent and strongly heterogeneous. Con-
sequently, the hydrodynamics in the vicinity of a tablet would likely be both position
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Figure 1.14: USP2-Paddle apparatus.
Figure 1.15: USP3-Reciprocating cylinder.
and time-dependent. Fluctuations in the flow introduce variability in the evolution of
processes that are affected by hydrodynamics, such as shearing of the tablet surface,
de-agglomeration of particles, mass transfer from the solid to the liquid, suspension and
mixing of tablet fragments. Changes in the agitation speed can alter the measured dis-
solution rates and impact the ability to correlate in vitro dissolution tests with in vivo
performance [125,126].
In experimental and computational fluid dynamics studies, a low recirculation zone
was observed in the lower part of the hemispherical vessel bottom, where the tablet
dissolution process takes place. This region is the most critical, considering that the
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Figure 1.16: USP4-Flow through cell.
dissolving tablet will likely be at this location during the dissolution test. The exact
tablet location has a significant impact on the dissolution profile [127,128].
Drug release in USP 3 can be significatively affected by different agitation patterns
[129].
The flow-through cell(USP 4), also referred to as the column (-type) method and
USP 4 apparatus, was born of the need to overcome some of the limitations set by
existing compendial methods, particularly the USP 1 and USP 2 apparatuses. It is now
in widespread use. The flow-through cell offers definite advantages in regards to its
low volume hold-up, the ability to maintain sink conditions (particularly for sparingly
soluble drugs), and the ease of changing dissolution media (by analogy with physiological
changes along the gastro-intestinal tract). Flow-through is also called the "infinite sink"
condition. The flow-through cell is claimed to possess ideal hydrodynamic conditions for
mild agitation, homogeneity and mathematically definable solvent flow pattern. Different
types of cells are available for testing tablets, powders, suppositories, hard- and soft-
gelatin capsules, implants, semisolids, suppositories, and drug-eluting stents. For orally
administered solid dosage forms, two different cells are described: the large cell (22.6-mm
internal diameter) and the small cell (12-mm internal diameter) that provide approximate
volumes of 19 ml and 8 ml, respectively, for dissolution (cell volumes without glass beads).
Usually the bottom cone of the cell is filled with small glass beads (about 1-mm
diameter), and one bead (about 5-mm diameter) is positioned at the apex to prevent
material from descending into the inlet tubing. Different amounts of small glass beads
can be used according to the experimental setup. The sample can be placed upon a
holder, but also on or within the glass-bead bed. For dispersed systems (i.e., suspensions,
powders), mixing of the sample within the glass-bead bed has also been reported [130–
133].
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1.2 Hydrogels for topical drug delivery
Topical preparations are used for the localized effects at the site of their application by
virtue of drug penetration into the underlying layers of skin or mucous membranes. The
main advantage of topical delivery system is to bypass first pass metabolism. Avoidance
of the risks and inconveniences of intravenous therapy and of the varied conditions of
absorption, like pH changes, presence of enzymes, gastric emptying time are other ad-
vantage of topical preparations. Semi-solid formulation in all their diversity dominate
the system for topical delivery, but foams, spray, medicated powders, solution, and even
medicated adhesive systems are in use.
The topical drug delivery system is generally used where the others system of drug
administration fails or it is mainly used in pain management, contraception, and urinary
incontinence. Over the last decades the treatment of illness has been accomplished by
administrating drugs to human body via various routes namely oral, sublingual, rectal,
parental, topical, inhalation etc.
Topical drug delivery can be defined as the application of a drug containing formu-
lation to the skin to directly treat cutaneous disorders (e.g. acne) or the cutaneous
manifestations of a general disease (e.g. psoriasis) with the intent of confining the phar-
macological or other effect of the drug to the surface of the skin or within the skin. Topical
activities may or may not require intra-cutaneous penetration or deposition [134, 135].
Topical drug delivery systems include a large variety of pharmaceutical dosage form like
semisolids, liquid preparation, sprays and solid powders. Most widely used semisolid
preparation for topical drug delivery includes gels, creams and ointments [136].
The advantages of topical drug administration are [137]
• Avoids gastrointestinal (GI) drug absorption difficulties caused by GI pH, enzymatic
activity and drug interactions with food, drink, and other orally administered drugs.
• A substitute for other routes of administration (e.g. oral administration, intra-
venous injection) when that route is unsuitable, as with vomiting, swallowing prob-
lems, resistant children and diarrhoea.
• Patient acceptability is better as this drug delivery system is non-invasive, avoiding
the inconvenience of parenteral therapy.
• Avoids the first-pass effect, possibly avoiding the deactivation by digestive and liver
enzymes.
• Reduction of doses as compare to oral dosage forms.
• Ability to dissolve a wide range of medications with different chemical properties,
making combination therapy with one transdermal cream possible.
• Provides extended therapy with a single application, improving compliance.
• Drug therapy may be terminated rapidly by removal of the application from the
skin surface.
• Less greasy and can be easily removed from the skin.
On the other hand, the limitations of transdermal drug delivery (TDD) are functions of
skin physiology and drug bio-activity [141]. The excellent barrier properties of skin are
well known [138,139], and currently limit TDD to only the most potent drugs.
In terms of dosage, this criterion implies that drugs, the daily dose of which is 10-20
mg or less, are potential candidates for TDD.
There are, in addition, further constraints determined by the physicochemical prop-
erties of the drug. For a drug molecule to reach the cutaneous microvasculature, and,
hence, the systemic circulation, it must traverse both the lipophilic stratum corneum and
the much more hydrophilic viable epidermis [140]. Therefore, drugs with a reasonable
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Figure 1.17: Longitudinal section of skin.
partition coefficient and possessing solubility both in oil and in water are most ideal.
A highly lipophilic compound, for example, may readily enter and diffuse within the
stratum corneum but be unable to penetrate deeper into the skin. The other major
disadvantage of TDD is the potential elicitation of either allergic or irritant responses by
the drug or the adhesive of the device.
1.2.1 Anatomy of skin
The human body has two systems that protect it from the harmful organisms existing
in the environment. The internal defense system destroys microorganisms and bacteria
that have already attacked the body. The external defense system prevents microbial
microorganisms to enter the body. Skin is biggest external defense system. Skin covers
the outside of the body but has other functions beside the defense mechanism. It serves
as a mechanical barrier between the inner part of the body and the external world
[142]. Temperature of skin varies in a range of 30 ◦C to 40 ◦C degree depending on the
environmental conditions [143].
Skin is the largest organ in the body. It consists of three layers(figure 1.17). The
outer layer is called epidermis, the middle layer is dermis and the inner most layer is
hypodermis [147–149].
Epidermis
Consists of epithelial cells. Among these cells, both living cells and dead cells can be
found. These new cells at the bottom of epidermis divide fast and push the older cells
upward. The epidermis does not have any direct source of blood veins to provide nu-
trition. It takes its nutrients from the diffusion of necessary molecules from a rich vas-
cular network in the underlying dermis. Epidermal cells are connected very strongly by
desmosomes. Desmosomes are in contact with the intracellular keratin filmates. Keratin
filmates produce keratin. Keratin cells accumulate and crosslink with the other keratin
cells in the cytosol during their maturation. Afterward when the older cells die, this
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network of keratin fibroses remains and provides a tough and hard protective layer in
epidermis, called protective keratinized layer. This layer is waterproof and airtight. It
prevents most substances to enter the body or leave from the body. In diseased skin,
particularly burns, epidermis is destroyed causing potential loss of body fluid and an
increase in susceptibility to microbial infections, leading to fatal consequences untreated.
Cell types that exist in the epidermis are (figure 1.19):
• Keratinocytes; these are the main cell types in epidermis (95% of cells);
• Melanocytes; these are the pigment producer cells and found in the basal layers of
epidermis;
• Langerhans cells; these cells are important immunological cells and can be found
in the mid dermis as well Merkel cells; these cells are found in the basal layer of
epidermis and are one part of amine precursor and decarboxylation system [144,
145].
Epidermis consists of five layers, namely from inside to outside(figure 1.18):
• stratum germinativum (basal layer);
• stratum spinosum;
• stratum granulosum;
• stratum lucidum;
• stratum corneum.
Stratum corneum is the outer most layer of epidermis and has a thickness of 10-20 µm
when it is dry and 40 µm when it is hydrated and becomes swollen [145].
Stratum corneum has a structure of "bricks and mortar" arrangement. In this model
the keratin rich corneocytes (bricks) are sitting in the intracellular lipid rich matrix
(mortar) [145].
Corneocytes (the bricks) create 85 % of stratum corneum and intracellular lipids
(15%) are arranged in 15-20 layers. Stratum corneum consists of 70% proteins, 15%
lipids and only 15% water [146].
Molecules can basically permeate through skin by two different pathways(figure 1.20).The
first pathway is called the transappendegeal route. In this route the molecules should
permeate through skin by permeation through sweat glands and across the hair folli-
cles. The number of molecules which can penetrate through this pathway is very limited.
The second pathway of penetration through skin is the transepidermal pathway. In this
pathway molecules should pass through stratum corneum as multilayered barrier. This
pathway has two micro pathways: the intracellular micro pathway and the transcellular
micro pathway [145].
Dermis
Dermis is positioned under epidermis and is characterized by lots of elastin fibres that
provide the stretching ability as well as lots of collagen that provides the strength to the
skin. Blood vessels found in dermis provide nutrients for both dermis and epidermis.
Dermis also plays a major role in temperature regulation. Nerves present there are re-
sponsible for pressure and pain sensations. Dermis has a thickness of 3-5 mm. In addition
to elastin fibres, blood vessels and nerves, an interfibrillar gel of glycosaminoglycan, salt,
water, lymphatic cells and sweet glands are parts of dermis [145]. Cell types found in
dermis are:
• Fibroblasts: collagen producing cells;
• Macrophages: scavenger cells
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Figure 1.18: Epidermal and skin layer.
Figure 1.19: Layers of epidermis.
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Figure 1.20: Structure of stratum corneum and penetration pathways.
• Mast cells: responsible for immunological reactions and interactions with eosinophils
[144]
Dermis plays an important role as connection to other skin layers also. Changes in the
metabolism in dermis can influence growth integrity of the epidermis, hair follicles and
skin glands [143].
Hypodermis
Hypodermis is the inner layer of skin. It is the contact layer between skin and the
underlying tissues in body such as muscles and bone [137]. Sweat glands, sebaceous
glands and hair follicles enfold in epidermis but they stem from dermis. Sweat glands
release a dilute salt solution into the surface of skin. The evaporation of this solution
makes skin cool and this is important for temperature regulation of both body and
skin. Sweet glands are present all over the body. The amount of dilutions (sweet) that
gets produced depends on environmental temperature, the amount of heat generating
skeletal muscle activity and various emotional factors. The sebaceous glands produce
sebum. Sebum is an oily liquid released into hair follicles and from there onto the skin
surface. Sebum protects both hair and skin from drying out and provides waterproof
layer [142].
1.2.2 Formulation design of Hydrogels
To treat skin infection various hydrogels based formulations are prepare and apply top-
ically for local action. Hydrogels have been used to deliver active component. Instead
of conventional creams, the hydrogels have been formulated for better patient compli-
ance [150].
Gels that consist of an aqueous dispersion medium that is gelled with a suitable
hydrophilic gelling agent are known as hydrogels. Hydrogels are three-dimensional hy-
drophilic polymer networks, which have the ability to absorb large quantities of wa-
ter [154]. Hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC), Car-
bopol and sodium alginate have been previously investigated as gelling agents [155,156].
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Hydrogels can be formed via chemical or physical crosslinks, which provide a networked
structure and physical stability. These physical crosslinks include entanglements, crys-
tallites, Van der Waals interactions or hydrogen bonding. Hydrogels formed from phys-
ical crosslinks are known as "reversible" or "physical" hydrogels [153, 157]. In contrast,
hydrogels known as "chemical" or "permanent" gels are formed via covalently bonded
crosslinked networks [151,152].
Some of the topically applied preparations are shown in figure 1.21.Topically applied
gels are classified by two schemes [158]. The first scheme divides gels in two types of gel
systems. These are called as inorganic and organic gel systems. Most inorganic hydrogels
Figure 1.21: General classification of gel.
are two-phase systems, such as aluminum hydroxide gel and bentonite magma. Bentonite
has also been used as an ointment base in about 10% to 25% concentrations. Most
organic gels are single-phase systems and may include such gelling agents as carbomer
and tragacanth and those that contain an organic liquid, such as Plastibase.
The second classification scheme divides gels into hydrogels and organogels with some
additional sub categories. Hydrogels include ingredients that are soluble in water; they
include organic hydrogels, natural and synthetic gums, and inorganic hydrogels. Ex-
amples include hydrophilic colloids such as silica, bentonite, tragacanth, pectin, sodium
alginate, methylcellulose carboxymethyl cellulose sodium, and alumina, which in high
concentration form semisolid gels. Sodium alginate has been used to produce gels that
can be employed as ointment bases. In concentrations greater than 2.5% and in the
presence of soluble calcium salts, a firm gel, stable between pH 5 and 10, is formed.
Methylcellulose, hydroxy ethylcellulose, and sodium CMC are among the commercial
cellulose products used in ointments. They are available in various viscosity types, usually
high, medium, and low. Organogels include the hydrocarbons, animal and vegetable fats,
soap base greases, and the hydrophilic organogels.
Topical gel may include the following components:
• Gel forming agent or polymer;
• Drug Substance;
• Penetration Enhancers;
Gel forming agent or Polymer [159–170].Different classes of polymeric materials
have been used to achieve rate controlled drug delivery. The mechanism of drug release
depends upon the physicochemical properties of the drug and polymer. The following
criteria should be satisfied for a polymer to be used in a topical system:
• Molecular weight, chemical functionality of polymer must allow diffusion and release
of the specific drug.
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• The polymer should permit the incorporation of a large amount of drug.
• The polymer should not react, physically or chemically with the drug.
• The polymer should be easily manufactured and fabricated into the desired product
and inexpensive.
• The polymer must be stable and must not decompose in the presence of drug and
other excipients used in the formulation, at high humidity conditions, or at body
temperature.
• Polymers and its degradation products must be nontoxic. No single material may
have all these attributes, certain excipients may be incorporated to alter some
properties for example Co-solvents such as ethanol, propylene glycol, PEG 400
could be added to increase drug solubility.
Gel forming polymers are classified as below:
• Natural Polymers:
– Proteins-E.g. Collagen, Gelatin, Xanthin, Gellum Gum;
– Polysaccharides-E.g. Agar, Alginic acid, Sodium or potassium carrageenan,
Tragacanth, Pectin, Guar Gum, Cassia tora;
• Semi synthetic Polymers:
– Cellulose Derivatives-E.g. Carboxymethyl cellulose Methylcellulose, Hydrox-
ypropyl cellulose, Hydroxypropyl methylcellulose, Hydroxyethyl cellulose;
• Synthetic Polymers:
– Carbomer-E.g. Carbopol-940, Carbopol-934, Carbopol -941;
– Poloxamer;
– Polyacrylamide;
– Polyvinyl Alcohol;
– Polyethylene and its copolymers;
• Inorganic Substances-E.g. Aluminum Hydroxide bentonite;
• Surfactants-E.g. Cetosteryl alcohol, Brij-96;
Drug Substance [159–170].Drug Substance plays a very important role in the suc-
cessful development of a topical product. The important drug properties that effect its
diffusion through gels as well as through skin are as follows.
• Physicochemical properties:
– Drug should have a molecular weight of less than 500 Daltons.
– Drugs highly acidic or alkaline in solution are not suitable for topical delivery.
– Drug must have adequate lipophilicity.
– A saturated aqueous solution of the drug should have a pH value between 5
and 9.
• Biological properties:
– The drug should not be directly irritated to the skin.
– Drugs, which degrade in gastrointestinal tract or are inactivated by hepatic
first pass effect, are suitable for topical delivery.
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– Tolerance to the drug must not develop under the near zero order release
profile of topical delivery.
– The drug should not stimulate an immune reaction in the skin.
– Drugs which have to be administered for a long time or which cause adverse
effects to non-target tissue can also be formulated for topical delivery.
Penetration Enhancer [171–183].Penetration enhancers (also called accelerants or
sorption promoters) are defined as substances that are capable of promoting penetra-
tion of drugs into skin, or their permeation through skin, by reversible reducing the skin
barrier resistance. Percutaneous absorption involves the passage of the drug molecule
from the skin surface into the stratum corneum under the influence of a concentration
gradient and its subsequent diffusion through the stratum corneum and underlying epi-
dermis, through the dermis, and into the blood circulation. The skin behaves as a passive
barrier to the penetrant molecule. The stratum corneum provides the greatest resistance
to penetration, and it is the rate-limiting step in percutaneous absorption.
A penetration enhancer acts by altering the skin as a barrier to the flux of a de-
sired penetrant and are considered as an integral part of most topical formulations. To
achieve and maintain therapeutic concentration of drug in the blood, the resistance of
skin (stratum corneum) to diffusion of drugs has to be reduced in order to allow drug
molecules to cross skin and to maintain therapeutic levels in blood. They can modify the
skin’s barrier to penetration either by interacting with the formulation that applied or
with the skin itself. Ideally, these materials should be pharmacologically inert, nontoxic,
non-irritating, non-allergenic, and compatible with the drug and excipients, odorless,
tasteless, colorless, and in-expensive and have good solvent properties. The enhancer
should not lead to the loss of body fluids, electrolytes, and other endogenous materials,
and skin should immediately regain its barrier properties on its removal.
An ideal penetration enhancer should have the following properties:
• It should be pharmacologically and chemically inert, and chemically stable.
• It should be non-toxic, non-irritant, noncomedogenic and non-allergenic.
• It should have a rapid onset of action, predictable duration of activity, as well as a
reproducible and reversible effect.
• It should be chemically and physically compatible with the formulation ingredients.
• After it is removed from the skin, the stratum corneum should rapidly and fully
recover its normal barrier property.
• It should be odorless, tasteless, colorless, and inexpensive.
• It should be pharmaceutically and cosmetically acceptable.
• It should have a solubility parameter similar to that of skin.
In spite of the fact that a variety of compounds have been proposed as skin penetra-
tion enhancers, to date, no substance has been found to possess all the aforementioned
ideal properties. Nevertheless, many known and newly developed compounds have been
assessed for their enhancing abilities and some have shown more promising characteris-
tics.
Preparation methods of Hydrogels
Hydrogels are polymeric networks. This implies that crosslinks have to be present in
order to avoid dissolution of the hydrophilic polymer chain in aqueous solution. The
various methods for crosslinking are as follows:
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Crosslinking of Polymers.In this method chemically crosslinked gels are formed
by radical polymerization of low molecular weight monomers, or branched homopoly-
mers, or copolymers in the presence of crosslinking agent. This reaction is mostly carried
out in solution for biomedical applications.
Copolymerization/Crosslinking Reactions.Copolymerization reactions are used
to produce polymer gels, many hydrogels are produced in this fashion, for example poly
(hydroxyalkyl methylacrylates).
Crosslinking by High Energy Radiation.High energy radiation, such as gamma
and electron beam radiation can be used to polymerize unsaturated compounds. Water
soluble polymers derivatized with vinyl groups can be converted into hydrogels using
high energy radiation.
Crosslinking Using Enzymes.Recently a new method was published using an en-
zyme to synthesize PEGbased hydrogels. A tetrahydroxy PEG was functionalized with
addition of glutaminyl groups and networks were formed by addition of transglutami-
nase into solution of PEG and poly (lysinecophenylalanine). The synthesis of hydrogel
in industry is Consist of solution and reversed suspension and reversed emulsion poly-
merizations [184–187].
1.2.3 Hydrogels evaluation
Gels should possess the following properties:
• Ideally, the gelling agent for pharmaceutical or cosmetic use should be inert, safe,
and should not react with other formulation components;
• The gelling agent included in the preparation should produce a reasonable solid-
like nature during storage that can be easily broken when subjected to shear forces
generated by shaking the bottle, squeezing the tube, or during topical application;
• It should possess suitable anti-microbial activity against microbial attack;
• The topical gel should not be tacky;
• The gels intended for ophthalmic use should be sterile; [188,189]
Hydrogels are water swollen polymer matrices, with a tendency to imbibe water when
placed in aqueous environment. This ability to swell, under biological conditions, makes
it an ideal material for use in drug delivery and immobilization of proteins, peptides,
and other biological compounds. Due to their high water content, these gels resemble
natural living tissue more than any other type of synthetic biomaterial. These networks,
have a three dimensional structure, crosslinked together either physically (entanglements,
crystallites), or chemically (tie-points, junctions). This insoluble crosslinked structure
allows immobilization of active agents, biomolecules effectively, and allows for its release
in well-defined specific manner.
Thus the hydrogels biocompatibility and crosslinked structure are responsible for
its varied applications [196, 197].Due to their hydrophilicity, hydrogels can imbibe large
amounts of water. Therefore, the molecule release mechanisms from hydrogels are very
different from hydrophobic polymers. Both simple and sophisticated models have been
previously developed to predict the release of an active agent from a hydrogel device as a
function of time. These models are based on the rate limiting step for controlled release
and are therefore categorized as diffusion, swelling et chemically controlled mechanism.
Diffusion controlled.It is most widely applicable mechanism relating to drug re-
lease. Fick’s law of diffusion is commonly used in modeling this release. Types of
diffusion-controlled hydrogel delivery systems are as follows:
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• Reservoir system(Drug depot is surrounded by a polymeric hydrogel membrane.
Fick’s first law describes drug release through the membrane);
• Matrix system(Drug uniformly dispersed throughout the matrix, unsteady state
drug diffusion in a one dimensional slap-shaped matrix may be described using
Fick’s second law);
Drug diffusion coefficient is assumed to be of diffusion constant. Other assumptions
are sink condition and a thin planar geometry where the release through the edges is
neglected. Drug diffusion coefficient is a function of drug concentration except in very
dilute solutions.
Diffusivities of encapsulated molecules depend on the degree of swelling and cross
linking density of the gels for hydrogel devices. Diffusion coefficient used to describe
drug release is sensitive to environmental changes or degradation of the polymer network
and varies over the time scale of release [149,195].
Swelling controlled.It occurs when diffusion of drug is faster than hydrogel swelling.
In this condition the modeling of drug involves moving boundary, where molecules are
released at the interface of the rubbery and glassy phases of swollen hydrogels. Transition
occurs from a glassy state where entrapped molecules remain immobile to a rubbery state
where molecules rapidly diffuse. Release of small molecule drugs from HPMC hydrogel
tablets are based on this mechanism.
Chemically controlled.It characterizes molecule release based on reactions occur-
ring within a delivery matrix. Most commonly occurring reactions are:
• Cleavage of polymer chains via hydrolytic or enzymatic degradation;
• Reversible or irreversible reactions occurring between the polymer network and
releasable drug.
Diffusion mechanism is regulated by movement through the polymer matrix or by bulk
erosion of the hydrogel. Chemical stimulated gels swell in response to external cues like
pH and temperature or by enzymatic action15 and effectively open their pores for release
of the entrapped drug. This type of mechanism can be used for targeted drug release
only for diseased tissues. Drug release via diffusion is more common for localized and
non specific drug release whereas drug release by chemical stimulation have seen its more
application for oral drug delivery and can offer control for selective treatment [192,193].
Generally hydrogels are characterized for their morphology, swelling property,chemical
structure and elasticity. Morphological study gives us information about porous struc-
ture of hydrogels. Swelling determines the release mechanisms of the drug from the
swollen polymeric mass while elasticity affects the mechanical strength of the network
and determines the stability of these drug carriers [194]. Some of the important features
for characterization of hydrogels are as follows.
General properties of hydrogel [190,191]
The gel is a state that is neither completely liquid nor completely solid. These half
liquid-like and half solid-like properties cause many interesting relaxation behaviors that
are not found in either a pure solid or a pure liquid. From the point of view of their
mechanical properties, the hydrogels are characterized by an elastic modulus which ex-
hibits a pronounced plateau extending to times at least of the order of seconds, and by
a viscous modulus which is considerably smaller than the elastic modulus in the plateau
region.
Swelling. When a gelling agent is kept in contact with liquid that solvates it, then an
appreciable amount of liquid is taken up by the agent and the volume increases. This
process is referred to as swelling. This phenomenon occurs as the solvent penetrates
the matrix. Gel-gel interactions are replaced by gel solvent interactions. The degree of
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swelling depends on the number of linkages between individual molecules of gelling agent
and on the strength of these linkages.
Syneresis. Many gels often contract spontaneously on standing and exude some fluid
medium. This effect is known as syneresis. The degree to which syneresis occurs, in-
creases as the concentration of gelling agent decreases. The occurrence of syneresis
indicates that the original gel was thermodynamically unstable. The mechanism of con-
traction has been related to the relaxation of elastic stress developed during the setting
of the gels. As these stresses are relieved, the interstitial space available for the solvent
is reduced, forcing the liquid out.
Ageing. Colloidal systems usually exhibit slow spontaneous aggregation. This process
is referred to as ageing. In gels, ageing results in gradual formation of a denser network
of the gelling agent. In gels, ageing results in gradual formation of a denser network of
the gelling agent. This process is similar to the original gelling process and continues
after the initial gelation, since fluid medium is lost from the newly formed gel.
Structure. The rigidity of a gel arises from the presence of a network formed by the
interlinking of particles gelling agent. The nature of the particles and the type of force
that is responsible for the linkages, which determines the structure of the network and
the properties of gel. The individual particles of hydrophilic colloid may consist of either
spherical or an isometric aggregates of small molecules, or single macromolecules.
Rheology. Solutions of the gelling agents and dispersion of flocculated solid are pseudo
plastic i.e. exhibiting Non- Newtonian flow behaviour, characterized by a decrease in vis-
cosity with increase in shear rate. The tenuous structure of inorganic particles dispersed
in water is disrupted by n gels, ageing results in gradual formation of a denser network
of the gelling agent.
1.2.4 In vitro release from Hydrogels
In vitro methods:Overview [198–204]
The vast majority of mathematical estimates of percutaneous absorption use, as their
primary input, information on the rate of passage, or permeability, of a chemical across
the skin. This is usually the permeability coefficient, kp, or the more infrequently used
(in the context of model development) maximum steady-state flux, Jmax. In addition, a
number of the physicochemical descriptors also modelled are measured experimentally,
including measures of lipophilicity (commonly referred to as the octanol–water partition
coefficient, log P) and melting point.
It should be first commented that the vast majority of mathematical models for
percutaneous absorption used data from, and therefore most closely reflect, in vitro
laboratory experiments. These are physical experiments that use membranes, which are
either mammalian or synthetic in nature, across which the permeation of a chemical
is measured experimentally. Such experiments are widely carried out and are an area
of substantial interest across a range of industries. They have been used to measure
the percutaneous absorption of pharmaceuticals, materials in cosmetic formulations, for
toxicology studies and for estimation of risk assessment and occupational exposure of
materials used in a variety of industrial applications.
In vitro methods are commonly used prior to in vivo experiments and in some cases
(such as for the assessment of new chemical entities) are solely used to provide an indica-
tion of potential toxicity prior to any human exposure. Consequently, in vitro models are
widely and commonly employed to assess the risks and hazards associated with exposure
of human skin to exogenous chemicals. Classically, in vivo studies have been conducted
and provided valuable information on the mechanism of percutaneous absorption.
However, these studies were generally non-invasive in that they measured a response
in the skin, such as vasodilatation or skin blanching, rather than taking blood samples
or punch biopsies of the skin for subsequent analysis. Despite their advantages, such
methods are clearly limited in their applicability to other chemicals, particularly those
that do not result in a non-invasively measurable physiological change. In addition, the
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non-invasive monitoring of certain topically applied chemicals, such as cosmetic formula-
tions, may be measured in terms of efficacy by a range of biophysical methods, but such
methods generally (with the exception of, for example, patch testing) do not provide any
indication of cutaneous toxicity.
In vitro methods for the characterization of percutaneous absorption, while ultimately
delivering the same outcome, are many and varied in the details of their methods. Se-
lection of the diffusion membrane, type of cell (i.e. the use of either "static" or "flow-
through" cell designs, described below), nature of the experiment (e.g. duration, occlu-
sion) and the composition of the phases that sit either side of the diffusion membrane are
some of the key parameters that add to the diversity of acceptable experimental protocols
from which the data to construct mathematical models is abstracted.
Membrane selection [205–222]
The use of various animal skins is also a commonly accepted constituent of in vitro
percutaneous penetration studies. Skin from a wide range of species, including pigs,
rats, guinea pigs, monkeys and snakes, among others, has been suggested as a suitable
replacement for human skin. Generally, skin from the pig and the rat has found the
most widespread use, with the former in particular offering similar barriers to diffusion
for the penetration through human skin of a wide range of molecules. Rat or mouse
skin may be much more (up to 10 times) permeable than human skin, while pigskin has
been claimed to be a better surrogate. However, rodent skin is still widely used as an in
vitro membrane, possibly due to the use of such species more broadly in pharmacological
research. Several researchers have developed artificial skin equivalents, often known as
living skin equivalents (LSEs) in an attempt to address some of the issues associated with
using animal tissue in place of human skin (such as the lack of similarity in diffusional
characteristics or complexity compared to human skin, and the stratum corneum in
particular). LSEs have been used with some success in skin grafting and in the surgical
treatment of burns. Such materials aim to replicate the hydrophilic and hydrophobic
balance of human stratum corneum, as well as the manifestation of its barrier function
in, for example, the control of transepidermal water loss (TEWL) and control of bacterial
ingress to the deeper epidermal and dermal tissues.
Artificial membranes have been used when human or animal skin is difficult to obtain,
or where a large number of experiments are to be carried out, particularly with regard to
pre formulation screening experiments. The most widely used artificial membranes are
polydimethylsiloxane (PDMS) and cellulose acetate (porous dialysis tubing). However,
these membranes have often been shown to overestimate significantly the flux across skin
and their use is significantly limited. For example, Moss et al. (2006) compared the
permeability of a series of prodrugs across pigskin and PDMS membranes in vitro. They
demonstrated a reasonable relationship for hydrophilic molecules, whereas an increase
in hydrophobicity resulted in a significant difference in permeability, with the PDMS
showing significant overestimation of permeability compared to pigskin.
The use of human tissue is optimal for in vitro experiments. However, it is not without
its problems. Human skin is usually obtained from skin banks or from tissue donated
by the patient as a result of surgery-generally, this can range from cosmetic procedures
including face lifts, "tummy tucks" and breast reduction or from medical procedures
including amputations. The experimenter therefore has little control over the handling
and quality of the skin obtained. For example, surgical procedures and protocols used
to remove skin may include the use of alcohol-based disinfectants; while this is clearly
essential for the surgical procedure and is a central part of infection control policies, it
may affect the permeability in subsequent experiments as the alcohol has the potential
to remove stratum corneum lipids and potentially affect its barrier properties. Further,
the skin may be frozen and stored prior to dispatch and use in experiments, and this
may result in damage to, or degradation of, the membrane.
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Selection of the diffusion cell apparatus [223–227]
Fundamentally, the aim of an in vitro percutaneous absorption study is to determine
the amount of permeant that passes into and across the skin. This involves the use
of a diffusion chamber in which the membrane (normally human or animal skin, or an
artificial membrane) separates the two compartments-the donor compartment is where
the formulation containing the permeant of interest is introduced at the start of the
experiment; and the receptor compartment is the chamber into which the permeant of
interest may diffuse, following passage into and across the membrane.
In addition to measuring the amount, and rate, of permeant that passes across the
membrane and into the receptor phase, the experiment also presents the experimenter
with the opportunity to determine how much of the material of interest has passed into
the skin and has remained there at the end of the experiment. This is usually achieved
by using adhesive tape to remove the stratum corneum and by digesting the remaining
tissue using acid/solvent mixtures. These samples can then be prepared for quantitative
analysis.
Thus, the experiment is essentially a passive diffusion process that is governed by
the diffusion gradient across the membrane as well as the experimental protocol and the
physicochemical properties of the permeant. Despite various designs, some more complex
than others (figure 1.22), the fundamentals of the process are very similar-passage of the
permeant of interest from the donor chamber to the receptor chamber while maintaining
a viable diffusion gradient and avoiding equilibrium between both compartments. The
receptor compartment normally has a sampling port-usually a sidearm-which is occluded
during the experiment to stop evaporative loss and from which aliquots of the receptor
media may be removed (and replaced with fresh receptor fluid) for analysis.
There are two main types of diffusion cells: static and flow-through cells. The vast
majority of in vitro percutaneous absorption experiments are conducted using upright
static glass diffusion cells, known as Franz or Franz-type cells. These involve the par-
tition of the permeant into a “static” receptor compartment of a fixed volume that is
maintained at a controlled temperature and is continually stirred throughout the ex-
periment to ensure complete mixing and to avoid the presence of any "dead" zones or
diffusion gradients within the receptor compartment.
Franz-type diffusion cells are found in a range of designs and sizes (figure 1.22) and
are therefore very flexible, with particular cells being chosen for particular purposes (e.g.
when a different surface area might be required, or when the receptor compartment
may need to be varied based on the solubility of a particular permeant). The simple
design of the upright cells allows a wide range of formulations to be applied to the skin
surface, including solutions, creams, ointments and various other semi-solid materials of
a pharmaceutical or cosmetic nature. A variation on the Franz-type cells is the side-by-
side cell, which allows both compartments to be stirred at the same time, although the
range of formulations suitable for use in such cells is clearly limited. One of the main
perceived limitations of the Franz-type cells is their susceptibility to "sink conditions".
As described above, the diffusion process requires a gradient to be established, and
maintained, across the membrane that divides the donor and receptor compartments.
Thus, in a static diffusion cell, it is important to maintain a concentration gradient such
that, normally, the concentration of the permeant of interest is not greater than 10 % of
its saturated solution in the receptor compartment.
Flow-through diffusion cells, often called "Bronaugh cells", offer an alternative ap-
proach to the issue of sink conditions and attempt to mimic in vivo conditions by utilizing
a constantly perfusing receptor compartment, flowing usually at 1–2 ml/h, which aims
to mimic the blood flow beneath the skin. This is normally achieved with the use of a
peristaltic pump which is connected to tubing that supplies a compartment beneath the
membrane. The receptor fluid flows into a receptacle and is analysed, either offline or,
more infrequently, via an online flow-through method of analysis. Either arrangement
provides the facility for substantial automation of sample collection. This arrangement
ensures that sink conditions are maintained throughout the experiment and that the
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Figure 1.22: Examples of commonly used diffusion cells.
receptor phase does not have to be replaced should a penetrant be rapidly absorbed.
While flow-through cells are more flexible (i.e. in terms of automation), they are
more complex and substantially more expensive than Franz cells. Consequently, the use
of Franz-type static diffusion cells is more common than the use of flow-through cells.
In either case, most experiments use between 6 and 24 cells per experiment in order to
ensure reproducibility. As mentioned above, the cell design can influence the formulation
type that can be applied to it. For example, the side-by-side cells, while having the
advantage of even stirring and mixing in both donor and receptor compartments, are
limited in the type of formulation that can be applied—pharmaceutical dosage forms
such as creams, gels, ointments and patches are very difficult to apply in this manner.
Thus, the cell design and the protocol used can all affect the outcome-the measure-
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ment of percutaneous absorption and the cell design should be considered when consid-
ering the uniformity of data that are to be used in the construction of mathematical
models of skin absorption.
1.3 Oral thin films and Hydrogels in this work
The next chapters of this paper will cover the description and study of releases from thin
films and hydrogels, as well as the characterization of pharmaceutical formulations for
potential use in drug delivery.
Chapter 3 will cover the release from hydrogel (Scleroglucan-CM as a polymer matrix)
of three types of drugs belonging to 3 different classes: Fluconazole, Diclofenac and
Betamethasone.
Chapter 4 will investigate the release from thin films (Gellan gum as a polymer
matrix), while in chapter 6 will be presented film GG:Glycerol and the technique for
preventing crystallization. In both cases, fluconazole is used as a model drug.
Chapter 5 illustrates the work done at the Pharma Lux Lab in Oslo, where HPMC5
films were analyzed using furosemide as a model drug.
Mathematical models have been developed to understand and analyze the data achieved
from the release profiles. Drug diffusion values were estimated in both hydrogels and thin
films.
1.3.1 Gellan gum, HPMC, Scleroglucan
It’s necessary to spend some words about the polymer used in this work:
• Gellan gum, for the production of swellable thin films;
• HPMC for the realization of erodible-fast dissolving thin films;
• Scleroglucan to make a biocompatible physical hydrogel.
Gellan gum
Gellan gum is an anionic polysaccharide hydrogel-forming polymer produced from the
bacteria Sphingomonas elodea [239]. Structurally, it comprises a tetrasaccharide repeat
unit of two β -D-glucoses, one β -D-glucuronate, and one α -L-rhamnose [228] (figure
1.23).
Figure 1.23: The structure of native (A) and low acyl (B) form of gellan gum.
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Gellan gum is available commercially under the trade names Gelriter and Kelcogelr
in ’high acyl’ and ’low acyl’ forms with the high acyl form being the native state [229].Na-
tive form of gellan contains two types of acyl substituents, namely L-glyceryl and acetyl
[240]. The low acyl gellan gum is prepared via alkali treatment of the native gellan gum
and is distinctively different in its gelation behaviour and mechanical properties [230].
The high acyl gellan gum will form a gel upon cooling from 65 ◦C creating a flexible, soft
hydrogel while low acyl gellan gum will form a gel upon cooling below 40 ◦C creating a
rigid and brittle hydrogel [231].
In recent years, low acyl gellan gum has become an attractive biopolymer for ap-
plications in tissue engineering as a cellular scaffold because it resembles the natural
extracellular matrix (ECM) and is bio-inert [232,233].
Gellan gum has also been used as an injectable and printable matrix for cellular
therapies and 3D tissue scaffold fabrication [234, 235]. There is therefore potential for
gellan gum based materials to be used for computer aided tissue engineering [229,236].
Gellan gum, like many anionic polysaccharides forms a physical gel by undergoing a
random coil to double helix transition upon cooling. Stronger gels are formed if cations
are present during the sol-gel transition. In this case, divalent cations form particularly
strong gels through the aggregation of helixes and monovalent cations form intermediate
strength hydrogels through electrostatic interactions with carboxylate groups [228]. The
presence of divalent cations also inhibits the ability of the un-hydrated gellan gum to
become hydrated [237]. In the food industry, it is common practice to add calcium
sequestrants (citrates and phosphates) to water to improve the ability of low acyl gellan
gum to be hydrated [238].
The presence of cations in commercially provided gellan gum is ordinarily minimal
and may not impede their use in food and pharmaceutical applications. However, very
small amounts of calcium present in commercial gellan gums may still affect the more
sophisticated chemistries used to modify gellan gum for tissue engineering applications
[229]. Calcium may also affect the gel transition temperature so significantly that it
precludes it from being utilised in rapid prototyping technology.
A method for the rapid purification of gellan gum was established two decades ago
which employed an ion-exchange resin to capture the cations present in commercial gellan
gum. They reported that after purifying the gellan gum of divalent cations, the acid form
gellan gum could be converted to a monovalent salt using a corresponding hydroxide salt.
Sodium or potassium gellanate salts were able to be hydrated at much lower temperatures
and formed gels of comparable strengths to un-purified gellan gum hydrogels. [230,237]
HPMC
Hydroxypropyl Methylcellulose (HPMC) is probably the most widespread employed poly-
mer for drug release. Hydroxypropyl methylcellulose is a semi-synthetic material derived
from cellulose. It is a linear polymer comprised of etherified anhydroglucose rings (figure
1.24). Its polymeric backbone is made of cellulose, a natural carbohydrate that con-
tains a basic repeating structure of anhydroglucose units. In the industrial production
of HPMC, cellulose fibers are heated with a caustic solution which in turn is treated
with methyl chloride and propylene oxide to obtain hydroxypropyl substitution on the
anhydroglucose units. The amount of substituent groups on the anhydroglucose units of
cellulose can be designated by the weight percent or by the average number of substituent
groups attached to the ring, a concept known as "degree of substitution"(D.S.).
Like all polymers, HPMC macromolecules exist as a distribution and may be char-
acterized by parameters such as the number average molecular weight (Mn), the weight
average molecular weight (Mw), and the polydispersity (Mw/Mn). These molecular
weight moments may be determined by a number of techniques, such as osmometry,
light scattering, or size exclusion chromatography.
The chemical modification to obtain HPMC is generally conducted under heteroge-
neous conditions and the substituents within a specific glucose unit, as well as along
the cellulose backbone, can be introduced within a large variation. This lack of control
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Figure 1.24: Structural formula of HPMC.
over the chemical composition within and between commercial HPMC batches results
in chemically inhomogeneous materials. This is undesired, and this heterogeneity some-
times affects the functionality of HPMC in pharmaceutical applications. A selection of a
proper grade has not always proven to give predictable release rates from hydrophilic ma-
trix tablets and batch-to-batch variations are frequently seen. Because of this variability,
a recent study shows the molecular sizes of the polymer chains cannot alone predict the
release and swelling, and it does not matter whether the polymer sizes are described in
terms of chain lengths (molecular weights), resistance against shear forces (viscosities)
or sizes of the polymer coils (intrinsic viscosity or radius of gyration).
The average values of parameters describing the hydrophilic/hydrophobic characters
such as the degree of substitution or cloud points can be related to the water transport
through the gel layer into the hydrophilic matrix and thus also to the macroscopic degree
of swelling [241,242].
Investigation of hydrophilic polymers, in particular cellulose derivatives, has attracted
considerable attention for the development of controlled release technology in the formu-
lation of pharmaceutical matrix products. Matrix tablets swell on contact with water,
and the release of a drug depends on interactions between water, polymer and drug. In
the field of controlled release, the influence of carriers on drug dissolution kinetics, which
are the result of differently acting mechanisms, was investigated frequently. Usually, two
main mechanisms are studied: diffusion and erosion.
In the case of cellulose ether based matrix tablets, drug release can be described as
being controlled by the rate of swelling. However, drug release in general is not purely
swelling controlled, since it occurs mostly as the result of a combination of polymer
relaxation and Fickian diffusion. Previous studies of matrix tablets led to the conclusion
that the rate and extension of drug release depend on the type of polymer, its viscosity
grade, hydration and polymer proportion in the formulation [243]. The extent and rate
of matrix swelling depends in turn on the viscosity grade of HPMC and the agitation
rate of the dissolving medium [244,245].
Moreover, swelling shows to be pH-dependent [246]. Erosion shows a cubic depen-
dence on time and, contrary to trep theories, no lag time was observed [247]. Interesting
results on swelling and erosion can be obtained using a simple optical method [248].
A new and very promising approach for a deeper characterization of HPMC compacts
behaviour is presented in [247] and involves UV-imaging in a buffer solution.
A statistical approach -QRS (Quantitative-Structure Property Relationship) tech-
nique identifies the aqueous solubility of drug (dipole moment), the size of the drug
molecule and the matrix erosion rate as the most significant parameters for drug re-
lease [249].
Scleroglucan
Scleroglucan (Scl) is an example of a natural polysaccharide produced by the fungi of the
genus Sclerotium [250], which possesses several structural properties particularly useful
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for the design of physical hydrogels for topical applications. Specifically, the polymer
consists of a main backbone of (1-3)-linked-β-D-glucopyranosyl residues with a single
(1-6)-linked-β-D-glucopyranosyl unit linked in side chain every third sugar molecule of
the main chain. In aqueous solutions, Scl reassembles in a triple helix conformation that
can only be broken into random coil chains at pH 12 or in dimethylsulfoxide(DMSO)
[251,252]. Scl finds application in the industrial and pharmaceutical field as a thickening
agent and for the preparation of modified release dosage forms for oral and topical delivery
[253–255].
In addition, Scl can be easily modified with pH-responsive groups, which have a
profound effect on the main characteristics of the polymer [256, 257]. For example, a
carboxymethyl derivative of Scleroglucan (Scl-CM, figure 1.25) is obtained by reaction
with chloroaceticacid in a basic medium, and the number of carboxylic groups introduced
has a significant influence on the corresponding gel properties. Specifically, a Scl-CM
Figure 1.25: Scheme of Scl-CM synthesis.
derivative with a high degree offunctionalization is capable of forming physical hydrogels
without the addition of any salt. These physical gels have been already proposed as
carriers for the oral administration of anti-inflammatory drugs proving to adequately
protect the gastrointestinal mucosa from any drug-induced damage while modulating
the release rate of the loaded molecules [258].
The peculiar physico-chemical properties of Scl suggested its suitability as a slow
release matrix; tablets prepared with the polymer show a remarkable swelling process,
that can slow down the diffusion of molecules previously loaded in the system [259].
1.3.2 Cyclodextrins(CD)
Cyclodextrins (CD), or cycloglucans, first discovered by A. Villiers in 1891 and also called
"cellulosines" are cyclic oligosaccharides consisting of α-D-glucopyranose monomer units
joined by α-1,4-glucosidic bond. Cyclodextrins originate from the hydrolysis degrada-
tion of potato or corn starch by cyclodextrin-glycosyl-transferase, an amylase secreted by
numerous microorganisms such as Bacillus macerans. The reaction of enzymatic degra-
dation produces a mixture containing three types of natural CD classified according to
the number of monomeric units of α-D-glucopyranosion in α-CD (6 units), β-CD (7 units)
and γ-CD (8 units) (figure 1.26).
Due to the "chair" configuration of α-D-glucopyranose units, the CDs have a trun-
cated cone shape [260]. The primary hydroxyl functions on the C-6 of the saccharides
units are oriented towards the narrowest side of the cavity and are the most reactive,
nucleophilic, and most easily accessible for poor steric impediment. They are also more
"mobile" than the -OH secondary ones, giving the cavity flexibility so that it can ac-
commodate hydrophobic molecules. The secondary hydroxyl functions are located on
the wider side of the cavity. In particular, the -OH group present on the C-2 is more
acidic and reactive than the C-3 hydroxyl, which is also less accessible within the cavity.
In solution, the hydroxyl groups establish hydrogen bonds with the surrounding water
molecules forming a hydration sphere that envelops the cyclodextrin [261].
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Figure 1.26: α-CD, β-CD and γ-CD.
The carbonaceous skeleton and the ethereal oxygen molecules of the glucose residues
form the central cavity and give it a relatively lipophilic character with a polarity that
has been estimated to be similar to that of an aqueous ethanol solution (figure 1.27).
The dual nature, inside lipophilic and hydrophilic on the outer surface, shape and
structure give the cyclodextrine solution the unique ability to trap inside a host molecule
forming an inclusion complex. The dynamic complexation equilibrium that regulates this
process does not involve the formation and / or break of covalent bonds. The displace-
ment of the water molecules from the apolar cavity of the cyclodextrin, an increase in the
number of hydrogen bonds due to the return in solution of the water molecules from the
cavity, a reduction in the repulsive interactions between the hydrophobic host and the
aqueous environment and an increase in hydrophobic interactions due to the insertion of
the host molecule into the cavity are driving forces that move the equilibrium towards
the formation of the inclusion complex (figure 1.28).
Of course, the possibility of forming a stable complex is inevitably related to the size
of the cyclodextrin and to the chemical-structural characteristics of the host molecule.
This must have adequate molecular weight and steric size, be sufficiently lipophilic and
possess good conformational freedom to allow it to settle inside the cavity in such a way
as to maximize interactions.
Pharmaceutical application of cyclodextrine
The ability of cyclodextrine to form inclusion complexes makes them particularly promis-
ing in the pharmaceutical technology. In particular, in the case of lipophilic or poorly
soluble drugs, the formation of a complex allows for an increase in the apparent solubility
of the drug itself [262]. In this way, it is both possible to bring into solution drugs that
are poorly soluble, allowing for parenteral administration, and also to obtain an increase
in dissolution rate as predicted by the Noyes-Whitney equation (equation (1.2) ):
dq
dt
= kSs(Cs − C) (1.2)
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Figure 1.27: Structure of cyclodextrin.
Figure 1.28: Complexation equilibrium.
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where q is the amount of solid released in time t, k is the proportionality coefficient, Ss is
the specific surface area of dissolved particles, Cs is the max concentration of saturation
(solubility of the drug),C is the drug concentration in biological fluid (between 0 and
Cs). Another benefit of using CD in the pharmaceutical field is related to increased drug
stability. Cyclodextrin provides greater protection to oxidative degradation reactions,
hydrolysis and thermal degradation by increasing its stability.
Finally, thanks to the formation of inclusion complexes with cyclodextrin, it is possible
to produce modified release formulations: is the complexity constant and related factors
that regulate the dynamic equilibrium between free drug and complex drug, defining the
kinetics release of the active ingredient.
In general, the use of CDs in the pharmaceutical field allows to obtain:
• an increase in drug solubility;
• an increase in the rate of dissolution;
• an increase in the bioavailability of the drug;
• a reduction in side effects;
• an increase in the stability of the pharmaceutical formulation;
• elimination of incompatibility: in multicomponent pharmaceutical forms
• masking odors and unpleasant flavors.
Hp-β-CD
Natural cyclodextrine, particularly β-CD, have limited solubility in water (18.5 mg /
ml) due to the numerous molecular hydrogen bonds present in the crystalline state and
do not have great versatility. In order to overcome these problems, which make these
cyclodextrine poorly usable in the pharmaceutical field, their derivatives have been pre-
pared and characterized. Among these, a particularly interesting is the (2-hydroxypropyl)
-β-cyclodextrin (HP-β-CD), a semi synthetic derivative of β-CD obtained by reaction of
the latter with propylene oxide and subsequent replacement of the hydroxyl group with
a hydroxypropyl chain (figure 1.29) [263]. There are many reasons why HP-β-CDs are
beneficial:
- High solubility in water: HP-β-CDs have good solubility in water at 25 ◦C;
- ease of complexation: with HP-β- CDs is possible the formation of an inclusion
complex for simple addition of the drug to an HP-β-CD aqueous solution and subsequent
agitation of the system;
- reduced toxicity: HP-β-CDs are not toxic if administered low and moderate doses.
Due to its high solubility, HP-β-CDs are not nephrotoxic and can be administered either
oral or parenterally.
Within the OTF, the introduction of HP-β-CD allows to increase the stability and
solubility of the active principle present in the formulation and, at the same time, to
obtain a modified release of the drug.
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Figure 1.29: Structure of HP-β-CD.
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Aim of the work
The aim of this work is to develop innovative pharmaceutical formulations in the form
of hydrogels and thin films that can improve existing solutions in the field of topical and
oral drug delivery.
The main objectives can be summarized as follows:
• to realize innovative pharmaceutical formulations with biocompatible polymers;
• to optimize concentrations and proportions of the various components to obtain
the best performances in terms of mechanical properties, workability, controlled or
modulated drug release;
• to prepare versatile pharmaceutical formulations for fast or sustained release of
drugs belonging to different pharmaceutical classes;
• to choose the dissolution apparatus most suitable for topical or buccal in-vitro
release experiment in order to reproduce release conditions as close as possible to
real/physiological ones;
• to critically evaluate already existing and commonly used apparatuses and to test
new or recently proposed ones.
• to develop mathematical models to properly describe the physics of release experi-
ments with the aim to:
– estimate the physical parameters (such as diffusivity values of the drug and
-or solvent within the polymeric matrix), which are essential for a proper
formulation design and development;
– predict the release time scales when changing the operating conditions or
changing from in-vitro to ex-vivo experiments.
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Chapter 3
Scleroglucan based hydrogel for
topical drug delivery
3.1 Introduction
Topical formulations are a valid strategy to treat common disorders, including acute and
chronic inflammations, skin infections and acute pain [265].The use of the skin as a portal
of entry for drugs is particularly attractive since it can overcome the challenges associ-
ated with other administration routes [266]. However, beside its great accessibility, the
skin possesses highly efficient barrier properties, which frequently hamper drug delivery
through it. In this context, hydrogels represent a primary solution to design innovative
topical formulations [267]. In fact, their soft consistency combined with their ability to
swell, make them the perfect candidate for topical applications. Moreover, they possess
a pleasant texture, which does not create any greasy residue on the skin compared to
creams and ointments [268].
Hydrogels properties can be modulated by varying the type of polymer and the
crosslinking step during their fabrication. Chemical or physical bonds can hold the poly-
meric matrix together, and its swelling behavior can be tuned by introducing pH-sensitive
functional groups [269].
For all these reasons, hydrogels offer a versatile platform as carriers of a variety
of drugs for topical delivery. This concept particularly holds true for physical hydro-
gels made of bio compatible polysaccharides where the presence of hydrogen bonds,
iondipole,and electrostatic interactions are the driving forces responsible for the hydro-
gel formation. The same interactions can influence the hydrogel strength and elasticity
as well as the release behavior of the loaded drugs from the hydrophilic matrix.
Among polysaccharides, scleroglucan (Scl) has been proposed for the preparation of
effective modified drug delivery systems. Scl is a water-soluble extra-cellular polysaccha-
ride produced by fungi of the genus Sclerotium.
The carboxymethyl derivative (Scl-CM) of scleroglucan is able to form physical hy-
drogels with divalent ions, such as Ca+2.The release rate of the drug critically depended
on the concentration of the salt and the molar ratio carboxylated repetitive units of the
polymer/Ca+2.
To further extend the potentiality of high carboxymethylated Scl-based hydrogels in
the pharmaceutical field, their use as a topical formulation for a variety of drugs including
anti fungal,steroidal and non-steroidal anti-inflammatory molecules, was here attempted.
Specifically, three different therapeutic drugs, namely diclofenac, betamethasone, and
fluconazole, were tested in this work. Flow curves and frequency sweep tests were carried
out on the loaded Scl − CM300 hydrogels along with release studies in a vertical Franz
cell.Particular attention was paid to possible interactions between the hydrogel matrix
and the loaded drugs, and how their presence could influence both the rheological and
release properties of the corresponding physical hydrogels.
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Mathematical models, describing transport and possible interactions between the se-
lected drugs and Scl−CM300 , were adopted to estimate the effective diffusion coefficient
of these molecules in the polymeric network. Numerical solutions were obtained by COM-
SOL 3.5 multiphysics.
Finally, preliminary in-vivo experiments were carried out on rabbits to verify the skin
tolerability of the Scl − CM300-based formulations.
3.2 Materials and methods
3.2.1 Chemicals
All used reagents were of analytical grade. Scleroglucan with Mw= 1.4 · 106, as evalu-
ated by viscosimetric measurements in 0.01 M NaOH, was provided by Carbomer (USA).
Dimethylsulfoxide (DMSO) and chloroacetic acid were purchased from Fluka(Switzerland).
Diclofenac sodium salt, DOWEX 50WX4-50 ion exchange resin, acetonitrile, and methanol
were purchased fromSigma-Aldrich (England). Betamethasone phosphate sodium salt
and fluconazole were received as gifts from Sigma-Tau (Italy) and Recordati S.p.A.
(Italy), respectively. Dialysis membranes with cut-off 12,000-14,000 Da were purchased
from Medicell International(UK).
3.2.2 Synthesis of carboxymethyl scleroglucan (Scl − CM300)
Scleroglucan was modified into its carboxymethyl derivative(Scl − CM300) following a
reported procedure [258].Scleroglucan (1.0 g) was dissolved in water (40 ml) at 60 ◦C
for 24 h. NaOH (28.0 g) was then added to the polymeric solution in an ice bath to
disrupt the triple helix. Finally, chloroacetic acid (40.0 g) was added drop wise to start
the reaction. The polymeric mixture was kept under stirring at 60 ◦C for 24 h followed
by neutralization with glacial acetic acid.The obtained Scl − CM300 was purified by
exhaustive dialysis (cellophane membrane, Visking tubing, cut-off 12,000-14,000 Da) to
remove the excess of salts and unreacted products. The dialyzed solution was eluted
through a DOWEX 50WX4-50 ion-exchange resin column previously treated with 2.0 M
HCl, to obtain all the carboxylic groups in the undissociated form.
The number of carboxylic groups added to the backbone of the polymer was quantified
by potentiometer titration. Fully protonated Scl−CM300(100 mg) was dissolved in water
and submitted to potentiometer titration using 1 · 10−2M NaOH. The amount of acid in
mmol (equal to the mmol of NaOH used) was inserted in the following equation:
Scl−CMamount(mg) = X ·MWrepetitive−unit+(mmol−of−acid)MWacid−group (3.1)
allowing the calculation of X which represents the mmoles of repetitive units of the
polymer. The ratio between the mmol of acid and the mmol of the repetitive units of the
polymer multiplied by 100 is necessary to obtain the degree of derivatization(DD). This
value represents the number of carboxylic groups per 100 repetitive units. A derivative
having a DD equal to 300 ± 10 was obtained (labeled as Scl − CM300) and used for all
the studies.The freeze-dried polymer was mixed with KBr and characterized by FT-IR
spectroscopy in the range of 4000–650 cm−1(resolution of 1 cm−1), using a FT-IR Perkin
Elmer Paragon 1000 spectrophotometer.
3.2.3 Hydrogel preparation
Solutions of Scl − CM300(2.0% w/v) were prepared by solubilizing Scl − CM300 (0.1
g) in 5 ml of distilled water. The mixtures were kept under stirring at 60 ◦C for 30
minutes to allow a complete solubilization of the polymer. The polymeric solutions were
then left to cool down at room temperature (20 ◦C), to obtain the formation of the
corresponding physical hydrogels.Hydrogels loaded with drugs were prepared following
the same procedure described above. Specifically, fluconazole, diclofenac sodium salt,
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and betamethasone phosphate sodium salt were selected as model molecules for the
preparation of the medicated physical hydrogels of Scl − CM300. Each drug was mixed
with the polymeric solution before the gel formation at 60 ◦C in the range of concentration
from 0.1 up to 0.5% w/v.
3.2.4 Rheological characterization
Rheological experiments were carried out with a Haake RheoStress 300 Rotational Rheome-
ter (Germany) equipped witha Haake DC10 thermostat. Flow curves were recorded with
a share stress in the range of 0.01–100 Pa at 37 ◦C ± 0,01 ◦C. Physical hydrogels of
Scl − CM300 (2% w/v) with and without drugs were placed on a cone-plate geometry
(angle of 1◦) in order to completely cover the surface. In addition, frequency sweep tests
were carried out on the same samples in the range of 0.01 up to 10 Hz. Mechanical
spectra were recorded within the linear viscoelastic region measuring hydrogels response
at a strain amplitude of 1%.
3.2.5 Release studies with Franz diffusion cell
Release studies were carried out from hydrogels loaded with fluconazole, diclofenac
sodium salt and betamethasone phosphate sodium salt (0.25% w/v) using a vertical
Franz cell [270]. The cylindrical donor chamber (cross-section area 0.5 cm2) was loaded
with a weighted amount (100 mg) of the drug-carrying hydrogel, gel thickness Lg= 2
mm.The donor chamber was separated by the receptor one with a dialysis membrane
(cellophane membrane, Visking tubing, cut-off 12,000-14,000 Da) having an area of 0.5
cm2and thickness Lm= 48 µm.
The receptor chamber was filled with 4.1 ml of phosphate buffer pH 7.4 under con-
stant stirring (50 rpm). pH 7.4 was chosen for this study because of the dependence
of diclofenac solubility from pH ( [271]). At pH 7.4 we have the maximum solubility
of diclofenac, therefore even if back-diffusion of the release medium towards the donor
compartment occurred during the study, no drug precipitation is expected within the
gel.
Release experiments were carried out keeping the diffusion cell in a water bath at
37 ◦C ± 0,01 ◦C for 24 h. Aliquots of 250 µl were withdrawn at fixed time intervals
and replaced with equal volumes of fresh buffer.The release rate of diclofenac from Scl−
CM300-based hydrogels was also studied at room temperature (20 ◦C) following the same
experimental set-up.In addition, diffusion profiles of 0.25% w/v aqueous solutions of the
three investigated drugs (0.1 ml, solvent thickness in the donor chamber Ls= Lg= 2 mm)
were used as blanks.Diffusion profiles of 0.25% w/v aqueous solutions of theophylline were
also used as blanks to investigate the dependence of the drug diffusion coefficient in the
dialysis membrane on the drug molecular weight.
All the drugs were quantified by HPLC analysis carried out with a Perkin-Elmer
apparatus equipped with a Perkin Elmer Series 200LC pump and a series 235 Diode
Array Detector, using a Merck Hibar LiChrocart (250-4, 5 µm) RP-18 column. The
three drugs were determined according to already reported analytical methods, with
some modifications. Diclofenac was analyzed using a mixture consisting of methanol and
0.01 M phosphoric acid (80:20, v:v), as the mobile phase, with a flow rate 0.7 ml/min
and measuring the drug at 215 nm ( [258]). Fluconazole was analyzed using a mobile
phase consisting of methanol, water and acetic acid(50:48:2, v:v:v), with a flow rate of
0.9 ml/min and monitoring the drug at 260 nm ( [272]). Betamethasone was instead
detected using a mobile phase made of methanol and 0.01 M phos-phoric acid (60:40,
v:v), with a flow rate 0.8 ml/min and detecting the drug at 215 nm ( [273]).
All the experiments were repeated in triplicate, and the results reported as mean
value ± standard deviation.
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3.2.6 Mathematical models of permeation experiments in a ver-
tical Franz cell
We present the time-dependent one-dimensional Fickian and non-Fickian transport mod-
els adopted to describe drug permeation in a Franz vertical cell, both accounting for the
presence of the cellophane (dialysis) membrane and finite volume of the receptor cham-
ber. Both transport models are numerically solved by Finite Element Method (FEM)
using Comsol 3.5 Multiphysics. The Convection-Diffusion Package in Transient Analysis
has been used. The linear solver adopted is UMFPACK, with relative tolerance 10−3and
absolute tolerance 10−6. The Time Stepping Method adopted is BDF with a Strict pol-
icy for Time steps taken by the solver. Lagrangian quadratic elements are chosen. The
number of finite elements is 2 · 104with a non-uniform mesh. Maximum-minimum ele-
ment sizes 2.5 · 10−3 − 2.5 · 10−7 in dimensionless units (total length of the domain in
dimensionless units 1.024). Smaller elements are located in the membrane domain and
close to the boundaries gel/membrane and membrane/receptor chamber to guarantee the
convergence of the numerical scheme and accurate resolution of concentration gradients.
Fickian diffusion model
Drug release from Scl − CM300 networks can be described as a purely one-dimensional
Fickian diffusion process (along the vertical coordinate z spanning the donor chamber),
assuming that no drug/hydrogel matrix interaction and no matrix erosion of the fully
swollen hydrogel occurs during the release experiments. A purely Fickian transport
model can be adopted to describe blank experimental release data as well as release data
from Scl − CM300 hydrogels for molecules that exhibit a typical Fickian behavior, i.e.
Mt/M∞ ∼ t1/2 at short-intermediate time scales. Let us indicate with Cg, Dg, Cm, and
Dm the drug concentrations and the effective diffusion coefficients in the hydrogel and
the dialysis membrane, respectively. C0 indicates the initial drug concentration in the
hydrogel (thickness Lg= 2 mm, volume Vg= 0.1 cm3). The dialysis membrane used in
the study has a thickness Lm= 48 µm and a volume Vm= 2.4 mm3. Let Cres be the
drug concentration in the perfectly mixed receptor chamber of volume Vres= 4.1 ml.
By introducing the dimensionless time and space variables τ ,ζ, β, αm and the diffu-
sivity ratio γg:
τ = tDm/L
2
g, ζ = z/Lg, αm = Lm/Lg, β = Vg/Vres, γg = Dg/Dm (3.2)
the transport equations and the boundary/initial conditions can be written as:
∂Cg
∂τ
= γg
∂2Cg
∂ζ2
for 0 < ζ < 1,
∂Cg
∂ζ
= 0 at ζ = 0, Cg(0, ζ) = C0 (3.3)
∂Cm
∂τ
=
∂2Cm
∂ζ2
for 0 < ζ < 1 + αm, Cm = Cg at ζ = 1 (3.4)
γg
∂Cg
∂ζ
=
∂Cm
∂ζ
at ζ = 1 , Cm = Cres at ζ = 1 + αm, Cm(0, ζ) = 0 (3.5)
dCres
dτ
= −β ∂Cm
∂ζ
at ζ = 1 + αm, Cres(0) = 0 (3.6)
We assume no mass-transfer resistance at the membrane-receptor chamber interface and
unitary partition coefficients at the membrane-receptor chamber interface as well as at the
gel membrane interface. The balance equation for Cres, equation (3.6), and the boundary
condition Cm= Cres at ζ = 1+αm account for the finite volume of the receptor chamber.
By solving the transport equations eq:(3.3)-(3.6) for Cg, Cm,and Cres,the drug-release
curve can be computed as follows:
Mτ
M∞
=
VresCres(τ)
VresC∞res
, M∞ = Vres
βC0
1 + β(1 + αm)
=
VgC0
1 + β(1 + αm)
(3.7)
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where M∞< VgC0 because of the finite volume of the receptor chamber. The same set
of transport equations can be used to describe the blanks, representing the drug release
studies from the aqueous solutions without the hydrogel. This is possible by simply
replacing Cg(drug concentration in the gel) with Cs(drug concentration in the aqueous
solution placed in the donor chamber) and considering the diffusivity ratio γs = Ds/Dm
instead of γg = Dg/Dm,where Ds represents the drug diffusivity in the solvent solution.
The Wilke-Chang correlation ( [274]) was used to estimate Ds for each model drug:
Ddrugs [
cm2
s
] = 7.4 · 10−8
√
ΨBMWBT )
ηBV 0.6drug
(3.8)
where B indicates the solvent (water, ΨB = 2.26) and Vdrug is the LeBas drug molar vol-
ume usually obtained from a group contribution approach, considering the contributions
of individual atoms,functional groups and cycles composing each molecule [274]. From
the blanks, we estimate the effective diffusion coefficient of the different model drugs in
the dialysis membrane Dm, by best fitting the only unknown parameter γs. Hence, from
the release data from Scl − CM300 hydrogel, we estimate the effective diffusion coeffi-
cient of each model drug Dg in the hydrogel by best fitting the only unknown parameter
γg = Dg/Dm. This model fits well blank experimental release data as well as release
data from Scl − CM300 hydrogel for molecules that exhibit a typical Fickian behavior,
i.e. Mτ/M∞ ∼ τ1/2 at short-intermediate time scales.
Drug/hydrogel interaction model
A second mathematical model was introduced to describe possible interactions between
a model drug and the hydrogel matrix and their effects on the drug release kinetics. This
model can be used to explain the apparent "anomalous" non-Fickian behaviorMτ/M∞ ∼
τncharacterized by an exponent n »1/2 that can be observed at short-intermediate time
scales in the presence of solute/polymeric matrix interactions (for a fully swollen gel).
In this case, a two-phases kinetic model, originally proposed by Adrover [275] for drug
release from water swollen scleroglucan matrices, is adopted to describe the system.
Specifically, it is possible to define a fraction  of the drug molecules that is capable
of interacting with the polymeric network, which can be separated from the other drug
molecules that are simply dissolved in the water phase of the hydrogel, where they are
free to diffuse with an effective diffusion coefficient Dg. A similar approach has been
adopted by Singh et al., modeling drug release from hydrogels via a diffusion transport
coupled with adsorption/desorption mechanism [276].
The "two-phases" model adopted in the present work actually describes the ad-
sorption/desorption mechanism in terms of a linear transfer rate from the adsorbed
"bounded" phase to the desorbed "free" (or gel-solvent) phase and viceversa. Let us
then indicate Cb and Cg as the drug concentrations in the bounded and free (gel-solvent)
phases, respectively. By assuming a reversible reaction and a linear transfer rate from
the bounded to the free phase −rb→g = KbgCb as well as a linear transfer rate from
the free to the bounded phase −rb→g = KgbCg, the dynamic equations describing the
phenomenon can be written as:
∂Cg
∂τ
= γg
∂2Cg
∂ζ2
+ φ2γg(Cb − Cg/Keq) for 0 ≤ ζ ≤ 1 (3.9)
∂Cb
∂τ
= −φ2γg(Cb − Cg/Keq) for 0 ≤ ζ ≤ 1 (3.10)
∂Cg
∂ζ
= 0 at ζ = 0, Cg = Cm at ζ = 1 (3.11)
Cg(0, ζ) = (1− )C0, Cb(0, ζ) = C0 (3.12)
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where Keq = Kgb/Kbg is the equilibrium constant (depending on the temperature of
the experiment) and φ2 =
KbgL
2
g
Dg
is a dimensionless parameter, equivalent to a square
Thiele modulus, representing the ratio between the characteristic diffusion time L2g/Dg
in the free(gel-solvent) phase and the characteristic time for the reversible transfer from
the bounded to the free phase 1/Kbg. No drug diffusion occurs in the bounded phase.
Balance equations for Cm and Cres,as well as the boundary conditions for Cg and Cm
remain unchanged with respect to the purely Fickian diffusion model.
In this case, the total amount of drug released up to an infinite time reads as:
lim
τ→∞Mτ =
VgC0
1 + β(1 + αm +K
−1
eq )
(3.13)
that can be significantly smaller than M∞ (see eq:(3.7)),depending on the value of
Keq, because for any finite value of Keq,part of the drug, namely the total amount
VgC0βK
−1
eq
1 + β(1 + αm +K
−1
eq )
, get trapped in the bounded phase and never released. The initial
partition coefficient  depends on the initial temperature of the gel sample. If the gel
sample is kept at constant ambient temperature T0 prior of the experiment and then, at
time t=0, placed in the donor chamber in contact with the solvent solution in the re-
ceptor chamber kept at constant temperature 37 ◦C ± 0,01 ◦C(temperature of the water
bath), the initial partition coefficient reads as:
 =
1
1 +Keq(T0)
(3.14)
The gel sample, initially at temperature T0, rapidly warms up(1–3 minutes) to the water
bath temperature T and the release process takes place at constant temperature T. The
equilibrium constant Keq(T0) at the initial temperature T0, and therefore the initial par-
tition coefficient , can be estimated from an independent release experiment performed
at temperature T0 of the water bath, by experimentally estimating limτ→∞Mτ at T = T0
and therefore Keq(T0) from equation (3.13) and  from equation (3.14).
3.2.7 Primary skin irritation experiments
Three healthy male New Zealand White rabbits were purchased from Charles River
(Calco Lecco, Italy) and acclimated to the laboratory for a week. The rabbits were
individually housed and received a standard diet and tap water ad libitum. Laboratory
animal care guidelines (EEC Directive of 1986; 86/609/EEC) were followed. The back of
the animals was clipped free of their fur with an electric clipper 24 h before application
of the samples. Clipped rabbit skin was divided into four sites of same area (30 ·30 mm).
Scl, Scl−CM300-based hydrogels were spread on two of the four different locations(500
mg/site), whereas the other two ones were kept free from any material application and
used as a visual control. The treated and the control areas were covered with a gauze, and
the back of the rabbit was wrapped with a non-occlusive bandage. After the treatment,
the animals were returned to their cages. Bandages and the test hydrogels were removed
after 4 h and rabbits were examined for skin irritation 1 hour later.
Observation of the different sites was repeated at 24, 48 and 72 h. The reaction,
defined as erythema or edema, was evaluated according to the score of the skin reactions
already reported. The score of primary irritation (SPI) was calculated for each rabbit
as the difference between the sum of the scores of erythema and edema at 24, 48 and
72 h in the treated sites and the control areas. These values were also divided by the
number of observations. The primary skin irritation index (PII) was calculated as the
arithmetical mean of the SPI values of the three animals.The evaluation of PII was
performed according to the categories reported in the literature [277].
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3.3 Results
3.3.1 Physical hydrogel preparation and characterization
Scleroglucan carboxymethyl (Scl−CM300) with a high degree of derivatization was ob-
tained following a previously established protocol [258]. FT-IR spectra of the polymer
prior and after ion exchange were recorded to evaluate the conversion of Scl in its car-
boxymethyl derivative. As expected, elution through DOWEX resin caused the complete
conversion of the polymer to the free acid derivative and a consequent increase in the
intensity of the corresponding stretching band at 1725 cm−1could be observed. In fact,
a shift in the equilibrium from the carboxylategroup (−COO−) to the carboxylic group
(-COOH) is evident from the overlapping of the FT-IR spectra.
Specifically, the stretching of the carbonyl group shifts from 1590 cm−1(before ionic
exchange) to 1725 cm−1(after ionic exchange), thus indicating a higher presence of car-
boxylic groups in the protonated form. The total amount of carboxylic groups added
to the polymer backbone was quantified through potentiometer titration and resulted in
being 300 ± 10. The high number of carboxymethyl functional groups introduced on the
Scl backbone promote interaction among the polymeric chains, making possible the for-
mation of physical hydrogels without the addition of any salt. Specifically, the carboxylic
groups introduced in the backbone of the polysaccharide can form hydrogen bonds and
ion-dipole interactions, responsible for the physical gel formation (figure 3.1A).
Hydrogels were formed at the concentration of 2.0% w/v in the presence and absence
of drugs.This concentration was chosen as the optimal one because of the homogeneous
consistency of the hydrogels suitable for topical application.The flow curve of the plain
hydrogel (without drugs) has been carried out to study the rheological properties of
the system at different shear rates (figure 3.1B). Scl − CM300 at 2.0% w/v showed a
shear-thinning behavior that is typical of a pseudoplastic macromolecular system. It
is noteworthy that the viscosity behavior of Scl-CM at a high degree of derivatization
resembles the flow properties of native scleroglucan at the same concentration ( [258]).
The preservation of the pseudoplastic flow behavior after derivatization is an essential
feature allowing the use of this system as a topical formulation, which can be applied to
the skin or to the mucosae. Frequency sweep tests carried out in the viscoelastic region
showed values of the elastic modulus G’ higher than the viscous modulus G” over the
range of frequencies tested (figure 3.1C), indicating the formation of a physical hydrogel.
The value of G’ slightly changes throughout the test showing the typical behavior of
a weak gel, for which the value of G’ is influenced by the frequency of the applied
deformation.
3.3.2 Rheological characterization of drug loaded Scl − CM300
physical hydrogels
A previous report [258] proposing Scl − CM300 hydrogels as drug carriers for oral drug
administration, showed that a reduction in the pH value can increase the hydrogel
strength(higher values of the G’ elastic modulus) and reduce the swelling capacity of
the matrix.
The focus of our investigation was to determine whether the presence of a loaded
drug could affect the rheological properties of Scl − CM300 hydrogels as drug carriers
for topical administration.To this end, three different therapeutic molecules, such as
fluconazole, diclofenac, and betamethasone phosphate were included in the polymeric
solution of Scl − CM300 2.0% w/v before hydrogel formation. Different concentrations
of the three drugs were tested varying from 0.1% w/v up to 0.5% w/v. Irrespective of
the drug considered and its amount, the corresponding physical hydrogels showed shear-
thinning behavior similar to the plain system, with almost no significant effects on the
viscosity values (see figure 3.2). Results of frequency sweep tests for the hydrogels loaded
with the selected drugs (0.25% w/v) showed different behaviors according to the type of
molecule loaded in the polymeric network (see figure 3.3).
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Figure 3.1: Rheological characterization of Scl−CM300 physical hydrogels. A) Schematic
representation of hydrogen bond formation among carboxyl and hydroxyl groups. B)
Flow curve showing the pseudoplastic behavior of the polymer at 37 ◦C ± 0,01 ◦C. C)
Representative picture of Scl−CM300 physical hydrogel and the corresponding frequency
sweep test carried out in the range of 0.01–10 Hz. Full circles represent the elastic
modulus G’ and empty circles the viscous modulus G”.
Fluconazole did not influence the hydrogel properties over the whole range of frequen-
cies investigated, and only a small decrease in the G” values was observed respect to the
hydrogel without the drug. Mechanical spectra of Scl−CM300 hydrogel loaded with be-
tamethasone showed a reduction of both G’ and G” when compared to the plain hydrogel,
indicating that the drug partially interferes with the formation of the polymeric network,
thus resulting in a softer hydrogel.On the contrary, the presence of diclofenac induced
a significant increase of both G’and G”, thus indicating the formation of a stronger gel
(figure 3.3C).
It is possible to assume that the presence of a carboxylic group in the diclofenac
molecule leads to additional hydrogen bonding interactions affecting the final rheological
properties of the physical hydrogel.Based on these results it may be expected a different
ability of the Scl−CM300 network to modulate the release of the three selected molecules.
In fact, besides the molecular weight and the chemical structure of the investigated drugs,
the strength of the drug-polymer interactions is an additional factor, which may affect the
molecular mobility of the incorporated model drug, playing a critical role in controlling
the release rate from the polymer matrix.For this reason, these findings were further
investigated through in-vitro release tests.
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Figure 3.2: Comparison of flow curves of Scl − CM300 physical hydrogels loaded with
different concentration (from 0.1% w/v up to 0.5% w/v) of A) fluconazole, B) diclofenac
and C)betamethasone. Flow curves were recorded at 37 ◦C ± 0,01 ◦C.
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Figure 3.3: Frequency sweep tests carried out in the range of 0.01–10 Hz for plain Scl−
CM300 hydrogel (red square and circular points for G’ and G”, respectively) and loaded
with different model drugs (upper and lower triangular points for G’ and G”, respectively).
A) fluconazole; B) betamethasone; C) diclofenac.
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3.3.3 Release studies
Analysis of release data from blanks
Figure 3.4 shows the release profiles of the three model drugs in aqueous solution (blank
systems, points with error bars) and the comparison with the Fickian model (continuous
lines).
It can be observed that diclofenac and fluconazole exhibit similar blank release curves
since they are characterized by very close values of the LeBas volume. A slower release
is obtained for betamethasone due to the significantly larger value of its LeBas vol-
ume. Model curves were obtained, for each model drug, by estimating Ds from the
Wilke-Chang correlation (3.8) and by best fitting the ratio γs = Ds/Dm in the Fickian
transport model (see table 3.1). The values of γsare in the order of 101for all the model
drugs,thus implying that the effective diffusion coefficient in the dialysis membrane is
one order of magnitude smaller than the diffusivity in water solution. Therefore the
dialysis cellophane membrane,even if extremely thin (Lm = 48µm), offers a significant
resistance to drug transport from the donor to the receptor compartment and its pres-
ence should be necessarily taken into account in the transport model [278]. This is in
agreement with other drug release studies from Scleroglucan hydrogels making use of the
same cellophane membrane (Visking tubing, cut-off 12,000-14,000 Da) in two or three
compartments diffusion cells [279].
This observation is further supported by the analysis of blank release data from a
0.25% w/v aqueous solutions of theophylline(TPH), usually adopted as a model drug
and characterized by both a low MW and a small LeBas volume.For TPH, the value of
the water diffusivity Ds = 8.39 ·10−6cm2/s estimated from the Wilke-Chang correlation,
is in perfect agreement with experimental literature data Ds = 8.2 · 10−6cm2/s at 37 ◦C
[279,280] and the best fit value of the diffusivity ratio is γs = 16± 0.2.
Figure 3.4B shows the effective diffusion coefficient in the dialysis membrane Dm as
a function of the molecular weight for all the model drugs analyzed, highlighting how
Dm is a linear decreasing function of the molecular weight over the whole range of MW
analyzed.
Analysis of release data from Scl − CM300 hydrogels
Figure 3.5 shows experimental release data of the three model drugs under investigation
from Scl − CM300 hydrogels at 37 ◦C. Continuous black lines a-b represent the short-
intermediate time-scale Fickian behavior Mt/M∞ ∼ t0.5 (in agreement with the release
data of fluconazole and betamethasone) while curve c represents the "anomalous" non-
Fickian behavior Mt/M∞ ∼ tn with n=1.2»1/2, in agreement with diclofenac release
profile (figure 3.5).
Drug-polymer interactions are here responsible for the time-lag observed in the early-
stage release curve of diclofenac that is a typical feature of non-Fickian transport. Similar
features have been observed in drug release experiments from sclerox and cross-linked
sclerox hydrogels [281].These results confirmed the trend observed in the frequency sweep
tests where diclofenac was the only tested drug capable of increasing the values of G’ and
G” due to the formation of drug-polymer hydrogen bonding interactions. The same in-
teractions are here responsible for the observed anomalous release.Specifically, diclofenac
is released at a significantly slower rate than fluconazole and betamethasone, despite the
fact that its LeBas molar volume is similar or significantly smaller than the ones reported
for fluconazole and betamethasone. Moreover, not the whole amount of drug initially
loaded is actually released after 24 h.
For these reasons, a Fickian transport model was adopted for fluconazole and be-
tamethasone, whereas the non-Fickian solute transport model taking into account drug
- hydrogel interactions, was introduced to describe diclofenac release curves.The half-life
time t0.5for drug molecules non interacting with the hydrogel matrix are t0.5=45.6 min
for fluconazole (MW=306) and t0.5= 96 min for betamethasone (MW=516).
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Figure 3.4: A) Experimental release data from 0.1 ml of aqueous solutions (0.25%
w/v)(blanks, points with error bars) containing different model drugs and the compari-
son with the Fickian transport model (continuous lines).Best fit values of the diffusivity
ratio γs = Ds/Dm are reported in table 3.1. The arrow indicates increasing values of the
LeBas volume. B) Dm vs MW for different model drugs, including TPH.
Therefore by almost doubling the molecular weight of the loaded drug, also the half-
life time doubles. Henceforth the hydrogel Scl − CM300 appears to be suitable for drug
delivery as the release is strongly dependent on the dimensions of the model drug and
therefore the delivery can be tailored in function of the steric hindrance of the en-
trapped molecule. Similar release features have been observed by Coviello et al.,2005
for Scl/Borax hydrogels, which they proposed as suitable hydrogels for a sustained drug
delivery. Coviello et al., 2005 observed a Fickian behaviour for the release curves of TPH
(MW=180), Vit. B12 (MW=1355) and myoglobin (MW=17800) from Scl/Borax hydro-
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gel in distilled water and showed how half-lives for Vit. B12 (about ten times bigger
than TPH in terms of MW) and myoglobin (about one hundred times bigger than TPH)
were respectively about two and five times bigger than the TPH half-life. Therefore, the
hydrogel of Scl−CM300 appears to be more sensitive to the drug molecular weight than
Scl/Borax hydrogel.
Figure 3.5: Experimental release data from Scl − CM300 hydrogel containing different
model drugs and the comparison with the Fickian short-intermediate time-scale behavior
Mt/M∞ ∼ t0.5(curves a-b) and the non-Fickian behavior Mt/M∞ ∼ tn with n=1.2»1/2
(curve c). The arrow indicates increasing values of LeBas molar volumes.
Release data modeling
Fig:3.6A shows fluconazole release data from an aqueous solution and from the hydrogel
in excellent agreement with the Fickian transport model with γs = γg, since release data
from the hydrogel and from the aqueous solution are almost coincident. It is therefore a
case of an ideal topical release, as this formulation does not offer additional resistance to
fluconazole release with respect to an aqueous solution. Figure 3.6B shows betamethasone
release data from aqueous solution and hydrogel in excellent agreement with the Fickian
transport model with γs = 19.4 and γg = 11.5.
Therefore, the Scl − CM300 formulation offers a small additional resistance to be-
tamethasone transport (larger LeBas molar volume) since Dg = (γg/γs) Ds ∼ 0.59Ds.
For a direct comparison between Dg and Ds for different model drugs see table 3.1.
Figure 3.6C shows diclofenac release data from aqueous solution and hydrogel at 37 ◦C
± 0,01 ◦C, together with the release data from hydrogel at room temperature 20 ◦C.
The release curve from Scl−CM300 hydrogel is significantly slower than that from wa-
ter solution although the diclofenac molecule exhibits the smallest LeBas volume among
the three model drugs analyzed. Rheological results support the idea of a chemical inter-
action between diclofenac and the hydrogel matrix. Release data at room temperature
are a direct evidence not only for the interaction between diclofenac and Scl − CM300,
but they also suggest that a very large amount of drug is bounded to the polymer matrix
and is unable to diffuse out from the hydrogel.
In fact, only 10% of the drug is released from the hydrogel after 24 h. From the
asymptotic value limt→∞Mt/M∞(20 ◦C) = 0.11± 0.02 and from equations:(3.13)-(3.14)
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Figure 3.6: Experimental release data of A) fluconazole from water solution and from
Scl − CM300 hydrogel and the comparison with the Fickian transport model with γs =
γg; B) betamethasone from water solution and from Scl − CM300 hydrogel and the
comparison with the Fickian transport model with γs = 19.4 and γg = 11.5; C) diclofenac
from water solution (at 37 ◦C) and from Scl − CM300 hydrogel at 37 ◦C and 20 ◦C.
Broken dot-line curve represents the Fickian transport model for blank with γs = 14.1.
Continuous line represents the non-Fickian drug/matrix interaction model with γg =
γs = 14.1 and φ2 = 0.74± 0.02.
we estimate Keq(20 ◦C) = 2.9 · 10−3 and the initial partition coefficient  = 0.001 for the
release experiment at the working temperature of 37 ◦C.
The three other parameters entering the non-Fickian transport model are γg ,Keq(37 ◦C)
and φ2. From the asymptotic value limt→∞Mt/M∞(37 ◦C) = 0.96±0.03 and from equa-
tions:(3.13) we estimate Keq(37 ◦C = 0.57) . For γg we set γg = γs = 14.1 because of
the small LeBas volume of the drug molecule. The only best fit parameter is the square
Thiele modulus φ2. Figure 3.6C shows the excellent agreement between the release data
from the hydrogel and the non-Fickian transport model with φ2 = 0.74± 0.02.
The best fit value of φ2, order of unity, indicates that the characteristic time for
the irreversible transfer from the bounded to the free-solvent phase is of the same order
as the characteristic diffusion time, thus explaining the significant slowing down of the
experimental release curve. The data obtained proved that Scl−CM300-based hydrogels
are useful for a sustained release of diclofenac, provided that the percentage of drug
released after 5 h is less than 80%.
3.3.4 Primary skin irritation experiments
Primary skin irritation experiments were carried out on rabbits, to assess possible use of
Scl − CM300-based hydrogels in topical formulations. Individual skin irritation scores,
were always equal to 0. No signs of erythema or edema were observed in the animals up
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to 72 h after the application of the samples. According to these data, the primary skin
irritation index (PII) of the tested materials was negligible, highlighting that Scl−CM300
possesses adequate properties for application as a modified drug delivery system in topical
formulations.
3.4 Conclusion
High-carboxymethylated scleroglucan can form physical hydrogels with negligible pri-
mary skin irritation index and adequate rheological properties even in the presence of
different therapeutic drugs such as fluconazole, diclofenac sodium salt, and betametha-
sone phosphate sodium.
The shear thinning behavior of the system was not affected by loading these molecules
within the polymeric network. A slightly weaker hydrogel was obtained with betametha-
sone. On the contrary, the carboxylic group of diclofenac made it able to interact with
Scl−CM300, thus strengthening the mechanical properties of the corresponding physical
gel.
These findings are supported by experimental drug release studies carried out on
drug-loaded Scl−CM300 hydrogels and further confirmed by mathematical modeling of
the release profiles. In fact, while betamethasone and fluconazole were released according
to a Fickian transport model, model analysis applied to diclofenac explained the non-
Fickian feature of its release profile. The estimated values of effective drug diffusion
coefficients in the hydrogel for betamethasone and fluconazole, compared to those in an
aqueous solution, led us to propose Scl − CM300 as an excellent formulation for fast
topical release.
The slower release rate observed for diclofenac, due to drug-polymer interactions,
made Scl − CM300 useful for a sustained topical release of this drug.
Chapter 4
Drug delivery from Oral thin
films
4.1 Introduction
Oral mucosal drug delivery is an alternative and promising method of systemic delivery
which offers several advantages [282, 283]. The oral mucosa is highly vascularized; for
this reason, drugs that are absorbed through it directly enter the systemic circulation,
bypassing the gastrointestinal tract and first-pass metabolism in the liver [284]. When
sublingual mucosa administration is chosen, a rapid onset of action results via a more
comfortable and convenient delivery route than the intravenous route [285].
Additional advantages include an improved bioavailability for certain drugs and an
easy access to the absorption sites so that the delivery system can be applied and removed
easily [286,287].
In this work, novel OTFs were prepared combining Gellan gum, along with Glycerol,
used as plasticizer. Gellan gum thin films were fabricated casting aqueous solutions of
the polymer containing different concentrations of glycerol and loaded with two different
amount of Fluconazole, used as model drug. The manufacturing process was optimized
monitoring some critical parameters including the rheological properties of the starting
polymeric solutions, air bubbles entrapped, content uniformity, residual water in the
final films and drying rate. All these parameters have an important part on the physical
appearance, thickness homogeneity, content uniformity, mechanical and release properties
of the resulting films and for this reason they were throughly investigated.
Moreover, the influence of the plasticizer on the swelling equilibrium and release of
the drug is investigated in simulated saliva (pH 6.7) at 37 ◦C. Release studies were carried
out in a novel millifluidic flow-through device that using a laminar tangential flow is able
to better mime physiological mouth conditions.
4.2 Materials and method
4.2.1 Chemicals
Fluconazole, Gellan gum and Glycerol used in this work were procured from Sigma
Aldrich. Cellulose membrane filters were purchased fromMedicell International. Methanol
(CH3OH), glacial acetic acid (CH3COOH), bidistilled water (for HPLC), potassium di-
hydrogen phosphate (KH2PO4), di-sodium hydrogen phosphate dehydrate (Na2HPO4),
sodium chloride (NaCl) and hydrochloric acid (HCl), (used to prepare simulated saliva
pH = 6.7), were supplied by Carlo Erba Reagents.
Gellan was added to glycerol to confer plasticity to the films. The glycerol is a triol,
that is, an organic structure with three -OH groups. Glycerol is a component of lipids
and phospholipids from which it is obtained by hydrolysis. At environment temperature
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Figure 4.1: BYK-Gardner square film applicator.
appears as a colorless, dense, viscous liquid: the presence of the three Hydroxide groups
make it miscible with water in any proportion.
The third component is fluconazole. This is an antimicotic of the category of azole
drugs. Is Used for prevention and the treatment of superficial and systemic fungal infec-
tions. It looks like a crystalline white powder, not soluble in water (8 mg/ml at 37 ◦C )
and soluble in alcool [288].
4.2.2 Film forming technology
Films were produced by a casting/solvent evaporation technique using different combi-
nations of Gellan (2% w/v) and the plasticizer Glycerol (from 0.5% to 6% w/v). Gellan
and Glycerol were dissolved in double distilled water, and the resulting solution was sol-
ubilized at 25 ◦C, under magnetic stirring, for five hours. The mixture was coated onto
silicone plate ( figure 4.2 ) or steel plate using BYK square film applicator ( figure 4.1 )
to prepare thin films, then dried by heating in a stove at 60 ◦C for 15 hours. Flucona-
zole thin films were produced with the same method by adding a Fluconazole solution
(14%w/w) to the casting solution. Thicknesses of OTFs are in the range 40− 60µm for
OTFs at 5% Glycerol and 60− 90µm for OTFs at 6% Glycerol.
4.2.3 Thermogravimetric analysis
Thermogravimetric analysis was performed is order to estimate the amount of solvent
in the dry films and therefore to estimate a lower bound for the minimum amount of
solvent required to initiate the glassy-rubbery transition. Thermogravimetric analysis
were performed using a Q600 TGA (TA Instruments), in a temperature range from 25 ◦C
to 120 ◦C, flowing nitrogen atmosphere (5ml/min), and the thermogravimetric data were
recorded at a constant heating rate of 5 ◦C/min.
Were evaluated three kind of samples (5 and 6% of glycerol):
• empty films (without fluconazole);
• 7%(w/w) fluconazole;
• 14%(w/w) fluconazole.
The picture 4.3 highlight that the content of residual water increase if increase the drug
amount in the films.
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Figure 4.2: Picture of silicon mold for casting solution.
Moreover films at 5% glycerol have more residual water than films at 6%.
Figure 4.3: Thermogravimetric tests for several kind of films. Wt is the weight of the
film at time t, while W0 is the weight at time 0, at the start of the thermogravimetric
test
4.2.4 Swelling
Films were cut, weighted and inserted in a beaker of 5 ml contained simulated saliva
pH 6.7. At regular time intervals, non-adsorbed water was drained and wet film was
weighted. Tests were performed at 37 ◦C and repeated in triplicate. From the swelling
tests is it possible to calculate the polymer volume fraction at equilibrium and the solvent
diffusion coefficient in the completely swollen film.
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4.2.5 USP II, Paddle apparatus
Dissolution tests were carried out in a conventional USP type II paddle apparatus. Sam-
ples of square shape fluconazole-loaded OTF (surface area 36 cm2) were placed in different
part of the vessel: a) taped on the side wall; b) taped on the bottom; c) anchored to
the bottom with a wire mesh. All the release studies were carried out in 500 mL of
simulated saliva (phosphate buffer, pH 6.7, containing 0.137M NaCl) at 37 ◦C ± 0,1 ◦C
with a rotation rate of 50 rpm. Aliquots of the release medium (2 mL) were taken at
appropriate time intervals from 1 to 30 min and immediately replenished with the same
volume of fresh simulated saliva.
Fluconazole concentrations were assayed by HPLC analysis as reported in the previous
chapter. Tests were repeated in triplicate and the results were expressed as mean values
± the standard deviation.
4.2.6 Novel millifluidic device
Drug release experiments were performed in the newly proposed continuous flow-through
device [289,290].
The existing in-vitro dissolution devices lead to results under expectations if applied
to pharmaceutical strips. This subject has been already extensively reviewed in the
previous part. A common feature is that the testing apparatuses known in the prior
art comprise dissolution chambers in vessels of several cm3 containing mechanical parts,
such as mixing and/or stirring means, beads or sample holders.
Thin films or strips to be tested are allocated in a number of different positions and
configurations by using fixing means such as glue or adhesive membranes. Dimensions
are here scaled down to cubic millimeter and the resulting flow-pattern deserves, the
name of millifluidic (figure 4.4). A new dissolution cell was designed ad applied in a
new dissolution method [264]. The cell and the dissolution system comprise a channel
with an operative volume of a fraction of cubic centimeter, connected with two balancing
basins of few cubic millimeters. Therefore the cell and apparatus have a far smaller
dissolution volume. The cell and apparatus strictly work in laminar flow conditions
between two plates, not in stirred vessels conditions, therefore the residence time is of
fraction of minutes or less, depending on the prescribed flow rate, also if the latter is
small. Moreover, the dissolution chamber is empty and the desired flow conditions are
obtained by the flow-through and the small geometry.
In the cell and the apparatus there is a unique possible set-up for film positioning
which completely prevents floating and detachment. The cell and the apparatus may
be completely transparent or optionally have a transparent region, as wide as desired,
with an optical path for spectrophotometry analysis far shorter than usual dissolution
cells. No mechanical mixing devices are required to influence the fluid flow because
non-stagnant conditions and laminar flow are obtained by means only of the geometrical
design of the objects and of adequate flow rates.
Moreover, there is no need for a sample holder since in the cell the thin film or strip
is tightly held during the dissolution, in a controlled layout, by the geometry itself. The
thin film or strip is placed in the cell and, when it is closed, a predetermined area part of
the film becomes a surface of the dissolution channel. Therefore, the unpredictable and
ruinous detachments and floating of the existing devices are avoided.
The picture 4.4 of this device shows:
• a superior plate (1) having an upper face (3) and a lower face (2) with two channels
(4) from the upper face (3) to the lower face (2) ending on the lower face (2) in two
basins (5) wherein one works as an inflow (4’) and the other works as an outflow(4”);
• An inferior plate (6);
• A sheet (7) of slightly deformable material and known thickness, inserted between
the plates (1) and (6), wherein a rectangular slit is cut out, deep as the thickness
of the sheet itself, and its extremities partially overlap with the two basins;
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Figure 4.4: Draw of the dissolution cell.
• A dissolution chamber (8) between the lower face (2) of the superior plate (1) and
the inferior plate (5), which coincides with the rectangular slit in the sheet (7).
The apparatus comprising the cell connection joints at the exit of each circular chan-
nel(4), a closure system, a support system, a thermal insulation system.
A dissolution system is formed by the apparatus, feed pump, a reservoir feeding the
feed pump, measurement devices and means for controlling temperature. It is a further
object of the present invention a method for testing thin film or strip comprising the
following steps:
• Inserting the thin film or strip sample to be tested comprising at least one active
ingredient in the dissolution chamber of the cell so that the exposed area is equal
to the area of the slit in the sheet (7);
• Feeding a dissolution media at controlled flow rate from the reservoir by the feed
pump (4) through the inflow channel and basin (4’);
• Continuously contacting the dissolution media with the thin film or strip in the
dissolution chamber (8) under laminar and tangential flow conditions;
• Analyzing the dissolution media exiting from the outflow channel (4”) wherein the
active ingredient is dissolved by means of a measurement device.
In a preferred embodiment the device is realized in two hard plates made of acrylic
polymer and a sheet made of Teflon wherein four screws are realized at the edges of the
plates and sheet and the cell is closed by a metallic mask. The inferior plate is smooth
and plain. Through the superior plate two circular channels of 2 mm diameter have been
drilled. On one face, channels end in two rectangular basins designed to set adequate
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Figure 4.5: Schematic representation of the flow-trough millifluidic device. Instruments
of analysis on the outlet flow.
laminar flow conditions. The first couple basin-channel works as inflow and connection
volumes, while the other, symmetrically, as outflow and connection volumes.
The device can work either horizontally or vertically. Two connection joints are put at
the exit of the cylindrical channels. The dissolution chamber is obtained by the insertion
of a sheet, wherein a rectangular slit is cut out, deep as the thickness of the sheet itself,
and its extremities partially overlap with the two basins, is inserted between the two
plates. The extremities of the rectangular slit overlap with the extremities of the basins.
If plates, sheet and oral strip are tightened together, a single free volume is obtained,
from one cylindrical channel to the other, passing over an OS’s area equal to the area
of the slit. The system is made water-tight by the sheet itself. The device can be easily
opened, and the OS substituted. The height of the dissolution chamber is equal to the
thickness of the sheet and can be easily changed by substituting the sheet itself. A likely
range is in the order of millimeters. The device is connected to a volumetric pump and
to a UV-vis spectrophotometer.
The flow rate is set by the rotation speed of the pump. The area exposed to the
dissolution media is constant and known in advance, since the strips is tightened by
the geometry itself and the exposed area is equal to the area of slit. The dissolution
process can be easily monitored through the transparent window. Figure 4.5 is a scheme
representing the set-up of the device if working with the analysis instruments on the
outlet flow.
Flow rates investigated in this work are in the range Q ∈ [2 − 11] ml/min corre-
sponding to laminar flow conditions with Reynolds numbers Re ∈ [3− 36], based on the
hydraulic radius d =3.27 mm. Low flow rates are comparable with salivary flow rates
Q ∈ [1 − 4]ml/min. Solution exiting the cell is sent to the UV/vis analyzer (Perkin
Elmer,continuous flow cell, optical path 1 mm) in order to quantify the amount of active
ingredient released from the swelling film (figure 4.6,4.7).
Drug concentration values Cs(t) mg/ml are recorded every 0.1 s. The amount of
drug released is calculated with a calibration curve. Calibration curve for Fluconazole
reference standard (RS) is obtained by measuring the UV absorption (λ = 260nm) in
dissolution medium (simulated saliva). Tests are repeated in triplicate at 37 ◦C. The
differential F(t) and integral I(t) release curves are subsequently computed from the
experimental data as follows:
F (t) =
QCs(t)∫ tf
0
QCs(t′)dt′
=
QCs(t)
M∞
(4.1)
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Figure 4.6: Millifluidic device.
Figure 4.7: Millifluidic model.
I(t) =
Mt
M∞
=
∫ tf
0
QCs(t
′)dt′
M∞
=
∫ t
0
F (t′)dt′ (4.2)
tf being a final time for the experimental test sufficiently long to ensure the complete
drug release. The final time tf depends on the flow rate Q. The smaller is the flow rate
Q, the longer is the time interval required for complete drug release.
4.3 Results
4.3.1 Swelling model for OTF
Figure 4.8 and figure 4.9 shows the swelling ratio Q = weight(t)/weight(t = 0) as
a function of time for OTFs at 5% Glycerol (average thickness L0 = 47µm) and 6%
Glycerol (average thickness L0 = 86µm), with and without Fluconazole. A polymer
volume fraction at swelling equilibrium is estimated from long term data. It can be
calculated as follow:
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Figure 4.8: Experimental swelling dynamics for OTFs at 5% glycerol.
Figure 4.9: Experimental swelling dynamics for OTFs at 6% glycerol.
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φ∞polymer =
x∞polymer
ρpolymer
x∞polymer
ρpolimero
+
x∞water
ρwater
+
x∞fluconazole
ρfluconazole
(4.3)
where ρpolimer, ρwater, ρfluconazole are respectively the density of polymer (average
based on the weight proportion of gellan gum and glycerol in the film at 5 or 6% glycerol),
water and fluconazole. x∞polymer, x
∞
water and x∞fluconazole can be calculated with the follow
equation:
x∞polymer = x
0
polymer · f (4.4)
x∞water = 1− f(x0polymer + x0fluconazole) (4.5)
x∞fluconazole = x
0
fluconazole · f (4.6)
where x0polymer and x
0
fluconazole are the mass fraction of polymer and fluconazole dried
films, while 1/f is derived from asymptotic value of experimental data:
1
f
=
W∞
W0
(4.7)
where W∞ is the mass of completely swelled film and W0 is the mass of dried film. The
table 4.1 shows the value of 1/f and φ∞polymer in both cases.
Table 4.1: Value of 1/f and φ∞polymer at 5 and 6% Gly
- 1/f φ∞polymer
5%Gly 2.86 0.28
6%Gly 2.24 0.36
Traditionally, gellan gum form solvent-activated films. The drug is immobilized and
packaged inside a solid polymeric structure well below its glass transition temperature.
In these conditions the diffusivity is very low (tending to zero). In the presence of water
the film is soaked and swollen.
There is a transition from the glassy to the rubbery state of the material with relax-
ation of the polymer chains and dissolution of the loaded drug. Gellan gum generally
forms structures with a good degree of derivatization and is crosslinked, so it does not
encounter erosion but only swelling. Polymer swelling and drug dissolution are the phe-
nomena that regulate the release of the drug from the matrix.
The kinetics of the problem is actually studied by the analysis of the movement of the
fronts of swelling, diffusion and erosion within the matrix. In particular, the position of
the erosion and swelling front define the thickness of the gum layer, which is considered
to be the key factor in the release kinetics of the drug.
Knowledge of an appropriate mathematical model capable of describing the phe-
nomenon is very important because it allows to simulate the effect of design and design
parameters on the release profiles [291–293].
The mathematical model is based on ordinary and partial differential equations (ODE,
PDE). To solve, we need the initial condition and the outline conditions. We also need to
know the law with which the bounds move. Depending on the complexity of the equation
system, we can get an analytical or numeric solution.
At the initial state, the glassy matrix of thickness S0 = R0 begins to swell due to the
penetration of the solvent. Two distinct fronts come to life (figure 4.10):
• swelling front R(t);
• erosion front S(t);
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Figure 4.10: Classical scheme of swelling.
Most swelling models are unidimensional. The phenomenon is painted as a Stefan’s
problem with two S(t) and R(t) mobile boundary. The mass balance for the solvent in
the rubbery phase (R(t) < z < S(t)) becomes:
∂c
∂t
+
∂(q + cv)
∂z
= 0 (4.8)
where c is the solvent concentration, t the time, z the spatial axis, q the diffusive flow and
v swelling rate. The total flow thus consists of a diffusive contribution q and a convective
term due to the global swelling rate.
The convection term can be calculated from the concentration gradient [294],
q = −D(c)∂c
∂z
, v = −q = D(c)∂c
∂z
, (4.9)
From the study and analysis of scientific literature [295–297] we can derive the one-
dimensional axial pattern for thin films. The material balance for the solvent expressed
in terms of the volumetric fraction of the polymer φ becomes:
∂φ
∂t
=
∂
∂z
(
Ds(φ)φ
∂φ
∂z
)
, R(t) < z < S(t), t > 0. (4.10)
whereDs(φ) represents the solvent diffusion coefficient that is the function of the polymer
fraction.
Ds(φ) = D
SG
s exp
[
−βs
(
φ− φeq
1− φeq
)]
(4.11)
where DSGs is the solvent diffusion coefficient in the fully swelled film, φeq the volumetric
fraction at equilibrium and βs a positive constant.
The movement of the erosion front S(t) and swelling front R(t) is described by Stefan’s
condition:
φ = φeq,
dS(t)
dt
= −DSGs
∂φ
∂z
, z = S(t). (4.12)
φ = φg, (φ0 − φ)dR
dt
= Ds(φ)φ
∂φ
∂z
, z = R(t). (4.13)
where φg represents the concentration of starting swelling.
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When R(t) reaches z = 0, the glass phase disappears and the flow is zero (symmetry
boundary condition).
∂φ
∂z
= 0, z = 0. (4.14)
The initial condition:
R(0) = S(0) =
L0
2
, φ = φ0 = 1, 0 ≤ z ≤ L0
2
(4.15)
with L02 which is half the thickness of the dry film.
The physical parameters that enter the model are therefore DSGs , βs, φeq and φg avail-
able from literature, swelling data obtained from the best fit of experimental data (dy-
namic swelling).
No significant erosion effect is observed up to 100 min. OTFs at 5% Glycerol exhibit
a slightly larger equilibrium swelling ratio (lower equilibrium polymer volume fraction),
but the swelling dynamics is slower than that observed for OTFS at 6% Glycerol (see
the diffusivity value in the picture4.8 and 4.9). Both swelling dynamics and equilibrium
polymer volume fraction are not influenced by the presence of Fluconazole. For both
OTFs complete swelling is obtained after 20 min.
Continuous lines represent numerical results obtained by numerical solution of a one-
dimensional moving boundary solvent transport problem (swelling along the z direction,
orthogonal to the x–y plane representing the flat surface of the thin polymeric film, two
moving fronts, the glassy-rubbery and the gel-solvent fronts) adopted for describing the
swelling behavior of the thin polymeric film [295], initially in the glassy state, when
in contact with simulated saliva (solvent). Glassy-rubbery threshold polymer volume
fraction is estimated from thermogravimetric experiments.
The numerical solution of the one-dimensional swelling model furnishes a quite ac-
curate estimate of the effective diffusion D of the solvent in the fully swollen film, con-
firming a swelling dynamics for OTFs at 5% Glycerol slower than that for OTFs at 6%
Glycerol.(D(5%) = 3.5 · 10−11m2/s < D(6%) = 5.25 · 10−11m2/s).
Through the use of Comsol Multiphysics 3.5, using the method of finite elements was
possible to solve numerically the swelling problem. Were used the packages ALE(Arbitrary
Lagrangian Eulerian) and Convection-diffusion. The linear solver adopted was UMF-
PACK with relative tolerance 10−3 and absolute tolerance 10−6. In this way it was
possible to see gradually how the glassy-rubbery faces (R/L0) and gel-solvent (S/L0)
evolve in time, depending on the different fraction of glycerol present in the films.
In Figure 4.11 we notice that the dynamics of the glassy-rubbery front is almost equal
in both films, while the behavior of the gel-solvent front is the same just in the first few
minutes, because films at 6% glycerol swell more quickly. Another aspect to point out is
that the transition from the Glassy state to the rubbery occurs in about 1 minute.
4.3.2 Drug release time scales
In vitro dissolution tests were carried out using the novel millifluidic device. The solvent
flow rates used are in the range Q ∈ [2− 11]ml/min.
Differential and integral release curves (and therefore the release time scales) are ex-
tremely sensitive to the initial thickness L0 of the dry film. For example, Figure 4.12
shows the differential curves obtained for Q=2 ml/min for three films at 6% Glycerol
loaded with the same amount of Fluconazole. The three films differ in their initial thick-
ness (L0 = 68, 71, 78µm) . As expected the thicker film exhibits a slower release curve
(larger diffusion path). In order to compare different release curves obtained in the same
operating conditions and to average over repeated experiments with films with slightly
different initial thickness, we need to analyze release data in terms of a dimensionless
time t/tref where tref = L20/D is the characteristic swelling time, accounting for the
initial dry film thickness.
Figure 4.13 shows that the same three release curves, expressed in terms of the di-
mensionless time t/tref , are actually consistent and can be taken as representative of the
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Figure 4.11: Representation of the position of the glassy-rubbery and gel-solvent front
depending on the time for the two kind of films.
same experiment, repeated in triplicate and associated to a film with average thickness
< L0 >= (68 + 71 + 78)/3 = 72.3µm.
Figure 4.14 and 4.15 shows the corresponding differential and integral release curves,
averaged over the three experiments. Error bars represent the standard deviation (STD),
supporting a good reliability and reproducibility of the experimental release curves.
Figure 4.16 shows integral release curves (dimensionless time) for OTFs at 6% Glycerol
for increasing values of the flow rate Q. Release curves are extremely sensitive to flow
rate for low values of Q in the salivary flow range Q ∈ [1 − 4]ml/min, while becomes
almost independent of Q for Q >8 ml/min. In point of fact, the mass transfer resistance
at the gel–solvent interface decreases for increasing values of the flow rate.
For flow rates sufficiently high, the dissolved drug is immediately swept away by the
solvent flow and diffusion through the polymeric swelling matrix becomes the controlling
step. At this point, any further increase in the flow rate does not improve drug release.
Figure 4.17 shows the comparison between release curves for OTFs at 5% Glycerol and
6% Glycerol in terms of the dimensionless time (t/swelling characteristic time). The
close similarity between the two sets of curves confirms that the release process occurs
simultaneously with the swelling process and that the swelling time scales control drug
release dynamics. Therefore, drug release from OTFs at 5% Glycerol is slower than
release from OTFs at 6% Glycerol, according with the fact that swelling dynamics at 5%
Glycerol is slower than 6% Glycerol.
From experimental tests at high flow rates, it was also possible to estimate the drug
diffusion coefficient in the swollen gel. The red curve in figure 4.18 shows the differential
curve at flow rate of 11 ml/min on adimensional scale, while the blue curve shows the
exponential behavior derived from the best fitting data at 11 ml / min. Because the
mass fraction of solute released in the time is given by equation (4.16):
Mt
M∞
= 1− 8
pi2
∞∑
n=0
1
(2n+ 1)2
exp
(
− (2n+ 1)
2pi2
4
tDSGd
L2f
)
(4.16)
and as the the differential curve is equal to the derivative of the integral curve, it is
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Figure 4.12: Experimental differential release curves for Fluconazole (6% Glycerol) at Q
= 2 ml/min for three films with different thicknesses.(physical time).
obtained the equation (4.17):
QCs
M∞
=
d( MtM∞ )
dt
∼ exp −pi
2tDSGd
4L2f
(4.17)
in which Lf is the thickness of the film, after having completely swelled. From here it
was possible to estimate the drug diffusion coefficient in the swollen gel, which was then
used in the simulations in Comsol. The same procedure it was done for the DSGd of film
5% glycerol.
4.3.3 Model of release
The drug release process from the OTFs was schematized according to a 2D model. Fixed
the x axis as the direction of the flow, this varies in range x ∈ [0−Lx], where Lx = 30mm
is the length of the channel. The z axis represents the vertical direction, varies in range
z ∈ [0 − Lz], where Lz = 2mm is the height of channel. Ly is the channel width of 9
mm. Thin film exposed at the flow has an area equal to Lx · Ly and an initial thickness
L0 << Lz. cG(x; z; t) and cF (x; z; t) are respectively the drug concentration in the gel
and in the channel.
The mass balance of drug in the gel is:
∂cG
∂t
= ∇(DGd ∇cG), 0 < x < Lx, R(t) < z < S(t). (4.18)
where DGd is the effective diffusion coefficient of drug in the gel, and it depend on the
volumetric fraction of polymer:
DGd (φ) = D
SG
d exp
[
−βd
(
φ− φeq
1− φeq
)]
(4.19)
being DSGd the drug diffusivity in the completely swollen gel and βd a positive factor of
decay. (4.18) must be resolved with the initial condition:
cG(x, z, 0) = c0 for 0 ≤ z ≤ L0,∀x, S(0) = R(0) = L0 (4.20)
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Figure 4.13: Experimental differential release curves for Fluconazole (6% Glycerol) at
Q=2 ml/min for three films with different thicknesses.(dimensionless time rescaled t/tref ,
tref being the characteristic swelling time).
Figure 4.14: Differential release curve averaged over three repeated experiments.
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Figure 4.15: Integral release curve averaged over three repeated experiments.
Figure 4.16: Integral release curves (dimensionless time) of Fluconazole for increasing
values of the flow rate Q.OTFs at 6% Glycerol. Error bars represent STD over three
repeated experiments.
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Figure 4.17: Integral release curves (dimensionless time) of Fluconazole for increasing
values of the flow rate Q. Comparison between OTFs at 6% Glycerol (continuous lines)
and OTFs at 5% Glycerol (dashed lines).
Figure 4.18: Differential curve (the red one) and the exponential behavior derived (the
blue one)at flow rate of 11 ml/min on adimensional scale.
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with the boundary condition of impermeable wall at x = 0, Lx and Stefan condition at
glassy-rubbery interface z=R(t):
∂cG
∂x
∣∣∣∣
0,z
=
∂cG
∂x
∣∣∣∣
Lx,z
= 0 (4.21)
dR(t)
dt
(c0 − cG)
∣∣∣∣
x,R(t)
= DGd
∂cG
∂z
∣∣∣∣
x,R(t)
(4.22)
The mass transport in the channel is characterize by diffusion and convection:
∂cF
∂t
= DFd ∇2cF − vx(z, t)
∂c
∂x
, 0 < x < Lx, S(t) < z < Lz. (4.23)
where DFd is the diffusivity of the drug in the channel and vx(z, t) is the velocity of the
solvent in the channel:
vx(z, t) =
6Q(z − S(t))(Lz − z)
Ly(Lz − S(t))3 ,
∫ Lz
S(t)
vx(z
′, t)dz′ =
Q
Ly
(4.24)
Equation (4.23) need the boundary condition in the channel to be solved:
cF (x, z, 0) = 0 for S(0) ≤ z ≤ Lx,∀x, S(0) = R(0) = L0 (4.25)
and the Danckwertz condition at the exit of the channel and null flow on the top wall
of the channel:
∂cF
∂x
∣∣∣∣
Lx,z
= 0 (4.26)
∂cF
∂z
∣∣∣∣
x,Lz
= 0 (4.27)
The concentration profiles of drug in the channel and gel are connected by the continuity
condition at the gel-solvent interface S(t):
cF
∣∣
x,S(t)
= cG
∣∣
x,S(t)
, DFd
∂cF
∂z
∣∣∣∣
x,S(t)
= DSGd
∂cG
∂z
∣∣∣∣
x,S(t)
(4.28)
the diffusion coefficient at equilibrium in the fully swelled gel was estimated from the
asymptotic value of exponential decay of the differential curve of release for high flow
rate values, while the diffusion coefficient of the solvent in the gel completely swelled film
it was estimated by the swelling tests.
4.3.4 2D-Model
Starting from the solution of the swelling problem, which provides the position of the
fronts gel-solvent and glassy-rubbery at any instant of time, was possible to solve the
problem of drug release from film. The two-dimensional drug release model from thin
films was solved numerically by means of the finite element method in Comsol Multi-
physics 3.5 using the convection-diffusion package.
To make easier the resolution of the problem, we have transformed a problem of trans-
port with mobile frontiers to one with static borders, including the motion of boundaries
in the transport equations [295].
The following adimensional space/time variables were defined:
χ =
x
Lx
, τ =
t
tref
, tref =
L20
DSGs
(4.29)
λz =
Lz
L0
>> 1, λx =
Lx
L0
>> 1 (4.30)
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R˜(τ) =
R(t/tref )
L0
, S˜(τ) =
S(t/tref )
L0
(4.31)
ς =
z/L0 − S˜(τ)
λz − S˜(τ)
for S˜(τ) ≤ z/L0 ≤ λz (4.32)
ς =
z/L0 − S˜(τ)
S˜(τ)− R˜(τ) for R˜(τ) ≤ z/L0 ≤ S˜(τ) (4.33)
The adimensional concentration in the gel is:
CG(χ, ς, τ) =
cG(x, z, t)
c0
, (χ, ς) = ([0, 1] · [−1, 0]) (4.34)
and in the channel:
CF (χ, ς, τ) =
cF (x, z, t)
c0
, (χ, ς) = ([0, 1] · [0, 1]) (4.35)
The velocity in the channel from equation (4.24) becomes:
vχ(ς, τ) =
6PeDFd ς(1− ς)
L0(λz − S˜(τ))
(4.36)
where Pe is equal to the ratio between the characteristic time of convection of the drug
in the channel and the characteristic time of diffusion of drug in the channel.
Pe =
Q
LyDFd
(4.37)
Other adimensional parameters entering the transport equation are:
γF =
DFd
DSGs
, γSG =
DGd
DSGs
(4.38)
Through the adimensionalisations carried out, we have moved from two domains by
mobile frontiers, to two square domains with fixed borders. In adimensional terms the
transport equation within the gel becomes:
c0∂C
G
∂t
= ∇(DGd c0∇CG) (4.39)
where
∂CG
∂t
=
∂CG
∂τ
DSGs
L20
+
∂CG
∂ς
∂ς
∂τ
DSGs
L20
(4.40)
and:
∇(DGd ∇CG) =
DGd
L2x
∂2CG
∂χ2
+
DSGd
L20
1
(S˜(τ)− R˜(τ))2
∂
∂ς
(
fd(φ)
∂CG
∂ς
)
(4.41)
by combining the various terms we get:
∂CG
∂τ
DSGs
L20
+
∂CG
∂ς
∂ς
∂τ
DSGs
L20
=
DGd
L2x
∂2CG
∂χ2
+
DSGd
L20
1
(S˜(τ)− R˜(τ))2
∂
∂ς
(
fd(φ)
∂CG
∂ς
)
(4.42)
and replacing the various terms previously defined we obtain:
∂CG
∂τ
+ vGς (ς, τ)
∂CG
∂ς
=
γSGfd(φ)
λ2x
∂2CG
∂χ2
+ γSG
1
(S˜(τ)− R˜(τ))2
∂
∂ς
(
fd(φ)
∂CG
∂ς
)
(4.43)
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The boundary conditions in equations(4.21) and (4.22) become:
∂cG
∂χ
∣∣∣∣
0,ς
=
∂cG
∂χ
∣∣∣∣
1,ς
= 0 (4.44)
∂R˜(τ)
∂τ
(1− CG)
∣∣∣∣
χ,−1
=
γSGfd(φG)
(S˜(τ)− R˜(τ))
∂CG
∂ς
∣∣∣∣
χ,−1
(4.45)
In adimensional terms, the transport equation (4.23) within the channel becomes:
c0
∂CF
∂t
= −vx(z, t)c0 ∂C
F
∂x
+DFd c0∇2CF (4.46)
where
∂CF
∂t
=
DSGs
L20
∂CF
∂τ
+ vFς (ς, τ)
DSGs
L20
∂CF
∂ς
(4.47)
DFd ∇2CF =
DFd
L2x
∂2CF
∂χ2
+
DFd
L20(λz − S˜(τ))2
∂2CF
∂ς2
(4.48)
vx(z, t)
∂CF
∂x
=
6Pe
Lx
DFd ς(1− ς)
L0(λz − S˜(τ))
∂CF
∂χ
(4.49)
by combining the various terms and replacing the terms defined before you get it:
∂CF
∂τ
+ vFς (ς, τ)
∂CF
∂ς
=
γF
λ2x
∂2CF
∂χ2
+
γF
(λz − S˜(τ))2
∂2CF
∂ς2
− 6Pe
λx
γF ς(1− ς)
(λz − S˜(τ))
∂CF
∂χ
(4.50)
The initial condition in equation (4.25) and the boundary conditions (4.26) and (4.27)
becomes:
CF |0,ς = 0 (4.51)
∂CF
∂ς
∣∣∣∣
χ,1
= 0 (4.52)
∂CF
∂χ
∣∣∣∣
1,ς
= 0 (4.53)
The terms vGς (ς, τ) vFς (ς, τ) in equations (4.43) and (4.50) are equal to:
vGς (ς, τ) =
−∂S˜(τ)∂τ
(
1 + ς
)
+ ς ∂R˜(τ)∂τ
S˜(τ)− R˜(τ) (4.54)
vFς (ς, τ) =
1
λz − S˜(τ)
(
− ∂S˜(τ)
∂τ
(1− ς)
)
(4.55)
where the evolution in time of front positions S˜(τ) and R˜(τ) are given by the solution
of swelling model 1D. There to avoid any singularity a for the spatial variable ς, the
position of the erosion and swelling faces are set to S˜(0) = 1 and R˜(0) = 0.99. In
this way we identify the two different fronts and define the corresponding domain of
swollen gel 0.99 ≤ z/L0 ≤ 1 at time τ = 0. Initial conditions for concentrations are
CG(χ, ς, 0) = 0 and CF (χ, ς, 0) = 0.
The continuity condition at interface gel-solvent (equation (4.28)) becames a discon-
tinuity condition of flows, due to the different rescaling of ς in the gel and in the channel:
CF |χ,0 = CG|χ,0 (4.56)
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Figure 4.19: Comparison between the experimental results and numerical solution at 6%
glycerol.
Table 4.2: Summary table of the most significant data.
- 5%Glycerol 6%Glycerol
φ0water 0.195 0.184
φ∞polymer 0.28 0.36
φ∞water 0.72 0.64
φg 0.7 0.7
DSGs 2.1 · 10−5[cm2/min] 3.75 · 10−5[cm2/min]
βs 0 0
DSGd 5.528 · 10−5[cm2/min] 6.75 · 10−5[cm2/min]
βd 0 0
DFd 6.925 · 10−5[cm2/min] 6.925 · 10−5[cm2/min]
γF
1
(λz − S˜(τ))
∂CF
∂ς
∣∣∣∣
χ,0
= γSG
1
S˜(τ)− R˜(τ)
∂CG
∂ς
∣∣∣∣
χ,0
(4.57)
Table 4.2 shows the most significant data deriving from the experimental tests and
numerical solution. From the comparison of the experimental results in integral terms
has been shown that the curves at 5% and 6% glycerol are perfectly coincident if we use
the adimensional variable through the time of swelling. For this reason it is decided to
show just the problem solution at 6% glycerol (figure 4.19 ).
In the end figure 4.20 shows a comparison between the release profiles from milliflu-
idic device and Sotax paddle apparatus (always 6% of glycerol) just to highlight as USP
II made an overestimating the time scale of release. In fact release data from milliflu-
idic device are more relaiable than USP II release data because can better mime the
physiological condition of the mouth, with laminar tangential flow rate that reproduce
the fluidodynamic buccal behavior, instead of Sotax that is useful to simulate the gastro
intestinal tract and gastroenteric release.
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Figure 4.20: Comparison between the release data from USP II and millifluidic device
(6% glycerol).
4.4 Conclusion
Through this work it was possible to study a new polymeric thin buccal films (thickness
less than 100µm) made up to gellan gum (2%), fluconazole (14%) and 5-6% glycerol
useful for drug administration. Before studying film from the point of view of release
times, were analyzed in terms of mechanical strength, residual water quantity in dry film
and typical times of swelling.
Specifically, from TGA tests, it was possible to detect residual water in the dry film.
At 5% glycerol the amount of residual water is greater than in the case at 6%. From
swelling tests have been obtained that film at 5% need much time than those at 6% to
swell completely and these tests have allowed to estimate the solvent diffusion coefficient
in the swollen gel.
We have studied the dynamic of release with the use of the novel millifluidic device,
that can better mime the physiological fluidodinamic condition of the mouth. This device
is characterized by a laminar tangential flow of simulated saliva, that lays only the upper
surface of the film, while the lower surface adheres perfectly to the bottom plate. In this
way the drug and the solvent can diffuse just from one side, as is the case within the oral
cavity.
It was noted that release kinetics is strongly influenced by the thickness of the dry
film and solvent flow, but for high flow rates the resistance to the mass transfer to the
gel-solvent interface is reduced drastically, so the integral release curves become almost
independent of flow. A model has been developed to simulate both the swelling process
as well as the release. The swelling model shows the evolution of glassy-rubbery and
gel-solvent fronts in function of the time and is then embedded in the release process, to
see how the release dynamics is dependent on the characteristic times of swelling through
the diffusion coefficient in the swollen gel.
The release of drug is modeled as a non-stationary process of Fickian diffusion, char-
acterized by mobile boundary that describe the swelling to which it is subject the film,
initially in the glassy state, once in contact with simulated saliva.
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Chapter 5
Release analysis from HPMC
based erodible thin films
5.1 Introduction
5.1.1 Rapid disintegrating film (RDF)
Many pharmaceutical dosages are administered in the form of pills, granules, powders and
liquids. Generally a pill design is for swallowing intact or chewing to deliver a precise
dosage of medication to patients. The pills, which include tablets and capsules, are
able to retain their shapes under moderate pressure. However some patients particularly
pediatric and geriatric patients have difficulty in swallowing or chewing solid dosage forms
[298]. Many pediatric and geriatric patients are unwilling to take these solid preparations
due to fear of choking. Oral fast dissolving drug delivery system (OFDDS) is one such
novel approach to increase consumer acceptance by virtue of rapid disintegration, self
administration without water or chewing [299].
It is estimated that 50% of the population is affected by dysphasia which results in
high incidence of non-compliance and ineffective therapy [300]. To overcome this problem,
Oral Disintegrating Tablets (ODTs) were developed which are also known as fast dissolve,
rapid dissolve, rapid melt and quick disintegrating tablets. ODTs have been defined as
"A solid dosage form containing medicinal substances which disintegrates rapidly, usually
within a matter of seconds, when placed upon the tongue".
United States Food and Drug Administration (US FDA) further defines ODTs as solid
oral preparations that disintegrate rapidly in the oral cavity, with an in-vitro disintegra-
tion time of approximately 30 s or less, when based on the United States Pharmacopeia
(USP) disintegration test method or alternative [301]. Oral drug delivery technology
has improved from conventional dosage forms to modified release dosage forms to oral
disintegrating tablet to the recent development of oral disintegrating films (ODF). Most
ODTs are fragile and brittle, which need special package for protection during storage
and transportation. But the films are flexible, they are not as fragile as ODTs, easy
transportation, handling and storage [298].
Oral disintegrating film or strip can be defined as a dosage form that employs a water
dissolving polymer which allows the dosage form to quickly hydrate by saliva, adhere
to mucosa, and disintegrate within a few seconds, dissolve and releases medication for
oromucosal absorption when placed on the tongue or oral cavity. The sublingual mucosa
is relatively permeable due to thin membrane and large veins [302].
Dissolvable oral thin films (OTFs) or oral strip (OS) or rapid disintegrating films
(RDF) evolved over the past few years from the confection and oral care markets in the
form of breath strips and became a novel and widely accepted form by consumers for
delivering vitamins and personal care products.
RDFs are useful in patients, such as pediatric, geriatric, bedridden, or developmen-
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tally disabled, who may face difficulty in swallowing conventional tablets or capsules
and liquid orals or syrup, leading to ineffective therapy, with persistent nausea, sudden
episodes of allergic attacks, or coughing for those who have an active life style [303,304].
RDFs are also applicable when local action in the mouth is desirable such as local anes-
thetic for toothaches, oral ulcers, cold sores, or teething [305, 306]. Many drugs like
cough/cold remedies, sore throat, erectile dysfunction drugs, antihistaminics, antiasth-
matics, gastrointestinal disorders, nausea, pain and CNS drugs can be incorporated into
these delivery systems. Other applications include the preparation of caffeine strips,
multivitamins, sleeping aid snoring aid, etc.
Fast dissolving oral film when placed in the oral cavity, rapidly disintegrates and
dissolves to release the medication without chewing and intake of water [317, 318]. It
gives quick absorption and bioavailability comparable to intravenous administration.
Bioadhesive sublingual formulations [319], such as tablets [320], patches, and films,
have been developed using mucoadhesive polymers that can establish a strong adhesive
contact with the mucosa, allowing for an increase in residence time of the delivery system
and optimizing drug bioavailability [321]. The release kinetics of a given drug from
a polymeric matrix could be governed predominantly by the polymer morphology and
excipients present in the system [322].
5.1.2 Furosemide features
Furosemide (FUR) is a loop diuretic used orally in the treatment of edematous states
associated with cardiac, renal, and hepatic failures and in the treatment of hypertension
[307]. The usual dosage is 40–120 mg/day.
Data on solubility, oral absorption, and permeability are sufficiently exhaustive to
classify FUR into Class IV of the Biopharmaceutics Classification System. Due to the
carboxyl and sulfonamidic groups in the structure, with pKa of 3.8 and 9.6, respectively
[308], FUR shows a very low solubility in water that increases as a function of pH from
0.01 mg/mL at pH 2 to 1.9 mg/mL at pH 7.4 [309], determining a higher absorption
in the gastric rather than intestinal tracts. The bioavailability problems, reported as
consequences of variable and erratic gastrointestinal absorption, are probably due to
the low and pH-dependent solubility together with various existing polymorphic forms of
FUR [310]. Indeed, FUR presents different polymorphic forms: four are true polymorphs
(I, II, III, IV), two are solvates (IV-DMSO and V-dioxane) and one is an amorphous
form [323,324].
It is well known that different polymorphic forms of an active administered in the
oral or topical form can modify many properties like solubility, stability, color, com-
pressibility, flowability, and workability and as a consequence can cause differences in
bioavailability, toxicological safety, clinical effectiveness, and productive efficiency [311].
Different approaches have been proposed to enhance FUR absorption and bioavailability
such as co-crystallisation [312,313], solid dispersion [314], microemulsification [315], and
supramolecular complexes formation [316].
A number of techniques are employed to improve solubility of low solubility drugs.
Supersaturation is, in fact, a reality; solubility enhancing techniques do not augment the
solubility of insoluble drugs. Rather, these approaches present the drug in a form which
is optimal to its solubility. These techniques include solid dispersion, solvent disposition,
co-solvents, salt formation, pH control, micronization, co-grinding, use of surfactants,
use of precipitation inhibitors, solid solution, selective adsorption on insoluble carriers
and complexation [325,326].
In solvent disposition, solvent free solid dispersion are prepared for solubility en-
hancement where dispersion of drug takes place in a highly water soluble matrix whereby
the drug is dispersed in a hydrophilic matrix and solid solution or eutectic mixture is
formed [327–332].
In this work, the aim is to try to improve the solubilisation of a greater amount of
furosemide using cyclodextrins that is able to make a complex. The release of furosemide
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from erodible films HPMC5 based with and with cyclodextrins are carried out [360–362,
364].
The research in the Pharma Lux Lab in Oslo focused mainly on the study and analysis
of releases from thin film HPMC5-based. Furosemide was the model drug used. Releases
were performed using three different dissolution / analysis apparatus:
• Vertical diffusion cell (Franz cell);
• Millifluidic device;
• USP II Paddle dissolver (Sotax).
.
5.2 Materials and method
Potassium phosphate monobasic (KH2PO4), Sodium phoshate dibasic dehydrate (Na2HPO4)
and Sodium chloride (NaCl) used for the preparation of simulated saliva were pur-
chased from Merck, Darmstadt, Germany. For the preparation of mobile phase were
used Methanol (MeOH,VWR BHD Prolabo, Singapore) and MQ water produced by dis-
penser Milli-Q Integral 3 Water Purification System, Merck Milliepore, Billerica, MA,
USA .
Release studies were carried out using a jacket Franz diffusion cell [270]. The cylin-
drical donor chamber (cross-section area 1 cm2) was loaded with 0.1 ml of furosemide
solution 0.5 mg/ml (or 0.5mg/ml furosemide +5%w/v CD). The donor chamber was
separated by the receptor one with a dialysis membrane (Spectra/Porr 3, Standerd
RC Discs, MWCO 3.5 kDa, Spectrumr Laboratories, Rancho Dominguez, CA, USA)
having an area of 1 cm2 and thickness Lm= 40 µm.
The receptor chamber was filled with 7.9 ml of simulated saliva pH 6.7 (7.9mL receptor
volume; PermeGear, Hellertown, PA, USA, at 37 ◦C) under constant stirring (500 rpm).
Aliquots of 200 µl were withdrawn at fixed time intervals and replaced with equal volumes
of fresh saliva.
All the samples were quantified by analysis carried out with HPLC system, Shimadzu,
Kyoto, Japan, equipped with:
• Pump, LC-20AD;
• Auto injector, SIL-9A;
• Detector, SPD-10A;
• Plotter, Chromatopak C-R5A;
• Column oven, IGLOO-CIL HPLC column thermostat, SPC GmbH, Germany;
• Separation column, C18, 4 µm, 3.9 · 150 mm Cartridge Nova−Pakr Waters, USA
with a Nova− Pakr Guard Column C18, 4 µm, 3.9 · 20 mm ;
Furosemide was analyzed using a mixture consisting of methanol and phosphate buffer(pH
6.8) (30:70, v:v), as the mobile phase, with a flow rate 1 ml/min and measuring the drug
at 276 nm.
Sotax, Paddle apparatus (USP II Prolabo Dissolution Tester, France) in figure 5.1
was used to test the release at 37 ◦C and 50 rpm. Thin films was fixed at the bottom of
the vessel and 500 ml of preheated simulated saliva was use to fill the vessel. Aliquots
of 2 ml were withdrawn at fixed time intervals and replaced with equal volumes of fresh
saliva. Tests are repeated in triplicate.
Drug release experiments are performed in the newly proposed continuous flow-
through device [289,290]. Flow rates investigated in this work are in the range Q ∈ [1−5]
ml/min. Solution exiting the cell is sent to the UV/vis analyzer (UV-2401 PC, Shimadzu
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Figure 5.1: Sotax paddle apparatus for releases analysis.
Corporation, Kyoto, Japan, continuous flow cell, optical path 1 mm) in order to quantify
the amount of active ingredient released from the swelling film. The amount of drug re-
leased is calculated with a calibration curve. Calibration curve for Furosemide reference
standard (RS) is obtained by measuring the UV absorption (λ = 276nm) in dissolution
medium (simulated saliva). Tests are repeated in triplicate.
To evaluate the swelling-erosion behaviour films were cut in square pieces (1·1 cm),
weighted and inserted in a wet beaker. The system film+beaker was weighted. Then was
add 1.5 ml of simulated saliva (pH 6.7) at 37 ◦C ± 0,1 ◦C to allow thin films to swell and
erode. At regular time intervals the excess of simulated saliva was removed, wet system
film + beaker weighed and new fresh saliva was added to continue the test.
Films were produced by a casting/solvent evaporation technique using HPMC5 8%
w/v (Hypromellose 5 (HPMC), 5 mPas (1 % w/w, 25 ◦C), NMD, Oslo, Norway) and the
plasticizer Glycerol 2% w/v (Glycerol, NMD, Oslo, Norway) with or without cyclodex-
trins 5%w/v (Hydroxypropyl-beta-Cyclodextrins (2-hydroxypropyl- β -cyclodextrin), Cava-
sol W7 HP Pharma, degree of substitution 0.6–0.9 mol per unit anhydroglucose, Mw: ∼
1396 g/mol, ISP, Koln, Germany).
HPMC5 and Glycerol and CD were dissolved in 100ml furosemide (Furosemide, Sigma
Aldrich, Steinheim, Germany) solution 0.5 mg/ml previous done. The resulting solution
was solubilized at 25 ◦C (room temperature), under magnetic stirring, for five hours. The
mixture was coated onto Coatmaster 510 ERICHSEN GmbH and CO. KG, Germany (
figure 5.2 ), equipped with the Wasag Model 288 Film Applicator System, then dried at
room temperature for 15 hours. Thicknesses of OTFs are in the range 60 − 80µm for
OTFs without cyclodextrins and 80− 100µm for OTFs with cyclodextrins.
Thin films were detached from the coatmaster with a pocket knife and preserved in
an alluminium sachet (furosemide need to be protected from the light).
5.3 Results and discussion
5.3.1 Preliminary analysis
Before starting the study of the releases, it is important to carry out a careful analysis
of the system’s swelling-erosion behavior. In fact, during the releases the films are able
to absorb water and swelling as in the case of the Franz cell or swelling and dissolving
as in the case of releases from Sotax and millifluidic device.
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Figure 5.2: Coat master film applicator and drying.
Specifically in the figure 5.3 are shown swelling-erosion tests on films with and without
cyclodextrins. At first the films tend to absorb water, they reach a maximum weight
(equal to 3.5 times the initial one) and then begin to dissolve. The dissolution is very
fast. In fact is complete in 5 min for film without cyclodextrin and 3 min for film with
cyclodextrins .
The value of the maximum is very important and indispensable for the study of the
Franz cell release. This is because the film absorbing water and increase thickness and
hence the distribution domain of the drug in the donor chamber. In particular we can
approximate the degree of swelling to 3.5 and consider it instantaneous. The following
equation shows how the value of film thickness can be calculated as a result of swelling:
Th = Thdried−film + Thwater−uptake = Thdried−film +
P 0f (W/W0 − 1)
ρwaterA
(5.1)
where Thdried−film is the initial thickness, P 0f is the initial weight, W/W0 is the swelling
degree (3.5 in this case), ρwater the water density, and A the exposed section. The values
are 0.45 mm for films without CD and 0.58 mm for CD films.
From the swelling-erosion test is possible to estimate the diffusivity coefficient of
the solvent in the films (DGs = 0.7 · 10−8m2/s) and the erosion factor (in this case the
maximum value).
5.3.2 Release from Franz Cell
The Franz cell release studies started from the analysis of the blank (0.18 µg/ml solution
of furosemide with and without CD). The model used for the description of the release
differs greatly from the classic model normally used that consider perfect mixing in the
accepting chamber. In fact despite the presence of mechanical agitation, the geometry
and the level of agitation, considering the diffusivity of the drug in the solvent, are not
such as to obtain a perfect mixing within the accepting chamber. Strong gradients of
concentrations are formed such that the approximation of the accepting department as
homogeneous is not acceptable. Especially the area around the arm is characterized by
great gradients of concentration compared to the rest of the room. So inside the cell there
are real domains characterized by different fluid dynamics and transport conditions.
This is quite evident if you consider the images 5.4 and 5.5 showing the release from
Franz cell of Eritrosin dye (1.46 mg / ml) loaded in the donor chamber, at different times.
It is noted that during the 24h the arm cell is always less concentrate and therefore the
department is not homogeneous overall.
The donor department is the first domain where we have a purely diffuse transport
mechanism for the drug.
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Figure 5.3: Swelling erosion tests. W (t)/W0 represents the weight value of the film at
time t with respect to the initial weight. The swelling degree is 3.5 in both cases (with
and without cyclodextrins)
After passing the membrane (D), the drug is in the second domain (A) hypothesized
to be the central body of the Franz cell where it can be assumed a perfect mix or at
least a very high diffusivity space. So we have the arm area (C) of the cell in which the
transport mechanism is purely diffuse. Here the drug comes with more difficulty and
with longer times. The two zones are then connected by a fourth portion (B) of space,
in which the samples comes out to be analyzed and fresh saliva reintegrated. In this
area we have the largest gradients of concentration, and drug diffusivity passes from an
almost infinite value to that physically detectable in the arm.
The figure 5.6 highlights this. The diffusivity decreases exponentially D(s) from the
great value in the acceptor department, perfectly blended with concentration Cres, to
D0, the same as in the donor chamber.
In particular D(s) has the following expression:
D(s) = (Dres −D0)exp(−βs) +D0 with β = 1000m−1. (5.2)
where Dres ' 105D0 represents the diffusivity coefficient in the reservoir (it can be
approximated almost infinity), β a parameter and D0 the real diffusion coefficient (in the
donor chamber and in the arm).
The mathematical description of a model that takes account of these inequalities in
the accepting department is necessary for a correct interpretation of the experimental
data.
In fact the experimental data represent the concentration of domain B (this is the
zone of the withdrawal) and therefore this value of concentration is not representative of
all compartment. So considering an average concentration of the chamber is an interpre-
tation error.
Of course, in addition to the physics illustrated, the mathematical model developed
must also take into account the sampling (and therefore the withdrawals) carried out
during the release tests.
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Figure 5.4: Eritrosin Franz cell release at different times: A) 10 min, B) 90 min, C) 4 h,
D) 24 h.
Figure 5.5: Domains within the Franz cell. A) central body, B) connection zone, C) arm,
D) membrane.
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Figure 5.6: Geometric mapping of the concentration domains in the cell:s represents the
curvilinear abscissa describing the arm. D0 is the real diffusivity value of furosemide
while D(s) is the exponential decay from infinity value to real one D0 .
Model of Franz Cell
The amount of drug released at time t will be:
Mt = VdC
0
d − C¯dVd − C¯mVm = C¯resVres + C¯bVb +
Ni∑
j=1
Cp(tj)Vp (5.3)
where Vd and C0d are the volume and concentration of the loaded solution, C¯m and Vm
average concentration and volume of the membrane, C¯d and Vd mean concentration and
volume of the donor unit, C¯res and Vres concentration and volume of the reservoir,C¯b
and Vb mean concentration and volume of the arm, Cp and V p concentration and volume
of the jth sample for a total of Ni samples.
So:
VdC
0
d = C¯dVd + C¯mVm + C¯resVres + C¯bVb +
Ni∑
j=1
Cp(tj)Vp (5.4)
and get it:
C¯res =
VdC
0
d − C¯dVd − C¯mVm + C¯resVres − C¯bVb −
∑Ni
j=1 Cp(tj)Vp
Vres
(5.5)
considering roughly: {
Varm = 0.775ml
Vres = 7.12ml
Let us indicate with, Df , and Dm the effective diffusion coefficients in the donor chamber
and in the dialysis membrane, respectively. Considering A=1cm2 the surface of the
cell, d=1.12cm the diameter of the cell, H=1cm the height of the donor chamber and
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Lm = 40µm the thickness of the membrane, the mass transport within the donor chamber
can be written as (for an isotropic Bi-dimensional problem):
∂Cd
∂t
= (Df∇2Cd), for 0 < χ < d, 0 < ζ < H, Cd(t = 0, χ, ζ) = C0d . (5.6)
∂Cd
∂χ
∣∣∣∣
0,ζ
=
∂Cd
∂χ
∣∣∣∣
d,ζ
= 0 (5.7)
∂Cd
∂ζ
∣∣∣∣
χ,0
= 0 (5.8)
Df
∂Cd
∂ζ
∣∣∣∣
χ,H
= Dm
∂Cd
∂ζ
∣∣∣∣
χ,H
(5.9)
taking in account the condition of insulation on the walls and on the top of the cell and
the flow continuity condition at the membrane interface. For the membrane:
∂Cm
∂t
= (Dm∇2Cm), for 0 < χ < d, H < ζ < H + Lm, Cm(t = 0, χ, ζ) = 0.
(5.10)
∂Cm
∂χ
∣∣∣∣
0,ζ
=
∂Cm
∂χ
∣∣∣∣
d,ζ
= 0 (5.11)
Vres
∂Cres
∂t
= Dm
∂Cm
∂ζ
A. (5.12)
For the arm considering Lb = 6.5cm the length and db = 0.4cm the diameter, using
curviline axis (s and l) the mass transport is written:
∂Cb
∂t
= Df (
∂2Cb
∂s2
+
∂2Cb
∂l2
), for 0 < s < Lb, 0 < l < db, Cb(t = 0, s, l) = 0. (5.13)
∂Cb
∂l
∣∣∣∣
s,0
=
∂Cb
∂l
∣∣∣∣
s,db
= 0 (5.14)
∂Cb
∂s
∣∣∣∣
Lb,l
= 0 (5.15)
Df
∂Cb
∂s
∣∣∣∣
0,l
= Dres
∂Cres
∂s
∣∣∣∣
0,l
(5.16)
The picture (5.7) shows the physical domain for the mass transport within the Franz
cell. This is just the visual or an easy way for the description of the equation that regulate
the mass transport of furosemide in the Franz cell.
Is highlighted the presence of the membrane with concentration Cres at the interface
with the reservoir with perfect mixing. Then the arm with diffusivity value equal to D0 =
Df as in the donor chamber and finally the zone for the transition of fluidodynamical
condition, where the value of the diffusivity decrease with an exponential decay (as
illustrated by equation (5.2)) from infinity value to D0 = Df detectable in the arm.
The figure 5.8 reports the concentrations (differential curve) according to time. In this
chart is even better evident as the perfect mixing model is not able to describe the physics
of the release properly. In fact, the classic model fails to approximate quantitatively the
release, even though the qualitative trend is similar. Quantities and concentrations are,
however, quite different from those provided by the perfect mixing model, which therefore
fails a more accurate quantitative analysis of the release.
In figure 5.9, the difference between a perfect mixing pattern and an unperfect mixing
pattern is highlighted. In this picture the experimental data represents the integral value
based on a perfect mixing model. However the continuous line Mt that represent the
"unperfect mixing" theoric model, shows how should be the release in the real case.
90 Release analysis from HPMC based erodible thin films
Figure 5.7: Domain for mass transport used fro the numerical simulation. s is the
curviline axis and Cres the reservoir concentration.
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Figure 5.8: Differential release profile for modified model Vs experimental data. Cp is
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92 Release analysis from HPMC based erodible thin films
 0
 0.2
 0.4
 0.6
 0.8
 1
 0  5  10  15  20  25
M
ts
/M
∞
s
t [h]
furosemide
furosemide + CD
Figure 5.10: Normalization of integral curve for a classic release model.
Therefore, only in the case of a normalization of the release curves relative to the
total amount released, the perfect mixing curve is capable to satisfying the experimental
data, but only for diffusivity values lower than the real ones (figure5.10).
FromWilke-Chang’s relations (equation (3.8)) considering a VLB = 317.6 for furosemide,
we can estimate the diffusivity that is 5.78 · 10−10m2/s ( [274]).
From the analysis of blanks, considering a concentration of C0 = 180 µg/ml and
Dm = Df ·α we obtain the best fitting of the experimental data for Df = 5.78·10−10m2/s
, α = 0.5 and Df+CD = 1.73 · 10−10m2/s , α = 0.25 in case with CD (Figure 5.11).
Therefore, assuming the same α values previously defined in the case with and without
CD, we get a good approximation of the experimental data only for very low values of the
diffusion coefficient. Specifically Df = 2.89 · 10−10m2/s , Df+CD = 0.867 · 10−10m2/s.
The non-homogeneity of the department, which is not considered by a classical model,
is downloaded to the diffusivity value that becomes so much smaller than the real one.
Then films were analyzed in Franz cell. The physics and the equations-model is the same
defined before in this section. Of course the value of H change and becomes the thickness
of the film and the donor chamber diffusivity become DGf or D
G
f+CD with cyclodextrins.
Usually the average thickness is 67 ± 12µm for films without and 110 ± 21µm for films
with cyclodextrins.
The amount of drug loaded in the film was calculated from content uniformity tests
(figure 5.12).
The best fit of the data is obtained from the definition of the parameter ϕ, which is
the ratio PH20−residual/Pfilm−dry:
Pfilm =
a
1− ϕPfurosemide (5.17)
where a is a parameter could be 201 or 301, respectively without and with cyclodextrins.
It is assumed that the amount of residual water is the same in both cases. So ϕ =
0.123± 0.006. The superficial drug concentration for the films tested in the Franz cell is
70± 0.06 and 53± 0.06 mg/cm2, respectively without and with cyclodextrins.
The concentrations considered thus give the releases illustrated in figure 5.13 and
5.14.
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Figure 5.15: Example of film after release. Detail of erosion.
Experimental data and model are in agreement with each other and the best fitting
diffusion values are: {
DGf = 0.65 · 10−10m2/s
DGf+CD = 0.6 · 10−10m2/s
where DGf and D
G
f+CD are respectively the diffusivity coefficient in the film of furosemide
without and with cyclodextrin. The two values are quite close. In fact there is not so
big difference in the two release profile and the time scale of the release is similar even if
the amount released is different. In all cases with cyclodextrins, we made the hypothesis
that the furosemide is completely complexed.
The diffusivity values DSf , D
G
f , D
S
f+CD and D
G
f+CD are necessary to describe the
release into the millifluid device. DSf and D
S
f+CD are the diffusivity coefficients of
furosemide in solution without and with cyclodextrins ( DSf = Df and D
S
f+CD = Df+CD
).
However, the films in the device goes to swell and loseout erosion (as is possible to
see in picture 5.15 that shows the film after release). These two effects should be taken
into account during the release to avoid making mistakes in evaluating experimental
data [291,293,357–359,363].
5.3.3 Swelling-Erosion tests
The water up-take causes the matrix swelling, and the polymer disentanglement at the
matrix surface causes the matrix erosion. Thus, these two phenomena, swelling and
erosion, cause the matrix surface to be a moving boundary. Specifically before to write
the drug release model, we must solve the swelling pattern associated with the film taking
into account erosion [294], adding a term in the swelling equation (4.12):
dS
dt
= −DSGs
∂φ
∂t
− −Cφ
1.625
M1.25
(5.18)
where C and M are two erosion constant. Using adimensional swelling time τ = t·DGs /L20
becomes:
dS˜
dτ
= −∂φ
∂z˜
− Cφ1.625 (5.19)
96 Release analysis from HPMC based erodible thin films
 0
 0.5
 1
 1.5
 2
 2.5
 3
 3.5
 4
 0  200  400  600  800  1000  1200
W
(τ)
/W
0
τ=t/tref
film furosemide
film furosemide + CD
Figure 5.16: Swelling-erosion test for film with and without CD.W (t)/W0 represents the
weight value of the film at time t with respect to the initial weight. tref = L¯
2
DGs
where L¯
is the thickness of dry films and DGs is the solvent diffusivity.
Figure 5.16, shows the results of the swelling/erosion tests from which it is possible
to estimate DSGs and the erosion parameter C. In this picture is evident that erosion of
films with cyclodextrin is significantly faster. In particular, the value of P (t)/P0 (P0 is
the dry weight or the weight at time t=0) in function of the swelling time is reported
to consider the effect of the thickness. In the first times, thin film swell and is able to
retain water, but then the phenomenon of erosion and disintegration of the polymer with
weight reduction prevails and subsequent complete dissolution.
The model is based on equation (4.10),(4.11),(4.13),(4.14),(4.15) defined in the pre-
vious chapter, plus the equation (5.19). Swelling/erosion tests are associated with an
erosion rate that is assumed to be maximum. Obviously in the millifluidic device we will
have erosion rates lower but increasing as the flow increase. The Sotax may be associated
with the case of maximum erosion rates.
5.3.4 Sotax Vs Millifluidic device
By simultaneously solving the release model (equations (4.18),(4.20),(4.21),(4.22),(4.23),
(4.25),(4.26),(4.27),(4.28)) and the Swelling/erosion model we can describe the mil-
lifluidic curves for different flow rates Q ∈ [1− 5] ml/min (for D
G
f
DGs
' 0.01 and D
S
f
DGs
' 0.1
ratios values), going to fix the erosion parameter C which gives us the best fit of the data
(figure 5.17 and 5.18). The values of parameter C in both cases (for different value of
flow) are defined in table (5.1) and (5.2). From the these tables and figures is possible
to understand again as the erosion increase with the flow. The release from Sotax are
faster in both cases than the fastest release in the millifluidic device. Is also evident as
the releases are erosion-controlled and films with cyclodextrins are associated with swift
erosion and, as a consequence, swift release.
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Table 5.1: Erosion values for different flow values, without CD.
Q(ml/min) C
1 0.01
2 0.015
4 0.03
5 0.08
Sotax(50rpm) 0.1
Table 5.2: Erosion values for different flow values, with CD.
Q(ml/min) C
1 0.08
3 0.13
Sotax(50rpm) 0.25
5.4 Conclusion
HPMC5 based films were studied in this work. The releases were analyzed by 3 dif-
ferent devices: Franz cell, millifluid device and Sotax. An accurate Franz cell study
has highlighted as release from Franz cell is far from being a "perfect mixing" release.
Mathematical modeling has supported this thesis. In fact, a classical model can not ap-
proximate the experimental data, instead of a modified model that describes the release
profile very well (even from a quantitative analysis).
Then the swelling-erosion kinetics of HPMC-based film was modeled, necessary to
describe the release kinetics. Thus, the integral release profiles of the millifluid device
and the Sotax were compared (release condition in Sotax corresponding to a maximum
erosion rate).
Cyclodextrin releases appear to be slower (compared to those without) in the Franz
cell, where no erosion phenomenon is associated, but only low diffusion. On the other
hand, they are faster in the millifluid device and in the USP II, where instead the release
kinetics is mainly controlled by film erosion.
Mucoadhesion test should be investigated to verify the residence time of the for-
mulation required for drug transfer, but the analysis reported and the results obtained
show that HPMC-based thin films represent a valid drug delivery solution and useful fast
release formulations.
Chapter 6
Preventing drug crystallization in
glycerol-plasticized gellan gum
thin films
6.1 Introduction
The design of efficient films as carriers for drug delivery applications requires a proper
selection of the polymer and excipients used for their fabrication as they can affect
the ability of the films to swell, degrade and modulate the release of the therapeutic
molecule included in the formulation [333, 334]. The type of polymer can also influence
the mechanical properties of the film produced that should be robust enough to ensure
excellent resistance during handling, and application to the target site.
A large variety of film-forming polymers have been investigated over the last decade,
and among them, gellan gum, an anionic and linear biopolymer produced by Pseu-
domonas elodea, presents a set of unique properties that make this polysaccharide a
valid option for the fabrication of films. Specifically, gellan gum has attracted much at-
tention in both academic and industrial research because of its biocompatibility as well as
its gelling, texturizing, thickening, emulsifying, suspending, stabilizing and film-forming
properties [335,336].
Gellan gum films have been investigated in a great variety of applications ranging
from protective coatings to preserve the integrity of food [337–340] to more biomedical
related fields. For instance, gellan gum-based films have been studied as protective and
biodegradable film in wound healing [341,342] and bone regeneration [343]. The unique
properties of gellan gum films should be particularly beneficial also for the design of drug
delivery systems, however their application in this field is still almost unexplored. In
fact, only few works have investigated the inclusion of an active principle in gellan gum
films and their application as dosage forms [344].
These premises have motivated this study on gellan gum-based thin monolayered film
as potential materials for drug delivery applications. Particular attention was focused on
the homogeneous distribution of the active principle within the polymeric thin films, as
it represents the main challenge for this type of formulation when used for drug admin-
istration [344]. In fact, both the reduced size and thickness characteristics of the thin
films as well as the large number of excipients used in their formulation, including sol-
uble polymers, plasticizers, preservatives, may severely limit the loading levels capacity
of the dosage form. Uncontrolled crystallization of drug upon fabrication or storage is
frequently described for this kind of delivery systems, especially in all that cases where
a high dose of the active molecule is required. High drug loadings throughout the hy-
drophilic polymeric system may lead to aggregation processes with the formation of
fractal-shaped aggregates randomly distributes within the matrix, which adversely affect
99
100 Preventing drug crystallization in glycerol-plasticized gellan gum thin films
the uniformity of the resulting film [345,346].
Moreover, considering that most of the polymers used for film fabrication are hy-
drophilic macromolecules, as it is the case for gellan gum, the always-troubling integration
of drugs within polymeric films becomes particularly critical for lipophilic molecules [347].
Upon fabrication and storage, uncontrolled crystallization and crystal growth of the drug
are frequently facilitated by the short diffusion distances of molecules embedded within
thin films, therefore the resulting fractal patterns formed in thin polymer films are often
related to diffusion-controlled growth processes. If the active pharmaceutical ingredient
is not freely soluble in the polymer and is present at a supersaturated concentration,
then it may phase-separate from the polymer and subsequently crystallize. Such effects
potentially cause inhomogeneous drug distribution within drug-loaded films affecting
uniformity of the system as well as drug release kinetics and physical stability during
storage.
Casting, solidification processing and drying conditions as well as the right drug-
polymer-plasticizer combinations can have a significant impact on the homogeneous dis-
tribution of the drug in the dried final product [348]. Therefore, from a pharmaceutical
perspective, the stability of the film and the investigation of strategies aimed to avoid
drug nucleation and crystal growth as well as inhomogeneous distribution of the thera-
peutic molecule within the matrix deserve special attention as these aspects are of critical
importance for the development of commercially viable formulations.
To this end, process conditions and bulk materials characteristics, such as the viscosity
of the polymeric systems prior to drying as well as the drying conditions, need to be deeply
investigated as they have a contribution in preventing inhomogeneous drug distribution in
the final dry product. These critical aspects have motivated a study on gellan gum based
thin monolayered film as potential materials for drug delivery applications. Film casting
method was used as preliminary screening technique to determine the optimum ratio
among drug, polymer and plasticizer in order to overcome diffusion limited aggregation
(DLA) phenomena during fabrication and storage.
Fluconazole (F) and glycerol (Gly) were used as BCS I model drug and plasticizer,
respectively. The manufacturing process was optimized monitoring some critical param-
eters including the rheological properties of the starting polymeric solutions, air bubbles
entrapped, residual water in the final films and drying rate. The physical appearance,
thickness, mechanical and release properties of the resulting films were thoroughly inves-
tigated.
6.2 Materials and method
6.2.1 Materials
Fluconazole [C13H12F2N6O, 1H−1, 2, 4−Triazole−1−ethanol, α−(2, 4−difluorophenyl)−
α − (1H − 1, 2, 4 − triazol − 1 −methyl], gellan gum and glycerol used in the present
study were purchased from Sigma Aldrich. Cellulose membrane filters were obtained
from Medicell International. Methanol (CH3OH), glacial acetic acid (CH3COOH),
bidistilled water (for HPLC), potassium dihydrogen phosphate (KH2PO4), di-sodium
hydrogen phosphate dehydrate (Na2HPO4), sodium chloride (NaCl) and hydrochloric
acid (HCl), (used to prepare simulated saliva, pH= 6.7), were supplied by Carlo Erba
Reagents. HP − β − CD was purchased from Roquette.
6.2.2 Preparation of polymeric films
Films were produced by casting polymeric solutions (6 ml) containing constant concen-
tration of GG (2% w/v) and different amounts of the glycerol, ranging from 0.5% to
6% w/v. In specific, the following GG:Gly weight ratios were investigated: 1:0; 1:0.25;
1:0.5; 1:1; 1:1.5; 1:2; 1:2.5 and 1:3 (w/w). For film preparation, GG and glycerol were
dissolved in double distilled water and solubilized at 60 ◦C , for 5 hours under mild mag-
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netic stirring to avoid air bubble incorporation. The hot polymeric mixtures were poured
onto leveled silicone plates (diameter = 5.6 cm), let set and then dried in an oven at the
constant temperature of 40 ◦C ± 2 ◦C for 15 hours.
The same procedure was followed to prepare fluconazole-loaded thin films and, in this
case, 6 ml of 9.25 mM fluconazole solution in water were used to dissolve the different
GG:Gly mixtures, before the drying process.
All the samples were labelled as OTFX , where X indicate the amount of Gly used
for film preparation respect to GG. Instead, OTFXF was used for films containing also
fluconazole. Other samples were prepared including HP−β−CD in the formulation. An
equimolar amount of the selected cyclodextrin and fluconazole was used for the prepara-
tion of OTFCD films.
6.2.3 Preparation of inclusion complex cyclodextrins-drug
Binary complexes between fluconazole and HP-β-CD are prepared by the kneading tech-
nique or lyophilization. In the first case, equimolar amounts of the two components are
triturated in mortar until a homogeneous mixture is obtained. To this, 0.5 ml of a 50:50
(v / v) ethanol-water mixture is added and the mixture obtained, after mixing in a mor-
tar for another 30 minutes, is placed in a stove for 24 hours at temperature of 70 ◦C. The
product obtained, after complete drying, is again reduced to powder.
Binary system fluconazole/HP-β-CD were produced even for lyophilization. A sto-
ichiometric amount of drug was added to a HP-β-CD solution in order to obtain an
equimolar solution 1:1 of this two component. The solution obtained was mixed for 24h
at 25 ◦C and then freezed at −30 ◦C. At the end the solution was lyofilizated for the time
that the operation need to complete.
6.2.4 Rheological studies
Rheological experiments were carried out with a Haake Rheo Stress 300 Rotational
Rheometer (Germany) equipped with a Haake DC10 thermostat. Flow curves of all the
polymeric solutions were obtained with a cone-plate geometry in the range of 0.01–1000
Pa, working at 60 ◦C ± 0,1 ◦C. The effect of temperature on the viscoelastic properties
of the polymeric mixtures was also investigated through temperature sweep analysis in
the range 60 ◦C - 30 ◦C. All the experiments were carried out at least in triplicate.
6.2.5 Thickness measurements
Thickness of dry films was measured by means of a Mitutoyo Digimatic Micrometer,
characterized by an instrument error ±2µm. Measurements were taken at least at three
different points of each film.
6.2.6 Thermogravimetric analysis
Thermogravimetric analyses were carried out using a Q600 TGA (TA Instruments). Sam-
ples of the films (30mg) were put in open aluminum pans and submitted to three heat-
ing/cooling cycles in the temperature range from 25 ◦C - 120 ◦C under nitrogen atmo-
sphere (5ml/min). Thermograms were recorded at the constant heating rate of 5 ◦C/min.
6.2.7 Differential scanning calorimetry
Calorimetric measurements were carried out using a DSC131 (Setaram, France) differ-
ential scanning calorimeter. Samples (5mg) of anhydrous dust fluconazole, freeze-dried
fluconazole, buccal film of fluconazole, gellan and glycerol with different concentrations
were weighted in sealed aluminum pans. Then were examined at three heating/cooling
cycles in a temperature range from 25 ◦C - 170 ◦C, flowing nitrogen atmosphere (20
ml/min). Thermograms were recorded at the constant heating rate of 5 ◦C/min. An
empty aluminum pan was used as reference.
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6.2.8 Tensile tests
Tensile tests were performed with a ZWICK-ROELL-Z010 mechanical testing machine,
using a normal load of 1kN and a strain rate of 1mm/min. Ten specimens of opportune
dimensions were cut from each film, mounted between the grips of the machine and
tested to fracture. Specimens were cut in three different directions (angle 0◦,45◦,90◦)
of the film, in order to verify the isotropy of the material. Stress-strain diagrams were
recorded and Young’s modulus, strain and stress at break were acquired. Results were
reported as mean values ± standard deviation.
6.2.9 Swelling studies
Films were cut in square pieces (2·2 cm), weighted and inserted in beaker containing sim-
ulated saliva (pH 6.7) at 37 ◦C ± 0,1 ◦C. At regular time intervals, wet films were drained
to remove excess water and weighed. The water-uptake capacity (Q) was expressed as:
Q =
Ws(t)−W0
W0
(6.1)
where Ws(t) and W0 are the weight of the swollen film at time t and that of the starting
dry film, respectively. Alternatively, the Q value was calculated according to Eq.2.
Q =
Ws(t)−Wd
Wd
(6.2)
whereWs(t) andWd are, respectively, the weight of the swollen film after 2h in simulated
saliva and that of the film recovered at the end of the swelling study and dried to constant
weight. Eq. 2 enables considering the amount of glycerol lost during the swelling process.
To this end, portions of the investigated films were kept for 2h in simulated saliva at 37 ◦C
± 0,1 ◦C, then they were removed from the medium and oven-dried at 70 ◦C to constant
weight, in order to calculate the amount of glycerol leached out the films. Each test was
repeated in triplicate and the results reported as mean ± SD.
6.2.10 Mucoadhesion tests
The mucoadhesive properties of GG:Gly films were evaluated in vitro, measuring the
force required for detaching the films from a mucin tablet. The measurements were
carried according to an already reported method, based on an in-house pulley system
apparatus [349]. Briefly, a mucin tablet (diameter 12.5 mm, thickness 1.34 mm) was
stucked onto a holder connected to one arm of the pulley system. Then, round-shaped
portions of the films (diameter 12.5 mm) were attached to the mucin tablets, previously
wetted with simulated saliva (pH 6.7). The mucoadhesiveness of the film was measured
by adding water to a container connected to the second arm of the pulley system until
the film was separated from the tablet. The weight of water needed to separate the film
from the mucin tablet was recorded and introduced in the following equation for the
calculation of the detachment force:
N = V ρg (6.3)
where V is the volume of added water, ρ is the density of water and g is the acceleration
due to gravity.
6.2.11 Uniformity of drug content tests
The uniformity of drug content within the films was assessed by dividing a sample of
fluconazole-loaded OTF2.5 in three parts. Each individual part of the film was weighted
and then it was extensively extracted with distilled water. The concentration of flucona-
zole in the obtained solutions was evaluated by HPLC analysis, carried out with a Perkin
Chapter 6 103
Elmer system composed of a Series 200 LC pump, a 235 Diode Array Detector, a Total
Chrom data processor and equipped with a RP-18 (250-4.5 µm) Merck Hibar LiChrocart
column. The analyses were carried out under isocratic conditions, using a mobile phase
composed of a methanol, bidistilled water and glacial acetic acid mixture in proportion
of 50:48:2 (v:v:v). The flow rate of the mobile phase was maintained at 0.8 ml/min and
the drug was monitored at λ = 260nm. Under these conditions, fluconazole retention
time was about 6 minutes. All experiments were carried out in triplicate.
6.2.12 In vitro release studies
Dissolution tests were carried out in a conventional USP type II paddle apparatus and
the millifluidic device. For the dissolution test in the paddle apparatus samples of round
shape fluconazole-loaded OTF (surface area 98.5 cm2) were placed in different part of
the vessel: a) taped on the side wall; b) taped on the bottom; c) anchored to the bottom
with a wire mesh. All the release studies were carried out in 500 mL of simulated saliva
(phosphate buffer, pH 6.7, containing 0.137M NaCl) at 37 ◦C ± 0,1 ◦C with a rotation
rate of 50 rpm. Aliquots of the release medium (2 mL) were taken at appropriate time
intervals from 1 to 30 min and immediately replenished with the same volume of fresh
simulated saliva. Fluconazole concentrations were assayed by HPLC analysis. Tests
were repeated in triplicate and the results were expressed as mean values ± the standard
deviation.
6.3 Results and discussion
6.3.1 Preparation of GG:Gly thin films
Deacylated gellan gum easily forms films for casting of its aqueous solutions. In this
work, film forming solutions of the polymer were casted in round-shaped silicone molds,
in order to obtain strips with defined dimensions and shape. In the solvent casting
process, film fabrication involves the initial deposition of a liquid polymeric film on an
opportune surface of a solid support and the subsequent evaporation of the solvent with
conversion of the viscous liquid polymeric film into a solid polymeric film. The quality and
characteristics of the final product are critically dependent on several physical properties
of the initial film-forming solution, as well as the manufacturing conditions, such as
the rate of solvent evaporation from the liquid film [350–352]. For this reason, both the
rheological properties of the starting gellan gum solutions and their temperature-induced
modification during casting of the liquid film and the evaporation step, were evaluated
in the present work as they have a significant impact on the final properties of the film
produced. In particular, absence of entrapped air bubbles or uniform distribution of
active pharmaceutical agents within the medicated strips represent the most important
and desired characteristics of polymeric films for drug delivery application, because they
critically affect the performance of the formulation as pharmaceutical products.
All that considered, the first step of the experimental work involved the rheological
characterization of the film-precursor polymer solutions, which were obtained stirring
gellan gum at 60 ◦C for five hours to enable the polymer to dissolve completely and ob-
tain a homogeneous solution. Figure 6.1 and 6.2 shows the viscosity curves of gellan
gum, at three different polymer concentrations 2.0, 2.5, 3.0% w/v, at 60 ◦C. As ex-
pected, all the solutions in the concentration range under investigation can be described
as non-Newtonian fluids, with a shear thinning behavior. Depending on the polymer
concentration, the viscosities of the investigated systems ranged from 100 to 10.000 Pa·s
at 60 ◦C and shear rate of 10−4s−1.
Gellan gum solutions with a concentration 2.5% w/v resulted in non-uniform de-
position of the polymer in a thin layer, probably as a consequence of their viscosity.
Therefore, in order to avoid casting defects within the dried products, 2%w/v gellan
gum solutions were selected for further studies. According to the literature, casting of
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Figure 6.1: Flow curves of GG solutions at 60 ◦C: effect of polymer concentration on
solution viscosity.
gellan gum solutions resulted, after the drying process, in the formation of very brittle
films, which were hardly removed from the silicon molds used for the casting process [338].
Without at least a minimal concentration of a plasticizer, pure gellan gum films show
interactions among the polymeric chains, which resulted in high rigid structures with
poor mechanical properties. For this reason, different amounts of glycerol ranging from
0.5% to 6% w/v were added to 2% (w/v) gellan gum solutions. Glycerol was selected on
the basis of the results reported by Yang L. and coworkers [338], who evaluated the effect
of different plasticizers on the mechanical properties of gellan gum films, observing that
glycerol-plasticized films were more stretchable and transparent, than PEG 400, sorbitol,
propylene glycol or ethylene glycol - plasticized films.
The addition of a plasticizer to gellan gum solutions may lead to a decrease in in-
termolecular forces along the macromolecular chains as glycerol penetrate the polymeric
network, and, in this way, it may influence both the flowing behavior of the film forming
solutions, through the development of polymer-plasticizer hydrogen bonds, and the film
formation process.
Therefore, preliminary experiments aiming to study the effect of glycerol concen-
tration on the viscosity properties of 2% w/v gellan gum solutions, were carried out.
Flow curves of gellan gum-glycerol mixtures at different polymer to glycerol ratio were
recorded and the results reported in figure 6.2. It can be observed that, irrespective from
the amount of plasticizer used, all gellan gum-glycerol mixtures showed almost the same
flowing behavior when shear stress was applied and linearly increased from 0.01 to 1000
Pa.
Besides investigating the flow behavior of gellan gum/glycerol mixtures, also the effect
of the plasticizer on the gelation process of the polymer was studied. The experimental
conditions for the formation of polymeric films with appropriate properties should be
optimized considering a low difference between the temperature of the polymer solution
before casting and the gelation point of the systems. Therefore, the behavior of storage
modulus and loss modulus (G’ and G”) and the relationship between gelation temperature
and plasticizer concentration were investigated through temperature sweep measurements
from 60 ◦C down to 37 ◦C. The results reported in table 6.1 show that the crossover point
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Figure 6.2: Flow curves of GG solutions at 60 ◦C: effect of glycerol concentration on GG
(2% w/v) viscosity.
Table 6.1: Effect of glycerol concentration on the gelation temperature of gellan gum
solutions, 2% (w/v).
% Glycerol(w/v) % Gellan gum (w/v) Gelation temperature (◦C)
0 2 49.3± 1.5
0.5 2 51.9± 0.4
1 2 51.0± 1.0
2 2 52.4± 0.2
5 2 51.7± 1.4
of G’ and G” slightly shifted toward higher temperature when glycerol was added to GG
solutions, with almost no differences for the different polymer-plasticizer combinations
analyzed. At 60 ◦C all the systems behave like solutions, as the loss modulus G” is, in
all the cases, higher than the corresponding storage modulus G’.
Therefore, in the film formation process, all the GG:Gly mixtures behave like solutions
when poured in the silicon molds, then they formed thin liquid layers, which experienced
a rapid temperature modification, due to the reduced thickness, and consequent sol-gel
transitions with the inversion of the G’ and G” moduli.
After the casting step, all the systems were dehydrated at the constant temperature
of 40 ◦C until polymeric films were obtained and easily peeled off from the molds. TGA
was used to monitor residual water content in the plasticized films during the drying
step. Residence time lower than 15 hours in the drying oven, did not produce films of
acceptable flexibility; instead clear and transparent films were obtained and easily peeled
off from the support, when the residual water content in the final plasticized film, was in
the range 9.4-11.5%, depending on the glycerol percentage. Such residual water content
was obtained keeping the systems at the constant temperature of 40 ◦C for 15 hours.
Therefore, the maximum drying time for complete film formation was set at 15 h,
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Figure 6.3: Thermogravimetric curves of OTF containing 2,3,5 and 6% (w/v) of glycerol.
because prolonging any further the drying process brought to excessive dehydration of
the films, which resulted in poor mechanical properties, even in high-plasticized systems.
In fact, beside glycerol, also the presence of water molecules within the constrained poly-
meric networks is able to increase the macromolecular mobility, while reducing the system
rigidity. As expected, to higher percentages of glycerol in the film-forming solutions cor-
responded higher amounts of residual water within the dried films, when same drying
times were applied, as observed from the thermogravimetric curves (figure 6.3).
Under the adopted experimental conditions (drying at 40 ◦C for 15 hours), films with
mean thickness values varying from 25.8 ± 2.8 to 157.7 ± 6.6 µm were obtained (table
6.2). Considering that the amount of gellan gum was maintained constant, the increase
of plasticizer concentration in the film-forming solutions rises the total mass of solids
casted in the molds and, consequently, an almost linear increase of the thickness of the
corresponding dried films was observed. Two different film formulations can be defined:
mucoadhesive buccal films and orodispersible films [353].
This classification is operated on the basis of the release rate of the drug included in
the formulation, whereas no specification about the thickness of film is reported. Anyway,
it is generally accepted that ultra-thin films for buccal delivery have a thickness comprised
in the range 50-150µm [333]. Therefore, irrespective from the amount of glycerol used,
all the systems prepared almost falls within the limits for ultra-thin film classification.
6.3.2 Mechanical properties of GG:Gly thin films
The mechanical properties of the final films were influenced by glycerol concentration.
For the dried films, the values of Young’s modulus suggest that the flexibility increased
linearly when plasticizer concentration increased from 0.5 to 6% w/v. A progressive
reduction of Young’s modulus and a corresponding increase in the percentage of defor-
mation at break can be observed in figure 6.4B-C for increasing amount of glycerol. The
high number of hydroxyl groups and carboxyl groups along gellan chains are responsible
for the formation of numerous hydrogen bonds and extensive intra- and inter-molecular
interactions, which may contribute to the high mechanical strength and low flexibility of
unplasticized or low plasticized gellan films.
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When small quantities of glycerol are used, a strong interaction might occur between
the polymer and the plasticizer, producing a "cross-linker" effect, which decreases the
free volume and the molecular mobility of the polymer, thus reducing the flexibility of
the films. Instead, incorporation of at least 50% w/w of glycerol within these systems
probably replaces some of the gellan–gellan hydrogen bonds with glycerol-gellan hydro-
gen bonds, increasing the intermolecular separation of the gellan chains, with consequent
increase in the chain segmental mobility. This effect results in a reduction of the mechan-
ical strength of the films, whereas their flexibility was enhanced (figure 6.4A-B). Beside
glycerol, also the residual water influences gellan gum mobility contributing to the elas-
ticity of the films. No preferential orientation of the polymeric chains was evidenced
along one specific direction of the films. In fact, tensile tests carried out on specimens
of each OTF cut in three different directions failed to evidence differences among the
obtained results, thus suggesting that all the films were completely isotropic in terms of
tensile properties.
6.3.3 Swelling studies
All the OTFs were studied for their swelling ability. In a first attempt, the swelling
degree of the thin films was calculated as the ratio between the weight of the swelled and
the starting dry film. The obtained results are reported in figure 6.5. It can be observed
a progressive reduction of the equilibrium Q values as the amount of glycerol in the films
was increased. However, considering the presence of glycerol, its small dimension and its
high solubility in water, it was subsequently evaluated whether a loss of the plasticizer
may occur during the swelling study and in what extent this eventual loss may affect
the results of the swelling measurements. In fact, as the OTFs prepared in this work did
not undergo any degradation process in the time frame of the swelling study, glycerol
may diffuse toward the swelling medium enabling water penetration within the polymeric
film.
All that considered, it was evaluated the rate of glycerol loss from the OTFs. To
this end, samples of the different films were let to swell in simulated saliva, then, at
regular time intervals, the films were removed from the swelling medium, weighted and
dried to constant weight. It was found that the plasticizer diffused out the films almost
completely within 20 minutes of contact with simulated saliva. In fact, the weight of the
samples, recovered at the end of this study and dried, almost corresponds to the value
expected for a film made only of gellan gum (figure 6.7).
Therefore, the equilibrium swelling data were corrected considering the loss of the
plasticizer towards the swelling medium and the results are reported in figure 6.6. An
opposite trend in the swelling capacity of the different OTF can be observed in this case.
In fact, the amount of water taken up by the films at equilibrium increases with the
percentage of glycerol originally present in the polymeric strip. In view of these results,
plasticized OTFs, specially those designed for sustained drug release, should be evaluated
considering that a loss of the plasticizer may occur within time, with consequent possible
effects on some of the properties of the films, such as the swelling capacity, the mechanical
properties and the release rate.
6.3.4 Evaluation of the mucoadhesive properties of GG:Gly thin
films
The mucoadhesive properties of GG:Gly films were evaluated in vitro measuring the
force required for detaching the films from a mucin tablet. The obtained results are
reported in table 6.3. A progressive reduction of the force required for detaching the
OTFs from mucin was observed when the increasing amounts of glycerol were used in the
formulation of the polymeric films. In particular, a marked drop in the mucoadhesive
properties of the films was measured for OTF1 containing equal amounts of polymer and
plasticizer. It is likely that the excess of plasticizer prevents GG from interpenetrating
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Figure 6.4: Mechanical properties of gellan based OTF containing different amount of the
plasticizer glycerol: A) tensile strength and break; B) Young modulus and C) elongation
at break.
and interacting with mucin thus negatively affecting the mucoadhesive properties of the
final formulation.
6.3.5 Drug loaded films
Glycerol-plasticized films were loaded with a BCS I model drug, namely fluconazole.
Although fluconazole is slightly soluble in water [354], uniform distribution of the drug
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Figure 6.5: Dynamic swelling study. Evaluation of the variation of the swelling capacity
within time for the gellan based OTFs containing different amount of the plasticizer
glycerol.
Table 6.3: Mucoadhesive properties of GG:Gly thin films.
Sample Weight ratio GG:Gly Force(N)
OTF0.25 1 : 0.25 0.71± 0.03
OTF0.5 1 : 0.5 0.58± 0.01
OTF1 1 : 1 0.13± 0.01
OTF2.5 1 : 2.5 0.05± 0.01
within gellan gum films was critically dependent on the amount of glycerol used, when
0.64mg/cm2 of fluconazole was included in the formulation. In fact, strips containing
concentration of the plasticizer lower than 70% w/w resulted in separation of white
aggregates within the polymeric matrix, probably due to phenomena of limited diffusion
aggregation of the drug molecules (figure 6.8).
After the drying process, all the systems showed an initial homogeneous appearance
with no presence of aggregates, as evidenced by visual observation and confirmed by DSC
analysis. In fact, no melting peaks of fluconazole were observed in the corresponding
thermograms. However, films containing an amount of glycerol 50% w/w shown the
appearance of some aggregates of fluconazole within few days from the preparation. It
was observed that fluconazole aggregation depends on glycerol concentration within the
films. In fact, a faster appearance of drug aggregates was observed in strips with lower
amount of the plasticizer, maybe because of the different ability of fluconazole to diffuse
within the differently plasticized systems. Low mobility of the drug may cause segregation
of fluconazole within drug-rich regions of the film where local concentration may exceed
its saturation limit, thus promoting its nucleation and crystallization, according to the
general believing that branch-structured dendritic crystallization is a result of phase
separation from supersaturated states [355,356].
In contrast, a more homogeneous drug distribution could be achieved when high
amount of the plasticizer were added to the formulation. According with the effect of
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Figure 6.6: Effect of glycerol content on the swelling capacity of gellan based OTFs.
The swelling degree was calculated as the weight ratio between the swollen film (Ws)
and the weight of the film before swelling (W0) (red line) or as the weight ratio between
the swollen film (Ws) and the weight of the dried residual film recovered after 2 h in
simulated saliva at 37 ◦C± 0,1 ◦C (blue line).
Figure 6.7: Analysis of the composition of the OTFs recovered after 2h in simulated
saliva (pH 6.7) at 37 ◦C± 0,1 ◦C and dried to constant weight.
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Figure 6.8: Photographs of (A) low-plasticized gellan based OTF containing 50% w/w
of glycerol and (B) high-plasticized films containing 70% w/w of glycerol. The presence
of crystals of fluconazole is well visible in low plasticized OTFs.
glycerol on the tensile properties of gellan films, it is likely that the presence of glycerol
reduced the intermolecular interaction among gellan gum chains producing the formation
of a less tight matrix, where fluconazole could be distributed more uniformly (figure 6.9).
According with this hypothesis, no signs of drug crystallization were observed when
equimolar amounts of fluconazole and HP −β−CD were introduced in the formulation.
The presence of HP − β −CD was able to suppress drug nucleation and further crystal
growth even in glycerol-free films. A quite low amount of HP − β − CD (76 mg, 0.055
mmoles) was used in the formulation, therefore the observed effect is more likely due
to an altered disposition of the drug in the final film caused by cyclodextrin, than to a
modified interaction between gellan gum chains. In fact, HP − β − CD may produce a
preferential localization of fluconazole in its internal cavity during the OTF formation,
thus preventing drug aggregation, with a minimal interference in the arrangement of the
polymeric chains in the dried film.
The presence of drug aggregates was confirmed by DSC analysis. The thermograms
reported in figure 6.10 show the presence of an endothermic peak, which can be attributed
to drug recrystallization within the polymeric matrix. It can also be observed a shift of the
melting temperature of fluconazole toward lower values and the progressive broadening
of the peak with increasing glycerol concentrations maybe due to certain amount of
plasticizer, which remains within the crystal lattice, introducing defects in the structure
during the crystallization process. The presence of fluconazole crystals was put into
evidence with thermal analysis for concentration of glycerol lower than 50% w/w, whereas
no endothermic peak of fluconazole could be observed in films containing 50% w/w of
plasticizer (OTF1), even though white aggregates were well visible within the strips.
It is likely that the inclusion of glycerol within fluconazole lattice first reduces the de-
gree of crystallinity of the drug, and then it converts the solid into a complete amorphous
structure. Similar results were already reported for felodipin loaded thin films [345]. An
alternative explanation may also be proposed for this behavior. In specific, consider-
ing the relatively high amount of glycerol employed in OTF1, the disappearance of the
melting peak of fluconazole may be consequent to drug solubilization in the excess of
plasticizer present in the film. In fact, as solubility increases with temperature, dissolu-
tion of fluconazole in glycerol may occur during the heating phase of the DSC analysis
which, for this reason, fail to evidence the presence of the drug in the sample [345].
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Figure 6.9: Schematization of the different distribution in low and high plasticized gellan
based OTFs.
Based on these results, high amounts of plasticizer need to be used in the formula-
tion of fluconazole loaded GG based OTFs in order to have a stable and homogeneous
molecular dispersion of the drug within the polymeric matrix. In specific, at least 70%
w/w of glycerol have to be present in the final formulation in order to avoid any drug
aggregation within the thin film.
Fluconazole loaded thin films containing a 1:2.5 (w/w) GG:Gly ratio were selected
for further investigation, because systems containing lower amounts of glycerol resulted
in fast drug aggregation within few days from the preparation. OTF2.5 were further
characterized in order to evaluate the effect of fluconazole on the main properties of the
OTFs and investigate their possible use as drug delivery systems.
The residual water content and the correlated tensile properties were not significantly
affected by the presence of fluconazole within the films with values similar to plain for-
mulation (data not shown).
6.3.6 Release studies
After evaluation of the uniform distribution of fluconazole within OTF2.5 and OTF3
films, these samples were studied for the release profile of the drug in simulated saliva
(pH 6.7) at 37 ◦C ± 0,1 ◦C using a USP type II apparatus. The results showed almost
no difference between films containing 70 or 75% w/w of glycerol (data not shown). In
both cases, fluconazole was completely release from the film within 15 min, in agreement
with the results of the swelling studies which evidenced similar Q values for OTF2.5 and
OTF3.
On the contrary, a slower release was observed from films containing HP − β − CD
(figure 6.11). These results can be explained assuming the formation of an inclusion
complex of fluconazole. The drug is free in OTF2.5 and OTF3 samples. This may
explain the faster release rate of the drug compared with OTFCD where fluconazole is,
at least partially, complexed and bonded in the cavity of the HP − β − CD and is able
to diffuse in the medium just with a low value of the diffusion coefficient due to the great
steric volume.
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Figure 6.10: Thermograms of free fluconazole and drug loaded OTFs containing different
amount of glycerol.
The release analysis were carried out also in the millifluidic device in the range of Q ∈
[1− 5] ml/min and 37 ◦C. Even in this case the release of fluconazole with cyclodextrins
is slower than the case without, as it’s possible to verify in figure 6.12
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Figure 6.11: Release profile of fluconazole from OTF3 and OTFCD in simulated saliva (
pH 6.7 ) at 37 ◦C± 0,1 ◦C ( USP II ).
In the figures 6.13 and 6.14 the same releases are shown on the basis of the adimen-
sional time. It is important to consider a reference time that takes into account the
different film thickness and the solvent diffusivity in the films. In particular, an aver-
age thickness of 70µm and 100 µm respectively for the film at 6% glycerol and with
cyclodextrins were considered, and a diffusivity of solvent in the film Ds = 5.25 · 10−11
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Figure 6.12: Release profile of fluconazole from OTF3 and OTFCD in simulated saliva
(pH 6.7) at 37 ◦C± 0,1 ◦C, Q=2ml/min (millifluidic device).
m2/s.
The adimensional analysis is very important as it highlight as the profiles are very
close. Then even lowering the amount of glycerol we can get good mechanical and
mucoadhesive properties while maintaining the same time scale for the release of the
same amount of loaded drug .
6.4 Conclusion
The potential of deacylated gellan gum thin films for drug delivery was investigated.
The addition of a plasticizer was required to improve the poor mechanical properties of
the polymer formulated as a thin film. It was observed that, while low amount of the
plasticizer glycerol were sufficient to increase the resistance and strength before rupture
of the films, they resulted to be completely inadequate to have the model drug fluconazole
homogeneously distributed within the polymeric matrix. In fact, much higher percentages
of glycerol were needed to prevent drug nucleation and crystallization within the film, at
least within a short timescale.
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Figure 6.13: Release profile of fluconazole from OTF3 and OTFCD in simulated saliva (
pH 6.7 ) at 37 ◦C± 0,1 ◦C ( USP II ). tref = L¯2Ds where L¯ is the average thickness and Ds
is the solvent diffusivity.
 0
 0.2
 0.4
 0.6
 0.8
 1
 0  2  4  6  8  10
M
t/M
∞
τ=t/tref 
2% Gly + Cyclodextrine
6% Gly
Figure 6.14: Release profile of fluconazole from OTF3 and OTFCD in simulated saliva
(pH 6.7) at 37 ◦C ± 0,1 ◦C, Q=2ml/min (millifluidic device). tref = L¯2Ds where L¯ is the
average thickness and Ds is the solvent diffusivity.
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General conclusions
The main results presented in this research work can be summarized as follows:
• the design and preparation of hydrogels and OTFs based on natural and biocompat-
ible polysaccharides for topical and buccal drugs delivery and the optimization of
concentrations of the main components (polymer, plasticizer and / or cyclodextrins)
to provide the best performances for an effective utilization of the formulation;
• a proper estimate of release time-scales from OTFs for buccal release by means of
the recently proposed millifluidic flow-through device;
• the development of mathematical models able to properly describe the experimental
data and release kinetics in different apparatuses. In particular:
– a double-moving boundary model describing swelling and release from OTFs
in the millifluic device;
– a polymer-drug interaction model for describing diffusion and release from
hydrogels in a vertical Franz cell;
– a new approach to the description and interpretation of Franz cell release
data including the effects of the "unperfect mixing" chamber and withdrawal
position.
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Grazie a Giorgio. Io l’ho sempre detto che eravamo un trio perfetto con Settimio.
Ogni volta hai qualcosa da raccontare, qualcosa da fare. Con te non ci si annoia mai. Mi
metti allegria. Pronti per un altro capodanno insieme.
Non posso dimenticarmi di Ludovico ed Edoardo. I miei compagni di banco per ec-
cellenza. Mi dispiace vederci solo saltuariamente. Ma il ricordo di come eravamo insieme
è sempre vivo. Da delvecchio a Costanzo ahah. Le classe di delvi e cette paole mita te
coddanno fazimmente ahah. Al matrimonio del capitano me avete fatto ammazza da ride.
E allora adesso devo passare a ringraziare tutta la squadra. Dal capitano Domenico a
Tommaso, Luca, Daniele, Michele, Mirko, Fabio, Iacopo, Alessandrino, Franz, Wurz. . . ..
Grazie a tutti. In quel di Borgonara quante botte, quante sconfitte ahah. Ma stare con
voi, giocare con voi è sempre il massimo del divertimento. Grazie per tutte le cene e gli
eventi di squadra in cui se sfonnamo. Poi dimo perché perdemo sempre ahahahah.
E alla fine mi sono sentito di ringraziare anche te Marika. Si penso sia giusto così.
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Perché comunque rappresenti il mio passato. 5 anni insieme non si cancellano così. Anzi
io non voglio nemmeno cancellarli. Perché sei stata importante per me in passato. Dispi-
ace solo sia finita così male. Ma se sono arrivato a fare il dottorato è anche grazie a te
che mi hai sostenuto durante gli anni universitari.
Ringrazio la mia famiglia: Francesco, Daniela e Alberto.
Ringrazio Mamma e Papà perché nonostante tante incomprensioni e alcuni che sem-
bravano punti di non ritorno, è grazie a voi se sono arrivato fin qua. Mi avete dato
tanto. Vi ringrazio di avermi dato la possibilità di studiare e intraprendere il percorso
che desideravo. Vi ti stimo tanto, per quello che siete e quello che fate tutti i giorni
tra casa e lavoro. Non c’è una mamma e un papà piu’ forte di voi. Mi dispiace che a
volte non ci capiamo. Forse perché siamo caratteri uguali. Forse perché siamo nervosi
tutti quanti. Forse perché tutti vorremmo dare di piu’ e non ce la facciamo, forse perché
abbiamo paura o forse perché vorremmo vedere andare le cose in modo diverso. Ma il
vostro affetto non mi è mai mancato. Vi voglio bene.
Ringrazio mio fratello perchè quando riesce ad essere calmo e tranquillo riusciamo an-
cora a giocare come un tempo in cui mi divertivo a passare del tempo insieme. Basterebbe
poco. In fondo so che ce la puoi fare. Basta liberare la mente da pensieri e fantasmi
inutili. Sei qui con noi va tutto bene.
Ringrazio Nonna perché sono cresciuto forse piu’ con lei e zio che con mamma. Quante
merende, quanti pranzi da piccolo. Adesso quanti caffè ogni giorno. Ha sempre qualcosa
da mangiare per il nipote ahah. Riempie il piatto in continuazione fino a scoppiare. In
linea con la tradizione calabrese. Quando se magna se fa sul serio.
Ringrazio i miei cugini Lorenzo e Iacopo, Raffaele e Tiziana per tutte le chiamate
skype durante il periodo Norvegese.
E se la tesi l’avevo dedicata a Nonno, il mio immenso Nonno, adesso questa tesi la
dedico a Ricky. La mia forza, il mio amico, mio zio. Tutti i giorni. Ci sono tanti modi
di amare. I primi 10 anni sono cresciuto mangiando insieme e giocando a carte con te.
Dormivo con te. Facevo tutto con te. E come farei senza vederti sorridere ogni giorno.
Senza vedere le partite della domenica insieme. Non si può. Mi basta vederti gioire
per riprendere forza. Fare qualcosa per farti stare meglio. Portarti in tutti i posti che
vorresti vedere. Per farti divertire. Quando guardi fuori dalla finestra lo so che pensi. Si
vede negli occhi. Forse chi non ha mai viaggiato riesce a vedere luoghi magici. Perché
l’immaginazione è libera di volare. Il tuo pensiero viaggia verso posti remoti. Che non
si possono descrivere. Vorrei farti vivere la magia. Almeno una volta. Spero di riuscirci.
Forse se Dio da una parte toglie dall’altra dona qualcosa di straordinario. Infatti solo te
hai il dono di dare gioia a tutti quelli che ti guardano sorridere. Una forza della natura
che ti fa rinvenire e capire come a volte essere tristi per della cavolate è davvero stupido.
Ringrazio il laboratorio 254-11-13 ed ogni pipetta becker, matraccio, beuta o pallone
con cui abbia lavorato. Rimarrò sempre affezionato a questi posti.
Sono stati tre anni intensi. Sono entrato in un modo ed esco totalmente cambiato.
Nel carattere e nella tecnica. Sono stati tre anni tosti in cui ho alternato periodi buii
(alcuni davvero darkness assoluto) e periodi positivi. Sono caduto e mi sono rialzato, per
poi cadere di nuovo e rialzarmi ancora. Non se sa quante volte l’ho fatto sto ciclo. Ma
anche grazie a tutti voi sono riuscito a farcela e ad andare avanti.
E allora sai che ti dico. . . .spero di continuare a cadere e rialzarmi. Perché in fondo è
cosi’ che deve andare. Se vuoi veramente una cosa rischia. Se senti che ne vale la pena
prova. Certo chi non rischia non cade mai. Chi rischia può cadere. Ma se non ti butti
mai non vedrai mai quello che c’è dietro. L’essenza vera. Rimane solo il rimpianto di
non averci provato.
Spero in futuro di avere questa forza. Ancora e per sempre. Quella di non avere
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paura mai. Di niente. Di provare sempre. Di seguire l’istinto. Di fare quello che sento
di fare. In tutti i campi. E se mai cadrò, di avere ancora piu’ forza a rialzarmi.
E se sei arrivato fin qui ti faccio i complimenti perchè io me sarei già stufato da un
pezzo de legge. . . . . . . . . .
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